

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 2261335 T3**

-
- (51) Int.Cl.: *C 12 N 15/12 (2006.01)* *A 01 K 67/027 (2006.01)* *A 61 K 38/18 (2006.01)*
A 61 P 19/10 (2006.01) *C 07 K 14/495 (2006.01)* *C 07 K 14/51 (2006.01)*
C 07 K 16/22 (2006.01) *C 12 N 5/10 (2006.01)* *C 12 N 15/62 (2006.01)*
C 12 N 15/63 (2006.01) *C 12 Q 1/68 (2006.01)* *G 01 N 33/53 (2006.01)*
- (45) Oversættelsen bekendtgjort den: **2017-09-18**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2017-06-14**
- (86) Europæisk ansøgning nr.: **10008049.8**
- (86) Europæisk indleveringsdag: **1999-11-24**
- (87) Den europæiske ansøgnings publiceringsdag: **2010-12-15**
- (30) Prioritet: **1998-11-27 US 110283 P**
- (62) Stamansøgningsnr: **06011535.9**
- (84) Designerede stater: **AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE**
- (73) Patenthaver: **UCB Pharma S.A., Allee de la Recherche 60, 1070 Bruxelles, Belgien**
- (72) Opfinder: **Brunkow, Mary E., 9829 Trinton Drive NW, Seattle, WA 98117, USA**
Galas, David J., 854 Guanajuato Drive, Claremont, CA 91711, USA
KOVACEVICH, Brian, 4308 N.E. 6th Place, Renton, WA 98059, USA
Mulligan, John T., 5823 17th Avenue Northeast, Seattle, WA 98105, USA
Paeper, Bryan W., 1617 Summit Avenue 43, Seattle, WA 98122, USA
VAN NESS, Jeffrey, 10020 49th Avenue Northeast, Seattle, WA 98125, USA
WINKLER, David G., 7037 20th Avenue Northeast, Seattle, WA 98115, USA
- (74) Fuldmægtig i Danmark: **Budde Schou A/S, Hausergade 3, 1128 København K, Danmark**
- (54) Benævnelse: **Sammensætninger og fremgangsmåder til forøgelse af knoglemineralisering**
- (56) Fremdragne publikationer:
WO-A-91/13152
WO-A-92/06693
US-A- 5 453 492
US-A- 5 780 263
BIRREN ET AL.: "Homo sapiens chromosome 17, clone HRPC905N1, complete sequence" EMBL SEQUENCE DATABASE, 14 November 1997 (1997-11-14), XP002133385 HEIDELBERG DE
HILLIER ET AL.: "WshU-Merck EST Project 1997" EMBL SEQUENCE DATABASE, 19 May 1997 (1997-05-19), XP002133386 HEIDELBERG DE
BONALDO ET AL.: "Normalization and subtraction: two approaches to facilitate gene discovery" EMBL SEQUENCE DATABASE, 4 September 1998 (1998-09-04), XP002133484 HEIDELBERG DE & BONALDO ET AL.: "Normalization and subtraction: two approaches to facilitate gene discovery" GENOME RES, vol. 6, no. 9, 1996, pages 791-806,
HSU D R ET AL: "The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that

Fortsættes ...

antagonize BMP activities" MOLECULAR CELL,US,CELL PRESS, CAMBRIDGE, MA, vol. 1, no. 5, April 1998
(1998-04), pages 673-683, XP002113640 ISSN: 1097-2765

DESCRIPTION

TECHNICAL FIELD

[0001] The present invention relates generally to pharmaceutical products and, more specifically, to compositions suitable for increasing the mineral content of bone. Such compositions may be utilized to treat a wide variety of conditions, including for example, osteopenia, osteoporosis, fractures and other disorders in which low bone mineral density are a hallmark of the disease.

BACKGROUND OF THE INVENTION

[0002] Two or three distinct phases of changes to bone mass occur over the life of an individual (see Riggs, West J. Med. 154:63-77, 1991). The first phase occurs in both men and women, and proceeds to attainment of a peak bone mass. This first phase is achieved through linear growth of the endochondral growth plates, and radial growth due to a rate of periosteal apposition. The second phase begins around age 30 for trabecular bone (flat bones such as the vertebrae and pelvis) and about age 40 for cortical bone (e.g., long bones found in the limbs) and continues to old age. This phase is characterized by slow bone loss, and occurs in both men and women. In women, a third phase of bone loss also occurs, most likely due to postmenopausal estrogen deficiencies. During this phase alone, women may lose an additional 10% of bone mass from the cortical bone and 25% from the trabecular compartment (see Riggs, *supra*).

[0003] Loss of bone mineral content can be caused by a wide variety of conditions, and may result in significant medical problems. For example, osteoporosis is a debilitating disease in humans characterized by marked decreases in skeletal bone mass and mineral density, structural deterioration of bone including degradation of bone microarchitecture and corresponding increases in bone fragility and susceptibility to fracture in afflicted individuals. Osteoporosis in humans is preceded by clinical osteopenia (bone mineral density that is greater than one standard deviation but less than 2.5 standard deviations below the mean value for young adult bone), a condition found in approximately 25 million people in the United States. Another 7-8 million patients in the United States have been diagnosed with clinical osteoporosis (defined as bone mineral content greater than 2.5 standard deviations below that of mature young adult bone). Osteoporosis is one of the most expensive diseases for the health care system, costing tens of billions of dollars annually in the United States. In addition to health care-related costs, long-term residential care and lost working days add to the financial and social costs of this disease. Worldwide approximately 75 million people are at risk for osteoporosis.

[0004] The frequency of osteoporosis in the human population increases with age, and

among Caucasians is predominant in women (who comprise 80% of the osteoporosis patient pool in the United States). The increased fragility and susceptibility to fracture of skeletal bone in the aged is aggravated by the greater risk of accidental falls in this population. More than 1.5 million osteoporosis-related bone fractures are reported in the United States each year. Fractured hips, wrists, and vertebrae are among the most common injuries associated with osteoporosis. Hip fractures in particular are extremely uncomfortable and expensive for the patient, and for women correlate with high rates of mortality and morbidity.

[0005] Although osteoporosis has been defined as an increase in the risk of fracture due to decreased bone mass, none of the presently available treatments for skeletal disorders can substantially increase the bone density of adults. There is a strong perception among all physicians that drugs are needed which could increase bone density in adults, particularly in the bones of the wrist, spinal column and hip that are at risk in osteopenia and osteoporosis.

[0006] Current strategies for the prevention of osteoporosis may offer some benefit to individuals but cannot ensure resolution of the disease. These strategies include moderating physical activity (particularly in weight-bearing activities) with the onset of advanced age, including adequate calcium in the diet, and avoiding consumption of products containing alcohol or tobacco. For patients presenting with clinical osteopenia or osteoporosis, all current therapeutic drugs and strategies are directed to reducing further loss of bone mass by inhibiting the process of bone absorption, a natural component of the bone remodeling process that occurs constitutively.

[0007] For example, estrogen is now being prescribed to retard bone loss. There is, however, some controversy over whether there is any long term benefit to patients and whether there is any effect at all on patients over 75 years old. Moreover, use of estrogen is believed to increase the risk of breast and endometrial cancer.

[0008] High doses of dietary calcium, with or without vitamin D has also been suggested for postmenopausal women. However, high doses of calcium can often have unpleasant gastrointestinal side effects, and serum and urinary calcium levels must be continuously monitored (see Khosla and Riggs, Mayo Clin. Proc. 70:978-982, 1995).

[0009] Other therapeutics which have been suggested include calcitonin, bisphosphonates, anabolic steroids and sodium fluoride. Such therapeutics however, have undesirable side effects (e.g., calcitonin and steroids may cause nausea and provoke an immune reaction, bisphosphonates and sodium fluoride may inhibit repair of fractures, even though bone density increases modestly) that may prevent their usage (see Khosla and Riggs, *supra*).

[0010] No currently practiced therapeutic strategy involves a drug that stimulates or enhances the growth of new bone mass. The present invention provides compositions which can be utilized to increase bone mineralization, and thus may be utilized to treat a wide variety of conditions where it is desired to increase bone mass. Further, the present invention provides other, related advantages.

SUMMARY OF THE INVENTION

[0011] As noted above, the present invention provides an antibody or fragment thereof that binds to a protein encoded by SEQ ID NO: 1.

[0012] Within one aspect of the present disclosure isolated nucleic acid molecules are provided, wherein said nucleic acid molecules are selected from the group consisting of: (a) an isolated nucleic acid molecule comprising sequence ID Nos. 1, 5, 7, 9, 11, 13, or 15, or complementary sequence thereof; (b) an isolated nucleic acid molecule that specifically hybridizes to the nucleic acid molecule of (a) under conditions of high stringency; and (c) an isolated nucleic acid that encodes a TGF-heta binding-protein according to (a) or (b). Within related aspects of the present disclosure isolated nucleic acid molecules are provided based upon hybridization to only a portion of one of the above-identified sequences (e.g., for (a) hybridization may be to a probe of at least 20, 25, 50, or 100 nucleotides selected from nucleotides 156 to 539 or 555 to 687 of Sequence ID No. 1). As should be readily evident, the necessary stringency to be utilized for hybridization may vary based upon the size of the probe. For example, for a 25-mer probe high stringency conditions could include: 60 mM Tris pH 8.0, 2 mM EDTA, 5x Denhardt's, 6x SSC, 0.1% (w/v) N-laurylsarcosine, 0.5% (w/v) NP-40 (nonidet P-40) overnight at 45 degrees C, followed by two washes with 0.2x SSC / 0.1% SDS at 45-50 degrees. For a 100-mer probe under low stringency conditions, suitable conditions might include the following: 5x SSPE, 5x Denhardt's, and 0.5% SDS overnight at 42-50 degrees, followed by two washes with 2x SSPE (or 2x SSC) / 0.1% SDS at 42-50 degrees.

[0013] Within related aspects of the present disclosure, isolated nucleic acid molecules are provided which have homology to Sequence ID Nos. 1, 5, 7, 9, 11, 13, or 15, at a 50%, 60%, 75%, 80%, 90%, 95%, or 98% level of homology utilizing a Wilbur-Lipman algorithm. Representative examples of such isolated molecules include, for example, nucleic acid molecules which encode a protein comprising Sequence ID NOs. 2, 6, 10, 12, 14, or 16, or have homology to these sequences at a level of 50%, 60%, 75%, 80%, 90%, 95%, or 98% level of homology utilizing a Lipman-Pearson algorithm.

[0014] Isolated nucleic acid molecules are typically less than 100kb in size, and, within certain embodiments, less than 50kb, 25kb, 10kb, or even 5kb in size. Further, isolated nucleic acid molecules, within other embodiments, do not exist in a "library" of other unrelated nucleic acid molecules (e.g., a subclone BAC such as described in GenBank Accession No. AC003098 and EMB No. AQ171546). However, isolated nucleic acid molecules can be found in libraries of related molecules (e.g., for shuffling, such as is described in U.S. Patent Nos. 5,837,458; 5,830,721; and 5,811,238). Finally, isolated nucleic acid molecules as described herein do not include nucleic acid molecules which encode Dan, Cerberus, Gremlin, or SCGF (U.S. Patent No. 5,780,263).

[0015] Also provided by the present disclosure are cloning vectors which contain the above-

noted nucleic acid molecules, and expression vectors which comprise a promoter (e.g., a regulatory sequence) operably linked to one of the above-noted nucleic acid molecules. Representative examples of suitable promoters include tissue-specific promoters, and viral - based promoters (e.g., CMV-based promoters such as CMV I-E, SV40 early promoter, and MuLV LTR). Expression vectors may also be based upon, or derived from viruses (e.g., a "viral vector"). Representative examples of viral vectors include herpes simplex viral vectors adenoviral vectors, adenovirus-associated viral vectors and retroviral vectors. Also provided by the disclosure are host cells containing any of above-noted vectors (including for example, host cells of human, monkey, dog, rat, or mouse origin).

[0016] Within other aspects of the present disclosure methods of producing TGF-beta binding-proteins are provided, comprising the step of culturing the aforementioned host cell containing vector under conditions and for a time sufficient to produce the TGF-beta binding protein. Within further embodiments, of the disclosure the protein produced by this methods may be further purified (e.g., by column chromatography, affinity purification, and the like). Hence, isolated proteins which are encoded by the above-noted nucleic acid molecules (e.g., Sequence ID NOs. 2, 4, 6, 8, 10, 12, 14, or 16) may be readily produced given the disclosure of the subject application.

[0017] It should also be noted that the aforementioned proteins or fragments thereof, may be produced as fusion proteins. For example, within one aspect of the disclosure fusion proteins are provided comprising a first polypeptide segment comprising a TGF-beta binding-protein encoded by a nucleic acid molecule as described above, or a portion thereof of at least 10, 20, 30, 50, or 100 amino acids in length, and a second polypeptide segment comprising a non-TGF-beta binding-protein. Within certain embodiments, the second polypeptide may be a tag suitable for purification or recognition (e.g., a polypeptide comprising multiple anionic amino acid residues - see U.S. Patent No. 4,851,341), a marker (e.g., green fluorescent protein, or alkaline phosphatase), or a toxic molecule (e.g., ricin).

[0018] Within another aspect of the present invention, antibodies or fragments thereof are provided which are capable of specifically binding to a protein encoded by SEQ ID NO: 1.

[0019] Within various embodiments, the antibody may be a polyclonal antibody, or a monoclonal antibody (e.g., of human or murine origin). Within further embodiments, the antibody is a fragment of an antibody which retains the binding characteristics of a whole antibody (e.g., an F(ab')₂, F(ab)₂, Fab', Fab, or Fv fragment, or even a CDR). Also provided are hybridomas and other cells which are capable of producing or expressing the aforementioned antibodies.

[0020] Within related aspects of the invention, methods are provided detecting a TGF-beta binding protein, comprising the steps of incubating an antibody as described above under conditions and for a time sufficient to permit said antibody to bind to a TGF-beta binding protein, and detecting the binding. Within various embodiments the antibody may be bound to a solid support to facilitate washing or separation, and/or labeled. (e.g., with a marker selected

from the group consisting of enzymes, fluorescent proteins, and radioisotopes).

[0021] Within other aspects of the present disclosure isolated oligonucleotides are provided which hybridize to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, 15, 17, or 18 or the complement thereto, under conditions of high stringency. Within further embodiments of the disclosure, the oligonucleotide may be found in the sequence which encodes Sequence ID Nos. 2, 4, 6, 8, 10, 12, 14, or 16. Within certain embodiments of the disclosure the oligonucleotide is at least 15, 20, 30, 50, or 100 nucleotides in length. Within further embodiments of the disclosure, the oligonucleotide is labeled with another molecule (e.g., an enzyme fluorescent molecule, or radioisotope). Also provided are primers which are capable of specifically amplifying all or a portion of the above-mentioned nucleic acid molecules which encode TGF-beta binding-proteins. As utilized herein, the term "specifically amplifying" should be understood to refer to primers which amplify the aforementioned TGF-beta binding-proteins, and not other TGF-beta binding proteins such as Dan, Cerberus, Gremlin, or SCGF (U.S. Patent No. 5,780,263).

[0022] Within related aspects of the present disclosure methods are provided for detecting a nucleic acid molecule which encodes a TGF-beta binding protein, comprising the steps of incubating an oligonucleotide as described above under conditions of high stringency, and detecting hybridization of said oligonucleotide. Within certain embodiments, the oligonucleotide may be labeled and/or bound to a solid support.

[0023] Within other aspects of the present disclosure ribozymes are provided which are capable of cleaving RNA which encodes one of the above-mentioned TGF-beta binding-proteins (e.g., Sequence ID NOs. 2, 6, 8, 10, 12, 14, or 16). Such ribozymes may be composed of DNA, RNA (including 2'-O-methyl ribonucleic acids), nucleic acid analogs (e.g., nucleic acids having phosphorothioate linkages) or mixtures thereof. Also provided by the disclosure are nucleic acid molecules (e.g., DNA or cDNA) which encode these ribozymes, and vectors which are capable of expressing or producing the ribozymes. Representative examples of vectors include plasmids, retrotransposons, cosmids, and viral-based vectors (e.g., viral vectors generated at least in part from a retrovirus, adenovirus, or, adeno-associated virus). Also provided by the disclosure are host cells (e.g., human, dog, rat, or mouse cells) which contain these vectors. In certain embodiments, the host cell may be stably transformed with the vector.

[0024] Within further aspects of the disclosure, methods are provided for producing ribozymes either synthetically, or by *in vitro* or *in vivo* transcription. Within further embodiments, the ribozymes so produced may be further purified and / or formulated into pharmaceutical compositions (e.g., the ribozyme or nucleic acid molecule encoding the ribozyme along with a pharmaceutically acceptable carrier or diluent). Similarly, the antisense oligonucleotides and antibodies or other selected molecules described herein may be formulated into pharmaceutical compositions.

[0025] Within other aspects of the present disclosure antisense oligonucleotides are provided

comprising a nucleic acid molecule which hybridizes to a nucleic acid molecule according to Sequence ID NOs. 1, 3, 5, 7, 9, 11, 13, or 15, or the complement thereto, and wherein said oligonucleotide inhibits the expression of TGF-beta binding protein as described herein (e.g., human BEER). Within various embodiments, the oligonucleotide is 15, 20, 25, 30, 35, 40, or 50 nucleotides in length. Preferably, the oligonucleotide is less than 100, 75, or 60 nucleotides in length. As should be readily evident, the oligonucleotide may be comprised of one or more nucleic acid analogs, ribonucleic acids, or deoxyribonucleic acids. Further, the oligonucleotide may be modified by one or more linkages, including for example, covalent linkage such as a phosphorothioate linkage, a phosphotriester linkage, a methyl phosphonate linkage, a methylene(methylimino) linkage, a morpholino linkage, an amide linkage, a polyamide linkage, a short chain alkyl intersugar linkage, a cycloalkyl intersugar linkage, a short chain heteroatomic intersugar linkage and a heterocyclic intersugar linkage. One representative example of a chimeric oligonucleotide is provided in U.S. Patent No. 5,989,912.

[0026] Within yet another aspect of the present disclosure methods are provided for increasing bone mineralization, comprising introducing into a warm-blooded animal an effective amount of the ribozyme as described above. Within related aspects, such methods comprise the step of introducing into a patient an effective amount of the nucleic acid molecule or vector as described herein which is capable of producing the desired ribozyme, under conditions favoring transcription of the nucleic acid molecule to produce the ribozyme.

[0027] Within other aspects of the disclosure transgenic, non-human animals are provided. Within one embodiment of the disclosure a transgenic animal is provided whose germ cells and somatic cells contain a nucleic acid molecule encoding a TGF-beta binding-protein as described above which is operably linked to a promoter effective for the expression of the gene, the gene being introduced into the animal, or an ancestor of the animal, at an embryonic stage, with the proviso that said animal is not a human. Within other embodiments, transgenic knockout animals are provided, comprising an animal whose germ cells and somatic cells comprise a disruption of at least one allele of an endogenous nucleic acid molecule which hybridizes to a nucleic acid molecule which encodes a TGF-binding protein as described herein, wherein the disruption prevents transcription of messenger RNA from said allele as compared to an animal without the disruption, with the proviso that the animal is not a human. Within various embodiments, the disruption is a nucleic acid deletion, substitution, or, insertion. Within other embodiments the transgenic animal is a mouse, rat, sheep, pig, or dog.

[0028] Within further aspects of the disclosure, kits are provided for the detection of TGF-beta binding-protein gene expression, comprising a container that comprises a nucleic acid molecule, wherein the nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15; (b) a nucleic acid molecule comprising the complement of the nucleotide sequence of (a); (c) a nucleic acid molecule that is a fragment of (a) or (b) of at least 15, 20, 30, 50, 75, or, 100 nucleotides in length. Also provided by the invention are kits for the detection of a TGF-beta binding-protein which comprise a container that comprise one of the TGF-beta binding protein antibodies described herein.

[0029] For example, within one aspect of the present disclosure methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing one or more candidate molecules with TGF-beta-binding-protein encoded by the nucleic acid molecule according to claim 1 and a selected member of the TGF-beta family of proteins (e.g., BMP 5 or 6), (b) determining whether the, candidate molecule alters the signaling of the TGF-beta family member, or alters the binding of the TGF-beta binding-protein to the TGF-beta family member. Within certain embodiments, the molecule alters the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation. Within this aspect of the present disclosure, the candidate molecule(s) may alter signaling or binding by, for example, either decreasing (e.g., inhibiting), or increasing (e.g., enhancing) signaling or binding.

[0030] Within yet another aspect of the disclosure, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the step of determining whether a selected molecule inhibits the binding of TGF-beta binding-protein to bone, or an analogue thereof. Representative examples of bone or analogues thereof include hydroxyapatite and primary human bone samples obtained via biopsy.

[0031] Within certain embodiments of the above-recited methods, of the disclosure, the selected molecule is contained within a mixture of molecules and the methods may further comprise the step of isolating one or more molecules which are functional within the assay. Within yet other embodiments, TGF-beta family of proteins is bound to a solid support and the binding of TGF-beta binding-protein is measured or TGF-beta binding-protein are bound to a solid support and the binding of TGF-beta proteins are measured.

[0032] Utilizing methods such as those described above, a wide variety of molecules may be assayed for their ability to increase bone mineral content by inhibiting the binding of the TGF-beta binding-protein to the TGF-beta family of proteins. Representative examples of such molecules include proteins or peptides, organic molecules, and nucleic acid molecules.

[0033] Within other related aspects of the disclosure methods are provided for increasing bone mineral content in a warm-blooded animal, comprising the step of administering to a warm-blooded animal a therapeutically effective amount of a molecule identified from the assays recited herein. Methods are disclosed for increasing bone mineral content in a warm-blooded animal, comprising the step of administering to a warm-blooded animal a therapeutically effective amount of a molecule which inhibits the binding of the TGF-beta binding-protein to the TGF-beta super-family of proteins, including bone morphogenic proteins (BMPs). Representative examples of suitable molecules include antisense molecules, ribozymes, ribozyme genes, and antibodies (e.g., a humanized antibody) which specifically recognize and alter the activity of the TGF-beta binding-protein.

[0034] Methods are disclosed for increasing bone mineral content in a warm-blooded animal, comprising the steps of (a) introducing into cells which home to the bone a vector which directs

the expression of a molecule which inhibits the binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs), and (b) administering the vector-containing cells to a warm-blooded animal. As utilized herein, it should be understood that cells "home to bone" if they localize within the bone matrix after peripheral administration. Such methods may further comprise, prior to the step of introducing, isolating cells from the marrow of bone which home to the bone. The cells which home to bone may be selected from the group consisting of CD34+ cells and osteoblasts.

[0035] Within other aspects of the present disclosure, molecules are provided (preferably isolated) which inhibit the binding of the TGF-beta binding-protein to the TGF-beta super-family of proteins.

[0036] The molecules may be provided as a composition, and can further comprise an inhibitor of bone resorption. Representative examples of such inhibitors include calcitonin, estrogen, a bisphosphonate, a growth factor having anti-resorptive activity and tamoxifen.

[0037] Representative examples of molecules which may be utilized in the afore-mentioned therapeutic contexts include, e.g., ribozymes, ribozyme genes, antisense molecules, and/or antibodies (e.g., humanized antibodies). Such molecules may depending upon their selection, used to, alter, antagonize, or agonize the signalling or binding of a TGF-beta binding-protein family member as described herein

[0038] The above-described molecules and methods of treatment or prevention may be utilized on conditions such as osteoporosis, osteomalasia, periodontal disease, scurvy, Cushing's Disease, bone fracture and conditions due to limb immobilization and steroid usage.

[0039] These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (e.g., plasmids, etc.), and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

[0040]

Figure 1 is a schematic illustration comparing the amino acid sequence of Human Dan; Human Gremlin; Human Cerberus and Human Beer. Arrows indicate the Cysteine backbone.

Figure 2 summarizes the results obtained from surveying a variety of human tissues for the expression of a TGF-beta binding-protein gene, specifically, the Human Beer gene. A semi-quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) procedure was used to amplify a portion of the gene from first-strand cDNA synthesized from total RNA (described in more detail in EXAMPLE 2A).

Figure 3 summarizes the results obtained from RNA *in situ* hybridization of mouse embryo sections, using a cRNA probe that is complementary to the mouse Beer transcript (described in more detail in EXAMPLE 2B). Panel A is a transverse section of 10.5 dpc embryo. Panel B is a sagittal section of 12.5 dpc embryo and panels C and D are sagittal sections of 15.5 dpc embryos.

Figure 4 illustrates, by western blot analysis, the specificity of three different polyclonal antibodies for their respective antigens (described in more detail in EXAMPLE 4). Figure 4A shows specific reactivity of an anti-H. Beer antibody for H. Beer antigen, but not H. Dan or H. Gremlin. Figure 4B shows reactivity of an anti-H. Gremlin antibody for H. Gremlin antigen, but not H. Beer or H. Dan. Figure 4C shows reactivity of an anti-H. Dan antibody for H. Dan, but not H. Beer or H. Gremlin.

Figure 5 illustrates, by western blot analysis, the selectivity of the TGF-beta binding-protein, Beer, for BMP-5 and BMP-6, but not BMP-4 (described in more detail in EXAMPLE 5).

Figure 6 demonstrates that the ionic interaction between the TGF-beta binding-protein, Beer, and BMP-5 has a dissociation constant in the 15-30 nM range.

DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

[0041] Prior to setting forth the invention in detail, it may be helpful to an understanding thereof to set forth definitions of certain terms and to list and to define the abbreviations that will be used hereinafter.

[0042] "Molecule" should be understood to include proteins or peptides (e.g., antibodies, recombinant binding partners, peptides with a desired binding affinity), nucleic acids (e.g., DNA, RNA, chimeric nucleic acid molecules, and nucleic acid analogues such as PNA); and organic or inorganic compounds.

[0043] "TGF-beta" should be understood to include any known or novel member of the TGF-beta super-family, which also includes bone morphogenic proteins (BMPs).

[0044] "TGF-beta receptor" should be understood to refer to the receptor specific for a particular member of the TGF-beta super-family (including bone morphogenic proteins (BMPs)).

[0045] "TGF-beta binding-protein" should be understood to refer to a protein with specific binding affinity for a particular member or subset of members of the TGF-beta super-family

(including bone morphogenic proteins (BMPs)). Specific examples of TGF-beta binding-proteins include proteins encoded by Sequence ID Nos. 1, 5, 7, 9, 11, 13, and 15.

[0046] Inhibiting the "binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs)" should be understood to refer to molecules which allow the activation of TGF-beta or bone morphogenic proteins (BMPs), or allow the binding of TGF-beta family members including bone morphogenic proteins (BMPs) to their respective receptors, by removing or preventing TGF-beta from binding to TGF-binding-protein. Such inhibition may be accomplished, for example, by molecules which inhibit the binding of the TGF-beta binding-protein to specific members of the TGF-beta super-family.

[0047] "Vector" refers to an assembly which is capable of directing the expression of desired protein. The vector must include transcriptional promoter elements which are operably linked to the gene(s) of interest. The vector may be composed of either deoxyribonucleic acids ("DNA"), ribonucleic acids ("RNA"), or a combination of the two (e.g., a DNA-RNA chimeric). Optionally, the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more selectable markers such as neomycin phosphotransferase or hygromycin phosphotransferase. Additionally, depending on the host cell chosen and the vector employed, other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may also be incorporated into the vectors described herein.

[0048] An "isolated nucleic acid molecule" is a nucleic acid molecule that is not integrated in the genomic DNA of an organism. For example, a DNA molecule that encodes a TGF-binding protein that has been separated from the genomic DNA of a eukaryotic cell is an isolated DNA molecule. Another example of an isolated nucleic acid molecule is a chemically-synthesized nucleic acid molecule that is not integrated in the genome of an organism. The isolated nucleic acid molecule may be genomic DNA, cDNA, RNA, or composed at least in part of nucleic acid analogs.

[0049] An "isolated polypeptide" is a polypeptide that is essentially free from contaminating cellular components, such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature. Within certain embodiments, a particular protein preparation contains an isolated polypeptide if it appears nominally as a single band on SDS-PAGE gel with Coomassie Blue staining. "Isolated" when referring to organic molecules means that the compounds are greater than 90 percent pure utilizing methods which are well known in the art (e.g., NMR, melting point).

[0050] "Sclerosteosis" Sclerosteosis is a term that was applied by Hansen (1967) (Hansen, H. G., Sclerosteose. In: Opitz, H.; Schmid, F., Handbuch der Kinderheilkunde. Berlin: Springer (pub.) 6 1967. Pp. 351-355) to a disorder similar to van Buchem hyperostosis corticalis generalisata but possibly differing in radiologic appearance of the bone changes and in the presence of asymmetric cutaneous syndactyly of the index and middle fingers in many cases. The jaw has an unusually square appearance in this condition.

[0051] "Humanized antibodies" are recombinant proteins in which murine complementary determining regions of monoclonal antibodies have been transferred from heavy and light variable chains of the murine immunoglobulin into a human variable domain.

[0052] As used herein, an "antibody fragment" is a portion of an antibody such as F(ab')₂, F(ab)₂, Fab', Fab, and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. For example, an anti-TGF-beta binding-protein monoclonal antibody fragment binds with an epitope of TGF-beta binding-protein.

[0053] The term "antibody fragment" also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. For example, antibody fragments include isolated fragments consisting of the light chain variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker ("sFv proteins"), and minimal recognition units consisting of the amino acid residues that mimic the hypervariable region.

[0054] A "detectable label" is a molecule or atom which can be conjugated to an antibody moiety to produce a molecule useful for diagnosis. Examples of detectable labels include chelators, photoactive agents, radioisotopes, fluorescent agents, paramagnetic ions, enzymes, and other marker moieties.

[0055] As used herein, an "immunoconjugate" is a molecule comprising an anti-TGF-beta binding-protein antibody, or an antibody fragment, and a detectable label. An immunoconjugate has roughly the same, or only slightly reduced, ability to bind TGF-beta binding-protein after conjugation as before conjugation.

[0056] Abbreviations: TGF-beta - "Transforming Growth Factor-beta"; TGF-bBP - "Transforming Growth Factor-beta binding-protein" (one representative TGF-bBP is designated "H. Beer"); BMP - "bone morphogenic protein"; PCR - "polymerase chain reaction"; RT-PCR - PCR process in which RNA is first transcribed into DNA at the first step using reverse transcriptase (RT); cDNA - any DNA made by copying an RNA sequence into DNA form.

[0057] As noted above, the present disclosure provides a novel class of TGF-beta binding-proteins, as well as compositions for increasing bone mineral content in warm-blooded animals. Briefly, the present disclosures are based upon the unexpected discovery that a mutation in the gene which encodes a novel member of the TGF-beta binding-protein family results in a rare condition (sclerosteosis) characterized by bone mineral contents which are one- to four-fold higher than in normal individuals. Thus, as discussed in more detail below this discovery has led to the development of assays which may be utilized to select molecules which inhibit the binding of the TGF-beta binding-protein to the TGF-beta family of proteins and bone morphogenic proteins (BMPs), and such molecules for use in increasing the bone material content of warm-blooded animals (including for example, humans).

DISCUSSION OF THE DISEASE KNOWN AS SCLEROSTEOSIS

[0058] Sclerosteosis is a term that was applied by Hansen (1967) (Hansen, H. G., Sklerosteose. In: Opitz, H.; Schmid, F., Handbuch der Kinderheilkunde. Berlin: Springer (pub.) 6 1967. Pp. 351-355) to a disorder similar to van Buchem hyperostosis corticalis generalisata but possibly differing in radiologic appearance of the bone changes and in the presence of asymmetric cutaneous syndactyly of the index and middle fingers in many cases.

[0059] Sclerosteosis is now known to be an autosomal semi-dominant disorder which is characterized by widely disseminated sclerotic lesions of the bone in the adult. The condition is progressive. Sclerosteosis also has a developmental aspect which is associated with syndactyly (two or more fingers are fused together). The Sclerosteosis Syndrome is associated with large stature and many affected individuals attain a height of six feet or more. The bone mineral content of homozygotes can be 1 to 6 fold over normal individuals and bone mineral density can be 1 to 4 fold above normal values (e.g., from unaffected siblings).

[0060] The Sclerosteosis Syndrome occurs primarily in Afrikaaners of Dutch descent in South Africa. Approximately 1/140 individuals in the Afrikaaner population are carriers of the mutated gene (heterozygotes). The mutation shows 100% penetrance. There are anecdotal reports of increased bone mineral density in heterozygotes with no associated pathologies (syndactyly or skull overgrowth).

[0061] It appears at the present time that there is no abnormality of the pituitary-hypothalamus axis in Sclerosteosis. In particular, there appears to be no overproduction of growth hormone and cortisone. In addition, sex hormone levels are normal in affected individuals. However, bone turnover markers (osteoblast specific alkaline phosphatase, osteocalcin, type 1 procollagen C' propeptide (PICP), and total alkaline phosphatase; (see Comier, C., Curr. Opin. in Rheu. 7:243, 1995) indicate that there is hyperosteoblastic activity associated with the disease but that there is normal to slightly decreased osteoclast activity as measured by markers of bone resorption (pyridinoline, deoxypyridinoline, N-telopeptide, urinary hydroxyproline, plasma tartrate-resistant acid phosphatases and galactosyl hydroxylysine (see Comier, *supra*)).

[0062] Sclerosteosis is characterized by the continual deposition of bone throughout the skeleton during the lifetime of the affected individuals. In homozygotes the continual deposition of bone mineral leads to an overgrowth of bone in areas of the skeleton where there is an absence of mechanoreceptors (skull, jaw, cranium). In homozygotes with Sclerosteosis, the overgrowth of the bones of the skull leads to cranial compression and eventually to death due to excessive hydrostatic pressure on the brain stem. In all other parts of the skeleton there is a generalized and diffuse sclerosis. Cortical areas of the long bones are greatly thickened resulting in a substantial increase in bone strength. Trabecular connections are increased in thickness which in turn increases the strength of the trabecular bone. Sclerotic bones appear

unusually opaque to x-rays.

[0063] As described in more detail in Example 1, the rare genetic mutation that is responsible for the Sclerosteosis syndrome has been localized to the region of human chromosome 17 that encodes a novel member of the TGF-beta binding-protein family (one representative example of which is designated "H. Beer"). As described in more detail below, based upon this discovery, the mechanism of bone mineralization is more fully understood, allowing the development of assays for molecules which increase bone mineralization, and use of such molecules to increase bone mineral content, and in the treatment or prevention of a wide number of diseases.

TGF-BETA SUPER-FAMILY

[0064] The Transforming Growth Factor-beta (TGF-beta) super-family contains a variety of growth factors that share common sequence elements and structural motifs (at both the secondary and tertiary levels). This protein family is known to exert a wide spectrum of biological responses on a large variety of cell types. Many of them have important functions during the embryonal development in pattern formation and tissue specification; in adults they are involved, e.g., in wound healing and bone repair and bone remodeling, and in the modulation of the immune system. In addition to the three TGF-beta's, the super-family includes the Bone Morphogenic Proteins (BMPs), Activins, Inhibins, Growth and Differentiation Factors (GDFs), and Glial-Derived Neurotrophic Factors (GDNFs). Primary classification is established through general sequence features that bin a specific protein into a general sub-family. Additional stratification within the sub-family is possible due to stricter sequence conservation between members of the smaller group. In certain instances, such as with BMP-5, BMP-6 and BMP-7, this can be as high as 75 percent amino acid homology between members of the smaller group. This level of identity enables a single representative sequence to illustrate the key biochemical elements of the sub-group that separates it from other members of the larger family.

[0065] TGF-beta signals by inducing the formation of hetero-oligomeric complexes of type I and type II receptors. The crystal structure of TGF-beta2 has been determined. The general fold of the TGF-beta2 monomer contains a stable, compact, cysteine knotlike structure formed by three disulphide bridges. Dimerization, stabilized by one disulphide bridge, is antiparallel.

[0066] TGF-beta family members initiate their cellular action by binding to receptors with intrinsic serine/threonine kinase activity. This receptor family consists of two subfamilies, denoted type I and type II receptors. Each member of the TGF-beta family binds to a characteristic combination of type I and type II receptors, both of which are needed for signaling. In the current model for TGF-beta receptor activation, TGF-beta first binds to the type II receptor (TbR-II), which occurs in the cell membrane in an oligomeric form with activated kinase. Thereafter, the type I receptor (TbR-I), which can not bind ligand in the absence of TbR-II, is recruited into the complex. TbR-II then phosphorylates TbR-I

predominantly in a domain rich in glycine and serine residues (GS domain) in the juxtamembrane region, and thereby activates T β R-I.

[0067] Thus far seven type I receptors and five type II receptors have been identified.

BONE MORPHOGENIC PROTEINS (BMPs) ARE KEY REGULATORY PROTEINS IN DETERMINING BONE MINERAL DENSITY IN HUMANS

[0068] A major advance in the understanding of bone formation was the identification of the bone morphogenic proteins (BMPs), also known as osteogenic proteins (OPs), which regulate cartilage and bone differentiation in vivo. BMPs/OPs induce endochondral bone differentiation through a cascade of events which include formation of cartilage, hypertrophy and calcification of the cartilage, vascular invasion, differentiation of osteoblasts, and formation of bone. As described above, the BMPs/OPs (BMP 2-14, and osteogenic protein 1 and -2, OP-1 and OP-2) are members of the TGF- β super-family. The striking evolutionary conservation between members the BMP/OP sub-family suggests that they are critical in the normal development and function of animals. Moreover, the presence of multiple forms of BMPs/OPs raises an important question about the biological relevance of this apparent redundancy. In addition to postfetal chondrogenesis and osteogenesis, the BMPs/OPs play multiple roles in skeletogenesis (including the development of craniofacial and dental tissues) and in embryonic development and organogenesis of parenchymatous organs, including the kidney. It is now understood that nature relies on common (and few) molecular mechanisms tailored to provide the emergence of specialized tissues and organs. The BMP/OP super-family is an elegant example of nature parsimony in programming multiple specialized functions deploying molecular isoforms with minor variation in amino acid motifs within highly conserved carboxy-terminal regions.

BMP ANTAGONISM

[0069] The BMP and Activin sub-families are subject to significant post-translational regulation. An intricate extracellular control system exists, whereby a high affinity antagonist is synthesized and exported, and subsequently complexes selectively with BMPs or activins to disrupt their biological activity (W.C. Smith (1999) TIG 15(1) 3-6). A number of these natural antagonists have been identified, and based on sequence divergence appear to have evolved independently due to the lack of primary sequence conservation. There has been no structural work to date on this class of proteins. Studies of these antagonists has highlighted a distinct preference for interacting and neutralizing BMP-2 and BMP-4. Furthermore, the mechanism of inhibition seems to differ for the different antagonists (S. Iemura et al. (1998) Proc Natl Acad Sci USA 95 9337-9342).

NOVEL TGF-BETA BINDING-PROTEINS

1. Background re: TGF-beta binding-proteins

[0070] As noted above, the present disclosure provides a novel class of TGF-beta binding-proteins that possess a nearly identical cysteine (disulfide) scaffold when compared to Human DAN, Human Gremlin, and Human Cerberus, and SCGF (U.S. Patent No. 5,780,263) but almost no homology at the nucleotide level (for background information, see generally Hsu, D.R., Economides, A.N., Wang, X., Eimon, P.M., Harland, R.M., "The Xenopus Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities," *Molecular Cell* 1:673-683, 1998).

[0071] One representative example of the novel class of TGF-beta binding-proteins is disclosed in Sequence ID Nos. 1, 5, 9, 11, 13, and 15. Representative members of this class of binding proteins should also be understood to include variants of the TGF-beta binding-protein (e.g., Sequence ID Nos. 5 and 7). As utilized herein, a "TGF-beta binding-protein variant gene" refers to nucleic acid molecules that encode a polypeptide having an amino acid sequence that is a modification of SEQ ID Nos: 2, 10, 12, 14 or 16. Such variants include naturally-occurring polymorphisms or allelic variants of TGF-beta binding-protein genes, as well as synthetic genes that contain conservative amino acid substitutions of these amino acid sequences. Additional variant forms of a TGF-beta binding-protein gene are nucleic acid molecules that contain insertions or deletions of the nucleotide sequences described herein. TGF-beta binding-protein variant genes can be identified by determining whether the genes hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID Nos: 1, 5, 7, 9, 11, 13, or 15 under stringent conditions. In addition, TGF-beta binding-protein variant genes should encode a protein having a cysteine backbone.

[0072] As an alternative, TGF-beta binding-protein variant genes can be identified by sequence comparison. As used herein, two amino acid sequences have "100% amino acid sequence identity" if the amino acid residues of the two amino acid sequences are the same when aligned for maximal correspondence. Similarly, two nucleotide sequences have "100% nucleotide sequence identity" if the nucleotide residues of the two nucleotide sequences are the same when aligned for maximal correspondence. Sequence comparisons can be performed using standard software programs such as those included in the LASERGENE bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Other methods for comparing two nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art (see, for example, Peruski and Peruski, *The Internet and the New Biology: Tools for Genomic and Molecular Research* (ASM Press, Inc. 1997), Wu et al. (eds.), *Information Superhighway and Computer Databases of Nucleic Acids and Proteins*, in *Methods in Gene Biotechnology*, pages 123-151 (CRC Press, Inc. 1997), and Bishop (ed.), *Guide to Human Genome Computing*, 2nd Edition (Academic Press, Inc. 1998)).

[0073] A variant TGF-beta binding-protein should have at least a 50% amino acid sequence

identity to SEQ ID NOs: 2, 6, 10, 12, 14 or 16 and preferably, greater than 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity. Alternatively, TGF-beta binding-protein variants can be identified by having at least a 70% nucleotide sequence identity to SEQ ID NOs: 1, 5, 9, 11, 13 or 15. Moreover, the present disclosure contemplates TGF-beta binding-protein gene variants having greater than 75%, 80%, 85%, 90%, or 95% identity to SEQ ID NO:1. Regardless of the particular method used to identify a TGF-beta binding-protein variant gene or variant TGF-beta binding-protein, a variant TGF-beta binding-protein or a polypeptide encoded by a variant TGF-beta binding-protein gene can be functionally characterized by, for example, its ability to bind to and/or inhibit the signaling of a selected member of the TGF-beta family of proteins, or by its ability to bind specifically to an anti-TGF-beta binding-protein antibody.

[0074] The present disclosure includes functional fragments of TGF-beta binding-protein genes. Within the context of this disclosure a "functional fragment" of a TGF-beta binding-protein gene refers to a nucleic acid molecule that encodes a portion of a TGF-beta binding-protein polypeptide which either (1) possesses the above-noted function activity, or (2) specifically binds with an anti-TGF-beta binding-protein antibody. For example, a functional fragment of a TGF-beta binding-protein gene described herein comprises a portion of the nucleotide sequence of SEQ ID Nos: 1, 5, 9, 11, 13, or 15.

2. Isolation of the TGF-beta binding-protein gene

[0075] DNA molecules encoding a binding-protein gene can be obtained by screening a human cDNA or genomic library using polynucleotide probes based upon, for example, SEQ ID NO:1.

[0076] For example, the first step in the preparation of a cDNA library is to isolate RNA using methods well-known to those of skill in the art. In general, RNA isolation techniques must provide a method for breaking cells, a means of inhibiting RNase-directed degradation of RNA, and a method of separating RNA from DNA, protein, and polysaccharide contaminants. For example, total RNA can be isolated by freezing tissue in liquid nitrogen, grinding the frozen tissue with a mortar and pestle to lyse the cells, extracting the ground tissue with a solution of phenol/chloroform to remove proteins, and separating RNA from the remaining impurities by selective precipitation with lithium chloride (see, for example, Ausubel et al. (eds.), *Short Protocols in Molecular Biology*, 3rd Edition, pages 4-1 to 4-6 (John Wiley & Sons 1995) ["Ausubel (1995)"]; Wu et al., *Methods in Gene Biotechnology*, pages 33-41 (CRC Press, Inc. 1997) ["Wu (1997)"]).

[0077] Alternatively, total RNA can be isolated by extracting ground tissue with guanidinium isothiocyanate, extracting with organic solvents, and separating RNA from contaminants using differential centrifugation (see, for example, Ausubel (1995) at pages 4-1 to 4-6; Wu (1997) at pages 33-41).

[0078] In order to construct a cDNA library, poly(A)⁺ RNA must be isolated from a total RNA preparation. Poly(A)⁺ RNA can be isolated from total RNA by using the standard technique of oligo(dT)-cellulose chromatography (see, for example, Ausubel (1995) at pages 4-11 to 4-12).

[0079] Double-stranded cDNA molecules are synthesized from poly(A)⁺ RNA using techniques well-known to those in the art. (see, for example, Wu (1997) at pages 41-46). Moreover, commercially available kits can be used to synthesize double-stranded cDNA molecules. For example, such kits are available from Life Technologies, Inc. (Gaithersburg, Maryland), CLONTECH Laboratories, Inc. (Palo Alto, California), Promega Corporation (Madison, Wisconsin) and Stratagene Cloning Systems (La Jolla, California).

[0080] The basic approach for obtaining TGF-beta binding-protein cDNA clones can be modified by constructing a subtracted cDNA library which is enriched in TGF-binding-protein-specific cDNA molecules. Techniques for constructing subtracted libraries are well-known to those of skill in the art (see, for example, Sargent, "Isolation of Differentially Expressed Genes," in *Meth. Enzymol.* 152:423, 1987, and Wu et al. (eds.), "Construction and Screening of Subtracted and Complete Expression cDNA Libraries," in *Methods in Gene Biotechnology*, pages 29-65 (CRC Press, Inc. 1997)).

[0081] Various cloning vectors are appropriate for the construction of a cDNA library. For example, a cDNA library can be prepared in a vector derived from bacteriophage, such as a λ gt10 vector (see, for example, Huynh et al., "Constructing and Screening cDNA Libraries in λ gt10 and λ gt11," in *DNA Cloning: A Practical Approach Vol. I*, Glover (ed.), page 49 (IRL Press, 1985); Wu (1997) at pages 47-52).

[0082] Alternatively, double-stranded cDNA molecules can be inserted into a plasmid vector, such as a pBluescript vector (Stratagene Cloning Systems; La Jolla, California), a LambdaGEM-4 (Promega Corp.; Madison, Wisconsin) or other commercially available vectors. Suitable cloning vectors also can be obtained from the American Type Culture Collection (Rockville, Maryland).

[0083] In order to amplify the cloned cDNA molecules, the cDNA library is inserted into a prokaryotic host, using standard techniques. For example, a cDNA library can be introduced into competent *E. coli* DH5 cells, which can be obtained from Life Technologies, Inc. (Gaithersburg, Maryland).

[0084] A human genomic DNA library can be prepared by means well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327). Genomic DNA can be isolated by lysing tissue with the detergent Sarkosyl, digesting the lysate with proteinase K, clearing insoluble debris from the lysate by centrifugation, precipitating nucleic acid from the lysate using isopropanol, and purifying resuspended DNA on a cesium chloride density gradient.

[0085] DNA fragments that are suitable for the production of a genomic library can be obtained by the random shearing of genomic DNA or by the partial digestion of genomic DNA with restriction endonucleases. Genomic DNA fragments can be inserted into a vector, such as a bacteriophage or cosmid vector, in accordance with conventional techniques, such as the use of restriction enzyme digestion to provide appropriate termini, the use of alkaline phosphatase treatment to avoid undesirable joining of DNA molecules, and ligation with appropriate ligases. Techniques for such manipulation are well-known in the art (see, for example, Ausubel (1995) at pages 5-1 to 5-6; Wu (1997) at pages 307-327).

[0086] Nucleic acid molecules that encode a TGF-beta binding-protein gene can also be obtained using the polymerase chain reaction (PCR) with oligonucleotide primers having nucleotide sequences that are based upon the nucleotide sequences of the human TGF-beta binding-protein gene, as described herein. General methods for screening libraries with PCR are provided by, for example, Yu et al., "Use of the Polymerase Chain Reaction to Screen Phage Libraries," in *Methods in Molecular Biology*, Vol. 15: PCR Protocols: Current Methods and Application, White (ed.), pages 211-215 (Humana Press, Inc. 1993). Moreover, techniques for using PCR to isolate related genes are described by, for example, Preston, "Use of Degenerate Oligonucleotide Primers and the Polymerase Chain Reaction to Clone Gene Family Members," in *Methods in Molecular Biology*, Vol. 15: PCR Protocols: Current Methods and Applications, White (ed.), pages 317-337 (Humana Press, Inc. 1993).

[0087] Alternatively, human genomic libraries can be obtained from commercial sources such as Research Genetics (Huntsville, AL) and the American Type Culture Collection (Rockville, Maryland).

[0088] A library containing cDNA or genomic clones can be screened with one or more polynucleotide probes based upon SEQ ID NO:1, using standard methods (see, for example, Ausubel (1995) at pages 6-1 to 6-11).

[0089] Anti-TGF-beta binding-protein antibodies, produced as described below, can also be used to isolate DNA sequences that encode TGF-beta binding-protein genes from cDNA libraries. For example, the antibodies can be used to screen λ gt11 expression libraries, or the antibodies can be used for immunoscreening following hybrid selection and translation (see, for example, Ausubel (1995) at pages 6-12 to 6-16; Margolis et al., "Screening λ expression libraries with antibody and protein probes," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), pages 1-14 (Oxford University Press 1995)).

[0090] The sequence of a TGF-beta binding-protein cDNA or TGF-beta binding-protein genomic fragment can be determined using standard methods. Moreover, the identification of genomic fragments containing a TGF-beta binding-protein promoter or regulatory element can be achieved using well-established techniques, such as deletion analysis (see, generally, Ausubel (1995)).

[0091] As an alternative, a TGF-beta binding-protein gene can be obtained by synthesizing

DNA molecules using mutually priming long oligonucleotides and the nucleotide sequences described herein (see, for example, Ausubel (1995) at pages 8-8 to 8-9). Established techniques using the polymerase chain reaction provide the ability to synthesize DNA molecules at least two kilobases in length (Adang et al., *Plant Molec. Biol.* 21:1131, 1993; Bambot et al., *PCR Methods and Applications* 2:266, 1993; Dillon et al., "Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes," in *Methods in Molecular Biology*, Vol. 15: *PCR Protocols: Current Methods and Applications*, White (ed.), pages 263-268, (Humana Press, Inc. 1993); Holowachuk et al., *PCR Methods Appl.* 4:299, 1995).

3. Production of TGF-beta binding-protein genes

[0092] Nucleic acid molecules encoding variant TGF-beta binding-protein genes can be obtained by screening various cDNA or genomic libraries with polynucleotide probes having nucleotide sequences based upon SEQ ID NO:1, 5, 9, 11, 13, or 15, using procedures described above. TGF-beta binding-protein gene variants can also be constructed synthetically. For example, a nucleic acid molecule can be devised that encodes a polypeptide having a conservative amino acid change, compared with the amino acid sequence of SEQ ID NOs: 2, 6, 8, 10, 12, 14, or 16. That is, variants can be obtained that contain one or more amino acid substitutions of SEQ ID NOs: 2, 6, 8, 10, 12, 14 or 16, in which an alkyl amino acid is substituted for an alkyl amino acid in a TGF-beta binding-protein amino acid sequence, an aromatic amino acid is substituted for an aromatic amino acid in a TGF-beta binding-protein amino acid sequence, a sulfur-containing amino acid is substituted for a sulfur-containing amino acid in a TGF-beta binding-protein amino acid sequence, a hydroxy-containing amino acid is substituted for a hydroxy-containing amino acid in a TGF-beta binding-protein amino acid sequence, an acidic amino acid is substituted for an acidic amino acid in a TGF-beta binding-protein amino acid sequence, a basic amino acid is substituted for a basic amino acid in a TGF-beta binding-protein amino acid sequence, or a dibasic monocarboxylic amino acid is substituted for a dibasic monocarboxylic amino acid in a TGF-beta binding-protein amino acid sequence.

[0093] Among the common amino acids, for example, a "conservative amino acid substitution" is illustrated by a substitution among amino acids within each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine, (2) phenylalanine, tyrosine, and tryptophan, (3) serine and threonine, (4) aspartate and glutamate, (5) glutamine and asparagine, and (6) lysine, arginine and histidine. In making such substitutions, it is important to, where possible, maintain the cysteine backbone outlined in Figure 1.

[0094] Conservative amino acid changes in a TGF-beta binding-protein gene can be introduced by substituting nucleotides for the nucleotides recited in SEQ ID NO:1. Such "conservative amino acid" variants can be obtained, for example, by oligonucleotide-directed mutagenesis, linker-scanning mutagenesis, mutagenesis using the polymerase chain reaction, and the like (see Ausubel (1995) at pages 8-10 to 8-22; and McPherson (ed.), *Directed*

Mutagenesis: A Practical Approach (IRL Press 1991)). The functional ability of such variants can be determined using a standard method, such as the assay described herein. Alternatively, a variant TGF-beta binding-protein polypeptide can be identified by the ability to specifically bind anti-TGF-beta binding-protein antibodies.

[0095] Routine deletion analyses of nucleic acid molecules can be performed to obtain "functional fragments" of a nucleic acid molecule that encodes a TGF-beta binding-protein polypeptide. As an illustration, DNA molecules having the nucleotide sequence of SEQ ID NO:1 can be digested with *Bal*/31 nuclease to obtain a series of nested deletions. The fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for activity, or for the ability to bind anti-TGF-beta binding-protein antibodies. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce deletions or stop codons to specify production of a desired fragment. Alternatively, particular fragments of a TGF-beta binding-protein gene can be synthesized using the polymerase chain reaction.

[0096] Standard techniques for functional analysis of proteins are described by, for example, Treuter et al., *Molec. Gen. Genet.* 240:113, 1993; Content et al., "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in *Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems*, Cantell (ed.), pages 65-72 (Nijhoff 1987); Herschman, "The EGF Receptor," in *Control of Animal Cell Proliferation*, Vol. 1, Boynton et al., (eds.) pages 169-199 (Academic Press 1985); Coumailleau et al., *J. Biol. Chem.* 270:29270, 1995; Fukunaga et al., *J. Biol. Chem.* 270:25291, 1995; Yamaguchi et al., *Biochem. Pharmacol.* 50:1295, 1995; and Meisel et al., *Plant Molec. Biol.* 30:1, 1996.

[0097] The present disclosure also contemplates functional fragments of a TGF-beta binding-protein gene that have conservative amino acid changes.

[0098] A TGF-beta binding-protein variant gene can be identified on the basis of structure by determining the level of identity with nucleotide and amino acid sequences of SEQ ID NOs. 1, 5, 9, 11, 13, or 15 and 2, 6, 10, 12, 14, or 16, as discussed above. An alternative approach to identifying a variant gene on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant TGF-beta binding-protein gene can hybridize under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID Nos: 1, 5, 9, 11, 13, or 15, or a portion thereof of at least 15 or 20 nucleotides in length. As an illustration of stringent hybridization conditions, a nucleic acid molecule having a variant TGF-beta binding-protein sequence can bind with a fragment of a nucleic acid molecule having a sequence from SEQ ID NO:1 in a buffer containing, for example, 5xSSPE (1xSSPE = 180 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA (pH 7.7), 5xDenhardt's solution (100xDenhardt's = 2% (w/v) bovine serum albumin, 2% (w/v) Ficoll, 2% (w/v) polyvinylpyrrolidone) and 0.5% SDS incubated overnight at 55-60°C. Post-hybridization washes at high stringency are typically performed in 0.5xSSC (1xSSC = 150 mM sodium chloride, 15 mM trisodium citrate) or in 0.5xSSPE at 55-60 °C.

[0099] Regardless of the particular nucleotide sequence of a variant TGF-beta binding-protein gene, the gene encodes a polypeptide that can be characterized by its functional activity, or by the ability to bind specifically to an anti-TGF-beta binding-protein antibody. More specifically, variant TGF-beta binding-protein genes encode polypeptides which exhibit at least 50%, and preferably, greater than 60, 70, 80 or 90%, of the activity of polypeptides encoded by the human TGF-beta binding-protein gene described herein.

4. Production of TGF-beta binding-protein in Cultured Cells

[0100] To express a TGF-beta binding-protein gene, a nucleic acid molecule encoding the polypeptide must be operably linked to regulatory sequences that control transcriptional expression in an expression vector and then introduced into a host cell. In addition to transcriptional regulatory sequences, such as promoters and enhancers, expression vectors can include translational regulatory sequences and a marker gene which is suitable for selection of cells that carry the expression vector.

[0101] Expression vectors that are suitable for production of a foreign protein in eukaryotic cells typically contain (1) prokaryotic DNA elements coding for a bacterial replication origin and an antibiotic resistance marker to provide for the growth and selection of the expression vector in a bacterial host; (2) eukaryotic DNA elements that control initiation of transcription, such as a promoter; and (3) DNA elements that control the processing of transcripts, such as a transcription termination/polyadenylation sequence.

[0102] TGF-beta binding-proteins of the present disclosure are preferably expressed in mammalian cells. Examples of mammalian host cells include African green monkey kidney cells (Vero; ATCC CRL 1587), human embryonic kidney cells (293-HEK; ATCC CRL 1573), baby hamster kidney cells (BHK-21; ATCC CRL 8544), canine kidney cells (MDCK; ATCC CCL 34), Chinese hamster ovary cells (CHO-K1; ATCC CCL61), rat pituitary cells (GH1; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat hepatoma cells (H-4-II-E; ATCC CRL 1548) SV40-transformed monkey kidney cells (COS-1; ATCC CRL 1650) and murine embryonic cells (NIH-3T3; ATCC CRL 1658).

[0103] For a mammalian host, the transcriptional and translational regulatory signals may be derived from viral sources, such as adenovirus, bovine papilloma virus, simian virus, or the like, in which the regulatory signals are associated with a particular gene which has a high level of expression. Suitable transcriptional and translational regulatory sequences also can be obtained from mammalian genes, such as actin, collagen, myosin, and metallothionein genes.

[0104] Transcriptional regulatory sequences include a promoter region sufficient to direct the initiation of RNA synthesis. Suitable eukaryotic promoters include the promoter of the mouse metallothionein I gene [Hamer et al., J. Molec. Appl. Genet. 1:273, 1982], the *TK* promoter of *Herpes* virus [McKnight, Cell 31:355, 1982], the *SV40* early promoter [Benoist et al., Nature

290:304, 1981], the *Rous* sarcoma virus promoter [Gorman et al., Proc. Nat'l Acad. Sci. USA 79:6777, 1982], the cytomegalovirus promoter [Foecking et al., Gene 45:101, 1980], and the mouse mammary tumor virus promoter (see, generally, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in Protein Engineering: Principles and Practice, Cleland et al. (eds.), pages 163-181 (John Wiley & Sons, Inc. 1996)).

[0105] Alternatively, a prokaryotic promoter, such as the bacteriophage T3 RNA polymerase promoter, can be used to control TGF-beta binding-protein gene expression in mammalian cells if the prokaryotic promoter is regulated by a eukaryotic promoter (Zhou et al., Mol. Cell. Biol. 10:4529, 1990; Kaufman et al., Nucl. Acids Res. 19:4485, 1991).

[0106] TGF-beta binding-protein genes may also be expressed in bacterial, yeast, insect, or plant cells. Suitable promoters that can be used to express TGF-beta binding-protein polypeptides in a prokaryotic host are well-known to those of skill in the art and include promoters capable of recognizing the T4, T3, Sp6 and T7 polymerases, the P_R and P_L promoters of bacteriophage lambda, the *trp*, *recA*, heat shock, *lacUV5*, *tac*, *lpp-lacSpr*, *phoA*, and *lacZ* promoters of *E. coli*, promoters of *B. subtilis*, the promoters of the bacteriophages of *Bacillus*, *Streptomyces* promoters, the *int* promoter of bacteriophage lambda, the *bla* promoter of pBR322, and the CAT promoter of the chloramphenicol acetyl transferase gene. Prokaryotic promoters have been reviewed by Glick, J. Ind. Microbiol. 1:277, 1987, Watson et al., Molecular Biology of the Gene, 4th Ed. (Benjamin Cummins 1987), and by Ausubel et al. (1995).

[0107] Preferred prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Suitable strains of *E. coli* include BL21(DE3), BL21(DE3)pLysS, BL21(DE3)pLysE, DH1, DH4I, DH5, DH5I, DH5IF', DH5IMCR, DH10B, DH10B/p3, DH11S, C600, HB101, JM101, JM105, JM109, JM110, K38, RR1, Y1088, Y1089, CSH18, ER1451, and ER1647 (see, for example, Brown (Ed.), Molecular Biology Labfax (Academic Press 1991)). Suitable strains of *Bacillus subtilis* include BR151, YB886, MI119, MI120, and B170 (see, for example, Hardy, "Bacillus Cloning Methods," in DNA Cloning: A Practical Approach, Glover (Ed.) (IRL Press 1985)).

[0108] Methods for expressing proteins in prokaryotic hosts are well-known to those of skill in the art (see, for example, Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in DNA Cloning 2: Expression Systems, 2nd Edition, Glover et al. (eds.), page 15 (Oxford University Press 1995); Ward et al., "Genetic Manipulation and Expression of Antibodies," in Monoclonal Antibodies: Principles and Applications, page 137 (Wiley-Liss, Inc. 1995); and Georgiou, "Expression of Proteins in Bacteria," in Protein Engineering: Principles and Practice, Cleland et al. (eds.), page 101 (John Wiley & Sons, Inc. 1996)).

[0109] The baculovirus system provides an efficient means to introduce cloned *TGF-beta binding-protein* genes into insect cells. Suitable expression vectors are based upon the *Autographa californica* multiple nuclear polyhedrosis virus (AcMNPV), and contain well-known promoters such as *Drosophila* heat shock protein (hsp) 70 promoter, *Autographa californica*

nuclear polyhedrosis virus immediate-early gene promoter (*ie-1*) and the delayed early 39K promoter, baculovirus p10 promoter, and the *Drosophila* metallothionein promoter. Suitable insect host cells include cell lines derived from IPLB-Sf-21, a *Spodoptera frugiperda* pupal ovarian cell line, such as Sf9 (ATCC CRL 1711), Sf21AE, and Sf21 (Invitrogen Corporation; San Diego, CA), as well as *Drosophila* Schneider-2 cells. Established techniques for producing recombinant proteins in baculovirus systems are provided by Bailey et al., "Manipulation of Baculovirus Vectors," in *Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols*, Murray (ed.), pages 147-168 (The Humana Press, Inc. 1991), by Patel et al., "The baculovirus expression system," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), pages 205-244 (Oxford University Press 1995), by Ausubel (1995) at pages 16-37 to 16-57, by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc. 1995), and by Lucknow, "Insect Cell Expression Technology," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 183-218 (John Wiley & Sons, Inc. 1996).

[0110] Promoters for expression in yeast include promoters from *GAL1* (galactose), *PGK* (phosphoglycerate kinase), *ADH* (alcohol dehydrogenase), *AOX1* (alcohol oxidase), *HIS4* (histidinol dehydrogenase), and the like. Many yeast cloning vectors have been designed and are readily available. These vectors include Ylp-based vectors, such as Ylp5, YRp vectors, such as YRp17, YEp vectors such as YEp13 and YCp vectors, such as YCp19. One skilled in the art will appreciate that there are a wide variety of suitable vectors for expression in yeast cells.

[0111] Expression vectors can also be introduced into plant protoplasts, intact plant tissues, or isolated plant cells. General methods of culturing plant tissues are provided, for example, by Miki et al., "Procedures for Introducing Foreign DNA into Plants," in *Methods in Plant Molecular Biology and Biotechnology*, Glick et al. (eds.), pages 67-88 (CRC Press, 1993).

[0112] An expression vector can be introduced into host cells using a variety of standard techniques including calcium phosphate transfection, liposome-mediated transfection, microprojectile-mediated delivery, electroporation, and the like. Preferably, the transfected cells are selected and propagated to provide recombinant host cells that comprise the expression vector stably integrated in the host cell genome. Techniques for introducing vectors into eukaryotic cells and techniques for selecting such stable transformants using a dominant selectable marker are described, for example, by Ausubel (1995) and by Murray (ed.), *Gene Transfer and Expression Protocols* (Humana Press 1991). Methods for introducing expression vectors into bacterial, yeast, insect, and plant cells are also provided by Ausubel (1995).

[0113] General methods for expressing and recovering foreign protein produced by a mammalian cell system is provided by, for example, Etcheverry, "Expression of Engineered Proteins in Mammalian Cell Culture," in *Protein Engineering: Principles and Practice*, Cleland et al. (eds.), pages 163 (Wiley-Liss, Inc. 1996). Standard techniques for recovering protein produced by a bacterial system is provided by, for example, Grishammer et al., "Purification of over-produced proteins from *E. coli* cells," in *DNA Cloning 2: Expression Systems*, 2nd Edition,

Glover et al. (eds.), pages 59-92 (Oxford University Press 1995). Established methods for isolating recombinant proteins from a baculovirus system are described by Richardson (ed.), *Baculovirus Expression Protocols* (The Humana Press, Inc., 1995).

[0114] More generally, TGF-beta binding-protein can be isolated by standard techniques, such as affinity chromatography, size exclusion chromatography, ion exchange chromatography, HPLC and the like. Additional variations in TGF-beta binding-protein isolation and purification can be devised by those of skill in the art. For example, anti-TGF-beta binding-protein antibodies, obtained as described below, can be used to isolate large quantities of protein by immunoaffinity purification.

5. Production of Antibodies to TGF-beta binding-proteins

[0115] Antibodies to TGF-beta binding-protein can be obtained, for example, using the product of an expression vector as an antigen. Particularly useful anti-TGF-beta binding-protein antibodies "bind specifically" with TGF-beta binding-protein of Sequence ID Nos. 2, 6, 10, 12, 14, or 16, but not to other TGF-beta binding-proteins such as Dan, Cerberus, SCGF, or Gremlin. Antibodies of the present invention (including fragments and derivatives thereof) may be a polyclonal or, especially a monoclonal antibody. The antibody may belong to any immunoglobulin class, and may be for example an IgG, for example IgG₁, IgG₂, IgG₃, IgG₄; IgE; IgM; or IgA antibody. It may be of animal, for example mammalian origin, and may be for example a murine, rat, human or other primate antibody. Where desired the antibody may be an internalising antibody.

[0116] Polyclonal antibodies to recombinant TGF-beta binding-protein can be prepared using methods well-known to those of skill in the art (see, for example, Green et al., "Production of Polyclonal Antisera," in *Immunochemical Protocols* (Manson, ed.), pages 1-5 (Humana Press 1992); Williams et al., "Expression of foreign proteins in *E. coli* using plasmid vectors and purification of specific polyclonal antibodies," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), page 15 (Oxford University Press 1995)). Although polyclonal antibodies are typically raised in animals such as rats, mice, rabbits, goats, or sheep, an anti-TGF-beta binding-protein antibody of the present invention may also be derived from a subhuman primate antibody. General techniques for raising diagnostically and therapeutically useful antibodies in baboons may be found, for example, in Goldenberg et al., international patent publication No. WO 91/11465 (1991), and in Losman et al., *Int. J. Cancer* 46:310, 1990.

[0117] The antibody should comprise at least a variable region domain. The variable region domain may be of any size or amino acid composition and will generally comprise at least one hypervariable amino acid sequence responsible for antigen binding embedded in a framework sequence. In general terms the variable (V) region domain may be any suitable arrangement of immunoglobulin heavy (V_H) and/or light (V_L) chain variable domains. Thus for example the V region domain may be monomeric and be a V_H or V_L domain where these are capable of

independently binding antigen with acceptable affinity. Alternatively the V region domain may be dimeric and contain V_H - V_H , V_H - V_L , or V_L - V_L , dimers in which the V_H and V_L chains are non-covalently associated (abbreviated hereinafter as F_v). Where desired, however, the chains may be covalently coupled either directly, for example via a disulphide bond between the two variable domains, or through a linker, for example a peptide linker, to form a single chain domain (abbreviated hereinafter as scF_v).

[0118] The variable region domain may be any naturally occurring variable domain or an engineered version thereof. By engineered version is meant a variable region domain which has been created using recombinant DNA engineering techniques. Such engineered versions include those created for example from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies. Particular examples of this type include those engineered variable region domains containing at least one CDR and optionally one or more framework amino acids from one antibody and the remainder of the variable region domain from a second antibody.

[0119] The variable region domain may be covalently attached at a C-terminal amino acid to at least one other antibody domain or a fragment thereof. Thus, for example where a V_H domain is present in the variable region domain this may be linked to an immunoglobulin C_H1 domain or a fragment thereof. Similarly a V_L domain may be linked to a C_K domain or a fragment thereof. In this way for example the antibody may be a Fab fragment wherein the antigen binding domain contains associated V_H and V_L domains covalently linked at their C-termini to a $CH1$ and C_K domain respectively. The $CH1$ domain may be extended with further amino acids, for example to provide a hinge region domain as found in a Fab' fragment, or to provide further domains, such as antibody $CH2$ and $CH3$ domains.

[0120] Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells (see, for example, Larrick et al., *Methods: A Companion to Methods in Enzymology* 2:106, 1991; Courtenay-Luck, "Genetic Manipulation of Monoclonal Antibodies," in *Monoclonal Antibodies: Production, Engineering and Clinical Application*, Ritter et al. (eds.), page 166 (Cambridge University Press 1995); and Ward et al., "Genetic Manipulation and Expression of Antibodies," in *Monoclonal Antibodies: Principles and Applications*, Birch et al., (eds.), page 137 (Wiley-Liss, Inc. 1995)).

[0121] Antibodies for use in the invention may in general be monoclonal (prepared by conventional immunisation and cell fusion procedures) or in the case of fragments, derived therefrom using any suitable standard chemical e.g. reduction or enzymatic cleavage and/or digestion techniques, for example by treatment with pepsin.

[0122] More specifically, monoclonal anti-TGF-beta binding-protein antibodies can be

generated utilizing a variety of techniques. Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art (see, for example, Kohler et al., *Nature* 256:495, 1975; and Coligan et al. (eds.), *Current Protocols in Immunology*, 1:2.5.1-2.6.7 (John Wiley & Sons 1991) ["Coligan"]; Picklesley et al., "Production of monoclonal antibodies against proteins expressed in *E. coli*," in *DNA Cloning 2: Expression Systems*, 2nd Edition, Glover et al. (eds.), page 93 (Oxford University Press 1995)).

[0123] Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising a TGF-beta binding-protein gene product, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

[0124] In addition, an anti-TGF-beta binding-protein antibody of the present invention may be derived from a human monoclonal antibody. Human monoclonal antibodies are obtained from transgenic mice that have been engineered to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described, for example, by Green et al., *Nature Genet.* 7:13, 1994; Lonberg et al., *Nature* 368:856, 1994; and Taylor et al., *Int. Immun.* 6:579, 1994.

[0125] Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography (see, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3; Baines et al., "Purification of Immunoglobulin G (IgG)," in *Methods in Molecular Biology*, Vol. 10, pages 79-104 (The Humana Press, Inc. 1992)).

[0126] For particular uses, it may be desirable to prepare fragments of anti-TGF-beta binding-protein antibodies. Such antibody fragments can be obtained, for example, by proteolytic hydrolysis of the antibody. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As an illustration, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted $F(ab')_2$. This fragment can be further cleaved using a thiol reducing agent to produce 3.5S Fab' monovalent fragments. Optionally, the cleavage reaction can be performed using a blocking group for the sulfhydryl groups that result from cleavage of disulfide linkages. As an alternative, an enzymatic cleavage using pepsin produces two monovalent Fab fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patent No. 4,331,647, Nisonoff et al., *Arch Biochem. Biophys.* 89:230, 1960, Porter, *Biochem. J.* 73:119, 1959, Edelman et al., in *Methods in Enzymology* 1:422 (Academic Press 1967), and

by Coligan at pages 2.8.1-2.8.10 and 2.10.-2.10.4.

[0127] Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

[0128] Alternatively, the antibody may be a recombinant or engineered antibody obtained by the use of recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and/or constant regions. Such DNA is known and/or is readily available from DNA libraries including for example phage-antibody libraries (see Chiswell, D J and McCafferty, J. *Tibtech.* 10 80-84 (1992)) or where desired can be synthesised. Standard molecular biology and/or chemistry procedures may be used to sequence and manipulate the DNA, for example, to introduce codons to create cysteine residues, to modify, add or delete other amino acids or domains as desired.

[0129] From here, one or more replicable expression vectors containing the DNA may be prepared and used to transform an appropriate cell line, e.g. a non-producing myeloma cell line, such as a mouse NSO line or a bacterial, e.g. *E.coli* line, in which production of the antibody will occur. In order to obtain efficient transcription and translation, the DNA sequence in each vector should include appropriate regulatory sequences, particularly a promoter and leader sequence operably linked to the variable domain sequence. Particular methods for producing antibodies in this way are generally well known and routinely used. For example, basic molecular biology procedures are described by Maniatis et al (*Molecular Cloning*, Cold Spring Harbor Laboratory, New York, 1989); DNA sequencing can be performed as described in Sanger et al (*PNAS* 74, 5463, (1977)) and the Amersham International plc sequencing handbook; and site directed mutagenesis can be carried out according to the method of Kramer et al (*Nucl. Acids Res.* 12, 9441, (1984)) and the Anglian Biotechnology Ltd handbook. Additionally, there are numerous publications, detailing techniques suitable for the preparation of antibodies by manipulation of DNA, creation of expression vectors and transformation of appropriate cells, for example as reviewed by Mountain A and Adair, J R in *Biotechnology and Genetic Engineering Reviews* (ed. Tombs, M P, 10, Chapter 1, 1992, Intercept, Andover, UK) and in International Patent Specification No. WO 91/09967.

[0130] Where desired, the antibody according to the invention may have one or more effector or reporter molecules attached to it and the invention extends to such modified proteins. The effector or reporter molecules may be attached to the antibody through any available amino acid side-chain, terminal amino acid or, where present carbohydrate functional group located in the antibody, always provided of course that this does not adversely affect the binding properties and eventual usefulness of the molecule. Particular functional groups include, for example any free amino, imino, thiol, hydroxyl, carboxyl or aldehyde group. Attachment of the antibody and the effector and/or reporter molecule(s) may be achieved via such groups and an appropriate functional group in the effector or reporter molecules. The linkage may be direct or indirect, through spacing or bridging groups.

[0131] Effector molecules include, for example, antineoplastic agents, toxins (such as enzymatically active toxins of bacterial or plant origin and fragments thereof e.g. ricin and fragments thereof) biologically active proteins, for example enzymes, nucleic acids and fragments thereof, e.g. DNA, RNA and fragments thereof, naturally occurring and synthetic polymers e.g. polysaccharides and polyalkylene polymers such as poly(ethylene glycol) and derivatives thereof, radionuclides, particularly radioiodide, and chelated metals. Suitable reporter groups include chelated metals, fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.

[0132] Particular antineoplastic agents include cytotoxic and cytostatic agents, for example alkylating agents, such as nitrogen mustards (e.g. chlorambucil, melphalan, mechlorethamine, cyclophosphamide, or uracil mustard) and derivatives thereof, triethylenephosphoramidate, triethylenethiophosphor-amide, busulphan, or cisplatin; antimetabolites, such as methotrexate, fluorouracil, floxuridine, cytarabine, mercaptopurine, thioguanine, fluoroacetic acid or fluorocitric acid, antibiotics, such as bleomycins (e.g. bleomycin sulphate), doxorubicin, daunorubicin, mitomycins (e.g. mitomycin C), actinomycins (e.g. dactinomycin) plicamycin, calichaemicin and derivatives thereof, or esperamicin and derivatives thereof; mitotic inhibitors, such as etoposide, vincristine or vinblastine and derivatives thereof; alkaloids, such as ellipticine; polyols such as taxicin-I or taxicin-II; hormones, such as androgens (e.g. dromostanolone or testolactone), progestins (e.g. megestrol acetate or medroxyprogesterone acetate), estrogens (e.g. dimethylstilbestrol diphosphate, polyestradiol phosphate or estramustine phosphate) or antiestrogens (e.g. tamoxifen); anthraquinones, such as mitoxantrone, ureas, such as hydroxyurea; hydrazines, such as procarbazine; or imidazoles, such as dacarbazine.

[0133] Particularly useful effector groups are calichaemicin and derivatives thereof (see for example South African Patent Specifications Nos. 85/8794, 88/8127 and 90/2839).

[0134] Chelated metals include chelates of di-or tripositive metals having a coordination number from 2 to 8 inclusive. Particular examples of such metals include technetium (Tc), rhenium (Re), cobalt (Co), copper (Cu), gold (Au), silver (Ag), lead (Pb), bismuth (Bi), indium (In), gallium (Ga), yttrium (Y), terbium (Tb), gadolinium (Gd), and scandium (Sc). In general the metal is preferably a radionuclide. Particular radionuclides include ^{99m}Tc , ^{186}Re , ^{188}Re , ^{58}Co , ^{60}Co , ^{67}Cu , ^{195}Au , ^{199}Au , ^{110}Ag , ^{203}Pb , ^{206}Bi , ^{207}Bi , ^{111}In , ^{67}Ga , ^{68}Ga , ^{88}Y , ^{90}Y , ^{160}Tb , ^{153}Gd and ^{47}Sc .

[0135] The chelated metal may be for example one of the above types of metal chelated with any suitable polydentate chelating agent, for example acyclic or cyclic polyamines, polyethers, (e.g. crown ethers and derivatives thereof); polyamides; porphyrins; and carbocyclic derivatives.

[0136] In general, the type of chelating agent will depend on the metal in use. One particularly useful group of chelating agents in conjugates according to the invention, however, are acyclic

and cyclic polyamines, especially polyaminocarboxylic acids, for example diethylenetriaminepentaacetic acid and derivatives thereof, and macrocyclic amines, e.g. cyclic tri-aza and tetra-aza derivatives (for example as described in International Patent Specification No. WO 92/22583); and polyamides, especially desferrioxamine and derivatives thereof.

[0137] Thus for example when it is desired to use a thiol group in the antibody as the point of attachment this may be achieved through reaction with a thiol reactive group present in the effector or reporter molecule. Examples of such groups include an α -halocarboxylic acid or ester, e.g. iodoacetamide, an imide, e.g. maleimide, a vinyl sulphone, or a disulphide. These and other suitable linking procedures are generally and more particularly described in International Patent Specifications Nos. WO 93/06231, WO 92/22583, WO 90/091195 and WO 89/01476.

ASSAYS FOR SELECTING MOLECULES WHICH INCREASE BONE DENSITY

[0138] As discussed above, the present disclosure provides methods for selecting and/or isolating compounds which are capable of increasing bone density. For example, within one aspect of the present disclosure methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing a selected molecule with TGF-beta binding protein and a selected member of the TGF-beta family of proteins, (b) determining whether the selected molecule stimulates signaling by the TGF-beta family of proteins, or inhibits the binding of the TGF-beta binding protein to the TGF-beta family of proteins. Within certain embodiments of the disclosure, the molecule enhances the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation.

[0139] Within other aspects of the disclosure methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) exposing a selected molecule to cells which express TGF-beta binding-protein and (b) determining whether the expression (or activity) of TGF-beta binding-protein from said exposed cells decreases, and therefrom determining whether the compound is capable of increasing bone mineral content. Within one embodiment of the disclosure, the cells are selected from the group consisting of the spontaneously transformed or untransformed normal human bone from bone biopsies and rat parietal bone osteoblasts. Such methods may be accomplished in a wide variety of assay formats including, for example, Countercurrent Immuno-Electrophoresis (CIEP), Radioimmunoassays, Radioimmunoprecipitations, Enzyme-Linked Immuno-Sorbent Assays (ELISA), Dot Blot assays, Inhibition or Competition assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see also *Antibodies: A Laboratory Manual*, *supra*).

[0140] Representative embodiments of such assays are provided below in Examples 5 and 6. Briefly, a family member of the TGF-beta super-family or a TGF-beta binding protein is first bound to a solid phase, followed by addition of a candidate molecule. The labeled family member of the TGF-beta super-family or a TGF-beta binding protein is then added to the

assay, the solid phase washed, and the quantity of bound or labeled TGF-beta super-family member or TGF-beta binding protein on the solid support determined. Molecules which are suitable for use in increasing bone mineral content as described herein are those molecules which decrease the binding of TGF-beta binding protein to a member or members of the TGF-beta super-family in a statistically significant manner. Obviously, assays suitable for use within the present disclosure should not be limited to the embodiments described within Examples 2 and 3. In particular, numerous parameters may be altered, such as by binding TGF-beta to a solid phase, or by elimination of a solid phase entirely.

[0141] Within other aspects of the disclosure methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) exposing a selected molecule to cells which express TGF-beta and (b) determining whether the activity of TGF-beta from said exposed cells is altered, and therefrom determining whether the compound is capable of increasing bone mineral content. Similar to the above described methods, a wide variety of methods may be utilized to assess the changes of TGF-beta binding-protein expression due to a selected test compound.

[0142] For example, within one aspect of the present disclosure methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the steps of (a) mixing a selected molecule with TGF-beta-binding-protein and a selected member of the TGF-beta family of proteins, (b) determining whether the selected molecule up-regulates the signaling of the TGF-beta family of proteins, or inhibits the binding of the TGF-beta binding-protein to the TGF-beta family of proteins. Within certain embodiments, of the disclosure, the molecule enhances the ability of TGF-beta to function as a positive regulator of mesenchymal cell differentiation.

[0143] Similar to the above described methods, a wide variety of methods may be utilized to assess stimulation of TGF-beta due to a selected test compound. One such representative method is provided below in Example 6 (see also Durham et al., *Endo.* 136:1374-1380).

[0144] Within yet other aspects of the present disclosure, methods are provided for determining whether a selected molecule is capable of increasing bone mineral content, comprising the step of determining whether a selected molecule inhibits the binding of TGF-beta binding-protein to bone, or an analogue thereof. As utilized herein, it should be understood that bone or analogues thereof refers to hydroxyapatite, or a surface composed of a powdered form of bone, crushed bone or intact bone. Similar to the above described methods, a wide variety of methods may be utilized to assess the inhibition of TGF-beta binding-protein localization to bone matrix. One such representative method is provided below in Example 7.

[0145] It should be noted that while the methods recited herein may refer to the analysis of an individual test molecule, that the present disclosure should not be so limited. In particular, the selected molecule may be contained within a mixture of compounds. Hence, the recited methods may further comprise the step of isolating a molecule which inhibits the binding of

TGF-beta binding-protein to a TGF-beta family member.

CANDIDATE MOLECULES

[0146] A wide variety of molecules may be assayed for their ability to inhibit the binding of TGF-beta binding-protein to a TGF-beta family member. Representative examples which are discussed in more detail below include organic molecules, proteins or peptides, and nucleic acid molecules. Although it should be evident from the discussion below that the candidate molecules described herein may be utilized in the assays described herein, it should also be readily apparent that such molecules can also be utilized in a variety of diagnostic and therapeutic settings.

1. Organic Molecules

[0147] Numerous organic molecules may be assayed for their ability to inhibit the binding of TGF-beta binding-protein to a TGF-beta family member

[0148] For example, within one embodiment of the disclosure suitable organic molecules may be selected from either a chemical library, wherein chemicals are assayed individually, or from combinatorial chemical libraries where multiple compounds are assayed at once, then deconvoluted to determine and isolate the most active compounds.

[0149] Representative examples of such combinatorial chemical libraries include those described by Agrafiotis et al., "System and method of automatically generating chemical compounds with desired properties," U.S. Patent No. 5,463,564; Armstrong, R.W., "Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses," WO 95/02566; Baldwin, J.J. et al., "Sulfonamide derivatives and their use," WO 95/24186; Baldwin, J.J. et al., "Combinatorial dihydrobenzopyran library," WO 95/30642; Brenner, S., "New kit for preparing combinatorial libraries," WO 95/16918; Chenera, B. et al., "Preparation of library of resin-bound aromatic carbocyclic compounds," WO 95/16712; Ellman, J.A., "Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support," U.S. Patent No. 5,288,514; Felder, E. et al., "Novel combinatorial compound libraries," WO 95/16209; Lerner, R. et al., "Encoded combinatorial chemical libraries," WO 93/20242; Pavia, M.R. et al., "A method for preparing and selecting pharmaceutically useful non-peptide compounds from a structurally diverse universal library," WO 95/04277; Summerton, J.E. and D.D. Weller, "Morpholino-subunit combinatorial library and method," U.S. Patent No. 5,506,337; Holmes, C., "Methods for the Solid Phase Synthesis of Thiazolidinones, Metathiazanones, and Derivatives thereof," WO 96/00148; Phillips, G.B. and G.P. Wei, "Solid-phase Synthesis of Benzimidazoles," Tet. Letters 37:4887-90, 1996; Ruhland, B. et al., "Solid-supported Combinatorial Synthesis of Structurally Diverse β -Lactams," J. Amer. Chem. Soc. 111:253-4, 1996; Look, G.C. et al., "The Identification of Cyclooxygenase-1

Inhibitors from 4-Thiazolidinone Combinatorial Libraries," Bioorg and Med. Chem. Letters 6:707-12, 1996.

2. Proteins and Peptides

[0150] A wide range of proteins and peptides may likewise be utilized as candidate molecules for inhibitors of the binding of TGF-beta binding-protein to a TGF-beta family member.

a. Combinatorial Peptide Libraries

[0151] Peptide molecules which are putative inhibitors of the binding of TGF-beta binding-protein to a TGF-beta family member may be obtained through the screening of combinatorial peptide libraries. Such libraries may either be prepared by one of skill in the art (see e.g., U.S. Patent Nos. 4,528,266 and 4,359,535, and Patent Cooperation Treaty Publication Nos. WO 92/15679, WO 92/15677, WO 90/07862, WO 90/02809, or purchased from commercially available sources (e.g., New England Biolabs Ph.D.™ Phage Display Peptide Library Kit).

b. Antibodies

[0152] Antibodies which inhibit the binding of TGF-beta binding-protein to a TGF-beta family member may readily be prepared given the disclosure provided herein. Within the context of the present invention, antibodies are understood to include monoclonal antibodies, polyclonal antibodies, anti-idiotypic antibodies, antibody fragments (e.g., Fab, and F(ab')₂, F_V variable regions, or complementarity determining regions). As discussed above, antibodies are understood to be specific against TGF-beta binding-protein, or against a specific TGF-beta family member, if they bind with a K_a of greater than or equal to 10⁷M, preferably greater than or equal to 10⁸M, and do not bind to other TGF-beta binding-proteins, or, bind with a K_a of less than or equal to 10⁶M. Furthermore, antibodies of the present invention should block or inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

[0153] The affinity of a monoclonal antibody or binding partner, as well as inhibition of binding can be readily determined by one of ordinary skill in the art (see Scatchard, Ann. N.Y. Acad. Sci. 51:660-672, 1949).

[0154] Briefly, polyclonal antibodies may be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows, various fowl, rabbits, mice, or rats. Typically, the TGF-beta binding-protein or unique peptide thereof of 13-20 amino acids (preferably conjugated to keyhole limpet hemocyanin by cross-linking with glutaraldehyde) is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or

subcutaneous injections, along with an adjuvant such as Freund's complete or incomplete adjuvant. Following several booster immunizations, samples of serum are collected and tested for reactivity to the protein or peptide. Particularly preferred polyclonal antisera will give a signal on one of these assays that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the protein, larger quantities of antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal.

[0155] Monoclonal antibodies may also be readily generated using conventional techniques (see U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993 which are incorporated herein by reference; see *also* Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988, which are also incorporated herein by reference).

[0156] Briefly, within one embodiment a subject animal such as a rat or mouse is immunized with TGF-beta binding-protein or portion thereof as described above. The protein may be admixed with an adjuvant such as Freund's complete or incomplete adjuvant in order to increase the resultant immune response. Between one and three weeks after the initial immunization the animal may be reimmunized with another booster immunization, and tested for reactivity to the protein utilizing assays described above. Once the animal has reached a plateau in its reactivity to the injected protein, it is sacrificed, and organs which contain large numbers of B cells such as the spleen and lymph nodes are harvested.

[0157] Cells which are obtained from the immunized animal may be immortalized by infection with a virus such as the Epstein-Barr virus (EBV) (see Glasky and Reading, Hybridoma 8(4):377-389, 1989). Alternatively, within a preferred embodiment, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibody. Suitable myeloma lines include, for example, NS-1 (ATCC No. TIB 18), and P3X63 - Ag 8.653 (ATCC No. CRL 1580).

[0158] Following the fusion, the cells may be placed into culture plates containing a suitable medium, such as RPMI 1640, or DMEM (Dulbecco's Modified Eagles Medium) (JRH Biosciences, Lenexa, Kansas), as well as additional ingredients, such as fetal bovine serum (FBS, *i.e.*, from Hyclone, Logan, Utah, or JRH Biosciences). Additionally, the medium should contain a reagent which selectively allows for the growth of fused spleen and myeloma cells such as HAT (hypoxanthine, aminopterin, and thymidine) (Sigma Chemical Co., St. Louis, Missouri). After about seven days, the resulting fused cells or hybridomas may be screened in order to determine the presence of antibodies which are reactive against TGF-beta binding-protein (depending on the antigen used), and which block or inhibit the binding of TGF-beta binding-protein to a TGF-beta family member.

[0159] A wide variety of assays may be utilized to determine the presence of antibodies which are reactive against the proteins of the present invention, including for example countercurrent

immuno-electrophoresis, radioimmunoassays, radioimmunoprecipitations, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, western blots, immunoprecipitation, inhibition or competition assays, and sandwich assays (see U.S. Patent Nos. 4,376,110 and 4,486,530; see *also* Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988). Following several clonal dilutions and reassays, a hybridoma producing antibodies reactive against the desired protein may be isolated.

[0160] Other techniques may also be utilized to construct monoclonal antibodies (see William D. Huse et al., "Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage Lambda," *Science* 246:1275-1281, December 1989; see *also* L. Sastry et al., "Cloning of the Immunological Repertoire in *Escherichia coli* for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA Library," *Proc. Natl. Acad. Sci. USA* 86:5728-5732, August 1989; see *also* Michelle Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas," *Strategies in Molecular Biology* 3:1-9, January 1990). These references describe a commercial system available from Stratagene (La Jolla, California) which enables the production of antibodies through recombinant techniques. Briefly, mRNA is isolated from a B cell population, and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in the λ ImmunoZap(H) and λ ImmunoZap(L) vectors. These vectors may be screened individually or co-expressed to form Fab fragments or antibodies (see Huse et al., *supra*; see *also* Sastry et al., *supra*). Positive plaques may subsequently be converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments from *E. coli*.

[0161] Similarly, portions or fragments, such as Fab and Fv fragments, of antibodies may also be constructed utilizing conventional enzymatic digestion or recombinant DNA techniques to incorporate the variable regions of a gene which encodes a specifically binding antibody. Within one embodiment, the genes which encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using nucleotide primers for the variable region. These primers may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources. Stratagene (La Jolla, California) sells primers for mouse and human variable regions including, among others, primers for $V_{H\alpha}$, $V_{H\beta}$, $V_{H\gamma}$, $V_{H\delta}$, C_{H1} , V_L and C_L regions. These primers may be utilized to amplify heavy or light chain variable regions, which may then be inserted into vectors such as ImmunoZAP™ H or ImmunoZAP™ L (Stratagene), respectively. These vectors may then be introduced into *E. coli*, yeast, or mammalian-based systems for expression. Utilizing these techniques, large amounts of a single-chain protein containing a fusion of the V_H and V_L domains may be produced (see Bird et al., *Science* 242:423-426, 1988). In addition, such techniques may be utilized to change a "murine" antibody to a "human" antibody, without altering the binding specificity of the antibody.

[0162] Once suitable antibodies have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques.

c. Mutant TGF-beta binding-proteins

[0163] As described herein and below in the Examples (e.g., Examples 8 and 9), altered versions of TGF-beta binding-protein which compete with native TGF-beta binding-protein's ability to block the activity of a particular TGF-beta family member should lead to increased bone density. Thus, mutants of TGF-beta binding-protein which bind to the TGF-beta family member but do not inhibit the function of the TGF-beta family member would meet the criteria. The mutant versions must effectively compete with the endogenous inhibitory functions of TGF-beta binding-protein.

d. Production of proteins

[0164] Although various genes (or portions thereof) have been provided herein, it should be understood that within the context of the present disclosure, reference to one or more of these genes includes derivatives of the genes that are substantially similar to the genes (and, where appropriate, the proteins (including peptides and polypeptides) that are encoded by the genes and their derivatives). As used herein, a nucleotide sequence is deemed to be "substantially similar" if: (a) the nucleotide sequence is derived from the coding region of the above-described genes and includes, for example, portions of the sequence or allelic variations of the sequences discussed above, or alternatively, encodes a molecule which inhibits the binding of TGF-beta binding-protein to a member of the TGF-beta family, (b) the nucleotide sequence is capable of hybridization to nucleotide sequences of the present invention under moderate, high or very high stringency (see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, NY, 1989); or (c) the DNA sequences are degenerate as a result of the genetic code to the DNA sequences defined in (a) or (b). Further, the nucleic acid molecule disclosed herein includes both complementary and non-complementary sequences, provided the sequences otherwise meet the criteria set forth herein. Within the context of the present invention, high stringency means standard hybridization conditions (e.g., 5XSSPE, 0.5% SDS at 65°C, or the equivalent).

[0165] The structure of the proteins encoded by the nucleic acid molecules described herein may be predicted from the primary translation products using the hydrophobicity plot function of, for example, P/C Gene or Intelligenetics Suite (Intelligenetics, Mountain View, California), or according to the methods described by Kyte and Doolittle (*J. Mol. Biol.* 157:105-132, 1982).

[0166] Proteins of the present disclosure may be prepared in the form of acidic or basic salts, or in neutral form. In addition, individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions, or additions may be made to the amino acid or nucleic acid sequences, the net effect of which is to retain or further enhance or decrease the biological activity of the mutant or wild-type protein. Moreover, due to

degeneracy in the genetic code, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid sequence.

[0167] Other derivatives of the proteins disclosed herein include conjugates of the proteins along with other proteins or polypeptides. This may be accomplished, for example, by the synthesis of N-terminal or C-terminal fusion proteins which may be added to facilitate purification or identification of proteins (see U.S. Patent No. 4,851,341, *see also*, Hopp et al., Bio/Technology 6:1204, 1988.) Alternatively, fusion proteins such as Flag/TGF-beta binding-protein be constructed in order to assist in the identification, expression, and analysis of the protein.

[0168] Proteins of the present disclosure may be constructed using a wide variety of techniques described herein. Further mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

[0169] Alternatively, oligonucleotide-directed site-specific (or segment specific) mutagenesis procedures may be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required. Exemplary methods of making the alterations set forth above are disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); and Sambrook et al. (*supra*). Deletion or truncation derivatives of proteins (e.g., a soluble extracellular portion) may also be constructed by utilizing convenient restriction endonuclease sites adjacent to the desired deletion. Subsequent to restriction, overhangs may be filled in, and the DNA religated. Exemplary methods of making the alterations set forth above are disclosed by Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, 1989).

[0170] Mutations which are made in the nucleic acid molecules of the present disclosure preferably preserve the reading frame of the coding sequences. Furthermore, the mutations will preferably not create complementary regions that could hybridize to produce secondary mRNA structures, such as loops or hairpins, that would adversely affect translation of the mRNA. Although a mutation site may be predetermined, it is not necessary that the nature of the mutation *per se* be predetermined. For example, in order to select for optimum characteristics of mutants at a given site, random mutagenesis may be conducted at the target codon and the expressed mutants screened for indicative biological activity. Alternatively, mutations may be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes a derivative having the desired amino acid insertion, substitution, or deletion.

[0171] Nucleic acid molecules which encode proteins of the present disclosure may also be

constructed utilizing techniques of PCR mutagenesis, chemical mutagenesis (Drinkwater and Klinedinst, PNAS 83:3402-3406, 1986), by forced nucleotide misincorporation (e.g., Liao and Wise Gene 88:107-111, 1990), or by use of randomly mutagenized oligonucleotides (Horwitz et al., Genome 3:112-117, 1989).

[0172] The present disclosure also provides for the manipulation and expression of the above described genes by culturing host cells containing a vector capable of expressing the above-described genes. Such vectors or vector constructs include either synthetic or cDNA-derived nucleic acid molecules encoding the desired protein, which are operably linked to suitable transcriptional or translational regulatory elements. Suitable regulatory elements may be derived from a variety of sources, including bacterial, fungal, viral, mammalian, insect, or plant genes. Selection of appropriate regulatory elements is dependent on the host cell chosen, and may be readily accomplished by one of ordinary skill in the art. Examples of regulatory elements include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a transcriptional terminator, and a ribosomal binding sequence, including a translation initiation signal.

[0173] Nucleic acid molecules that encode any of the proteins described above may be readily expressed by a wide variety of prokaryotic and eukaryotic host cells, including bacterial, mammalian, yeast or other fungi, viral, insect, or plant cells. Methods for transforming or transfecting such cells to express foreign DNA are well known in the art (see, e.g., Itakura et al., U.S. Patent No. 4,704,362; Hinnen et al., Proc. Natl. Acad. Sci. USA 75:1929-1933, 1978; Murray et al., U.S. Patent No. 4,801,542; Upshall et al., U.S. Patent No. 4,935,349; Hagen et al., U.S. Patent No. 4,784,950; Axel et al., U.S. Patent No. 4,399,216; Goeddel et al., U.S. Patent No. 4,766,075; and Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, 1989; for plant cells see Czako and Marton, Plant Physiol. 104:1067-1071, 1994; and Paszkowski et al., Biotech. 24:387-392, 1992).

[0174] Bacterial host cells suitable for carrying out the present disclosure include *E. coli*, *B. subtilis*, *Salmonella typhimurium*, and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, as well as many other bacterial species well known to one of ordinary skill in the art. Representative examples of bacterial host cells include DH5 α (Stratagene, LaJolla, California).

[0175] Bacterial expression vectors preferably comprise a promoter which functions in the host cell, one or more selectable phenotypic markers, and a bacterial origin of replication. Representative promoters include the β -lactamase (penicillinase) and lactose promoter system (see Chang et al., Nature 275:615, 1978), the T7 RNA polymerase promoter (Studier et al., Meth. Enzymol. 185:60-89, 1990), the lambda promoter (Elvin et al., Gene 87:123-126, 1990), the *trp* promoter (Nichols and Yanofsky, Meth. in Enzymology 101:155, 1983) and the *tac* promoter (Russell et al., Gene 20:231, 1982). Representative selectable markers include various antibiotic resistance markers such as the kanamycin or ampicillin resistance genes. Many plasmids suitable for transforming host cells are well known in the art, including among others, pBR322 (see Bolivar et al., Gene 2:95, 1977), the pUC plasmids pUC18, pUC19,

pUC118, pUC119 (see Messing, Meth. in Enzymology 101:20-77, 1983 and Vieira and Messing, Gene 19:259-268, 1982), and pNH8A, pNH16a, pNH18a, and Bluescript M13 (Stratagene, La Jolla, California).

[0176] Yeast and fungi host cells suitable for carrying out the present disclosure include, among others, *Saccharomyces pombe*, *Saccharomyces cerevisiae*, the genera *Pichia* or *Kluyveromyces* and various species of the genus *Aspergillus* (McKnight et al., U.S. Patent No. 4,935,349). Suitable expression vectors for yeast and fungi include, among others, YCp50 (ATCC No. 37419) for yeast, and the amdS cloning vector pV3 (Turnbull, Bio/Technology 7:169, 1989), YRp7 (Struhl et al., Proc. Natl Acad. Sci. USA 76:1035-1039, 1978), YEp13 (Broach et al., Gene 8:121-133, 1979), pJDB249 and pJDB219 (Beggs, Nature 275:104-108, 1978) and derivatives thereof.

[0177] Preferred promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem. 255:12073-12080, 1980; Alber and Kawasaki, J. Mol. Appl. Genet. 1:419-434, 1982) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, Meth. Enzymol. 101:192-201, 1983). Examples of useful promoters for fungi vectors include those derived from *Aspergillus nidulans* glycolytic genes, such as the *adh3* promoter (McKnight et al., EMBO J. 4:2093-2099, 1985). The expression units may also include a transcriptional terminator. An example of a suitable terminator is the *adh3* terminator (McKnight et al.; *ibid.*, 1985).

[0178] As with bacterial vectors, the yeast vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant phenotype for which a phenotypic assay exists to enable transformants to be selected. Preferred selectable markers are those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include *leu2* (Broach et al., *ibid.*), *ura3* (Botstein et al., Gene 8:17, 1979), or *his3* (Struhl et al., *ibid.*). Another suitable selectable marker is the *cat* gene, which confers chloramphenicol resistance on yeast cells.

[0179] Techniques for transforming fungi are well known in the literature, and have been described, for instance, by Beggs (*ibid.*), Hinnen et al. (Proc. Natl. Acad. Sci. USA 75:1929-1933, 1978), Yelton et al. (Proc. Natl. Acad. Sci. USA 81:1740-1747, 1984), and Russell (Nature 301:167-169, 1983). The genotype of the host cell may contain a genetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art.

[0180] Protocols for the transformation of yeast are also well known to those of ordinary skill in the art. For example, transformation may be readily accomplished either by preparation of spheroplasts of yeast with DNA (see Hinnen et al., PNAS USA 75:1929, 1978) or by treatment with alkaline salts such as LiCl (see Itoh et al., J. Bacteriology 153:163, 1983). Transformation of fungi may also be carried out using polyethylene glycol as described by Cullen et al. (Bio/Technology 5:369, 1987).

[0181] Viral vectors include those which comprise a promoter that directs the expression of an isolated nucleic acid molecule that encodes a desired protein as described above. A wide variety of promoters may be utilized within the context of the present invention, including for example, promoters such as MoMLV LTR, RSV LTR, Friend MuLV LTR, adenoviral promoter (Ohno et al., Science 265:781-784, 1994), neomycin phosphotransferase promoter/enhancer, late parvovirus promoter (Koering et al., Hum. Gene Therap. 5:457-463, 1994), Herpes TK promoter, SV40 promoter, metallothionein IIa gene enhancer/promoter, cytomegalovirus immediate early promoter, and the cytomegalovirus immediate late promoter. Within particularly preferred embodiments of the disclosure, the promoter is a tissue-specific promoter (see e.g., WO 91/02805; EP 0,415,731; and WO 90/07936). Representative examples of suitable tissue specific promoters include neural specific enolase promoter, platelet derived growth factor beta promoter, bone morphogenic protein promoter, human alpha1-chimaerin promoter, synapsin I promoter and synapsin II promoter. In addition to the above-noted promoters, other viral-specific promoters (e.g., retroviral promoters (including those noted above, as well as others such as HIV promoters), hepatitis, herpes (e.g., EBV), and bacterial, fungal or parasitic (e.g., malarial) -specific promoters may be utilized in order to target a specific cell or tissue which is infected with a virus, bacteria, fungus or parasite.

[0182] Mammalian cells suitable for carrying out the present disclosure include, among others COS, CHO, SaOS, osteosarcomas, KS483, MG-63, primary osteoblasts, and human or mammalian bone marrow stroma. Mammalian expression vectors for use in carrying out the present disclosure will include a promoter capable of directing the transcription of a cloned gene or cDNA. Preferred promoters include viral promoters and cellular promoters. Bone specific promoters include the bone sialo-protein and the promoter for osteocalcin. Viral promoters include the cytomegalovirus immediate early promoter (Boshart et al., Cell 41:521-530, 1985), cytomegalovirus immediate late promoter, SV40 promoter (Subramani et al., Mol. Cell. Biol. 1:854-864, 1981), MMTV LTR, RSV LTR, metallothionein-1, adenovirus E1a. Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), a mouse V_{κ} promoter (Bergman et al., Proc. Natl. Acad. Sci. USA 81:7041-7045, 1983; Grant et al., Nucl. Acids Res. 15:5496, 1987) and a mouse V_H promoter (Loh et al., Cell 33:85-93, 1983). The choice of promoter will depend, at least in part, upon the level of expression desired or the recipient cell line to be transfected.

[0183] Such expression vectors may also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Suitable polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, *ibid.*), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., Nuc. Acids Res. 9:3719-3730, 1981). The expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites. Preferred vectors may also include

enhancer sequences, such as the SV40 enhancer. Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable expression vectors can be obtained from commercial sources (e.g., Stratagene, La Jolla, California).

[0184] Vector constructs comprising cloned DNA sequences can be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987). To identify cells that have stably integrated the cloned DNA, a selectable marker is generally introduced into the cells along with the gene or cDNA of interest. Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. The selectable marker may be an amplifiable selectable marker. Preferred amplifiable selectable markers are the DHFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers, Stoneham, Massachusetts).

[0185] Mammalian cells containing a suitable vector are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest. Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an amplifiable, selectable marker the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels. Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level. Cells that satisfy these criteria can then be cloned and scaled up for production.

[0186] Protocols for the transfection of mammalian cells are well known to those of ordinary skill in the art. Representative methods include calcium phosphate mediated transfection, electroporation, lipofection, retroviral, adenoviral and protoplast fusion-mediated transfection (see Sambrook et al., *supra*). Naked vector constructs can also be taken up by muscular cells or other suitable cells subsequent to injection into the muscle of a mammal (or other animals).

[0187] Numerous insect host cells known in the art can also be useful within the present disclosure, in light of the subject specification. For example, the use of baculoviruses as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. (Pestic. Sci. 28:215-224, 1990).

[0188] Numerous plant host cells known in the art can also be useful within the present disclosure, in light of the subject specification. For example, the use of *Agrobacterium rhizogenes* as vectors for expressing genes in plant cells has been reviewed by Sinkar et al. (J. Biosci. (Bangalore) 11:47-58, 1987).

[0189] Within related aspects of the present disclosure, proteins of the present disclosure may be expressed in a transgenic animal whose germ cells and somatic cells contain a gene which encodes the desired protein and which is operably linked to a promoter effective for the expression of the gene. Alternatively, in a similar manner transgenic animals may be prepared that lack the desired gene (*e.g.*, "knock-out" mice). Such transgenics may be prepared in a variety of non-human animals, including mice, rats, rabbits, sheep, dogs, goats and pigs (see Hammer et al., *Nature* 315:680-683, 1985, Palmiter et al., *Science* 222:809-814, 1983; Brinster et al., *Proc. Natl. Acad. Sci. USA* 82:4438-4442, 1985, Palmiter and Brinster, *Cell* 41:343-345, 1985, and U.S. Patent Nos. 5,175,383, 5,087,571, 4,736,866, 5,387,742, 5,347,075, 5,221,778, and 5,175,384). Briefly, an expression vector, including a nucleic acid molecule to be expressed together with appropriately positioned expression control sequences, is introduced into pronuclei of fertilized eggs, for example, by microinjection. Integration of the injected DNA is detected by blot analysis of DNA from tissue samples. It is preferred that the introduced DNA be incorporated into the germ line of the animal so that it is passed on to the animal's progeny. Tissue-specific expression may be achieved through the use of a tissue-specific promoter, or through the use of an inducible promoter, such as the metallothionein gene promoter (Palmiter et al., 1983, *ibid*), which allows regulated expression of the transgene.

[0190] Proteins can be isolated by, among other methods, culturing suitable host and vector systems to produce the recombinant translation products of the present invention. Supernatants from such cell lines, or protein inclusions or whole cells where the protein is not excreted into the supernatant, can then be treated by a variety of purification procedures in order to isolate the desired proteins. For example, the supernatant may be first concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit. Following concentration, the concentrate may be applied to a suitable purification matrix such as, for example, an anti-protein antibody bound to a suitable support. Alternatively, anion or cation exchange resins may be employed in order to purify the protein. As a further alternative, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps may be employed to further purify the protein. Other methods of isolating the proteins of the present disclosure are well known in the skill of the art.

[0191] A protein is deemed to be "isolated" within the context of the present disclosure if no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by Coomassie blue staining. Within other embodiments, of the disclosure, the desired protein can be isolated such that no other (undesired) protein is detected pursuant to SDS-PAGE analysis followed by silver staining.

3. Nucleic Acid Molecules

[0192] Within other aspects of the disclosure, nucleic acid molecules are provided which are capable of inhibiting TGF-beta binding-protein binding to a member of the TGF-beta family. For example, within one embodiment antisense oligonucleotide molecules are disclosed which specifically inhibit expression of TGF-beta binding-protein nucleic acid sequences (see

generally, Hirashima et al. in *Molecular Biology of RNA: New Perspectives* (M. Inouye and B. S. Dudock, eds., 1987 Academic Press, San Diego, p. 401); *Oligonucleotides: Antisense Inhibitors of Gene Expression* (J.S. Cohen, ed., 1989 MacMillan Press, London); Stein and Cheng, *Science* 261:1004-1012, 1993; WO 95/10607; U.S. Patent No. 5,359,051; WO 92/06693; and EP-A2-612844). Briefly, such molecules are constructed such that they are complementary to, and able to form Watson-Crick base pairs with, a region of transcribed TGF-beta binding-protein mRNA sequence. The resultant double-stranded nucleic acid interferes with subsequent processing of the mRNA, thereby preventing protein synthesis (see Example 10).

[0193] Within other aspects of the disclosure, ribozymes are provided which are capable of inhibiting the TGF-beta binding-protein binding to a member of the TGF-beta family. As used herein, "ribozymes" are intended to include RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity. The catalytic strand cleaves a specific site, in a target RNA at greater than stoichiometric concentration. A wide variety of ribozymes may be utilized within the context of the present disclosure, including for example, the hammerhead ribozyme (for example, as described by Forster and Symons, *Cell* 48:211-220, 1987; Haseloff and Gerlach, *Nature* 325:596-600, 1988; Walbot and Bruening, *Nature* 334:196, 1988; Haseloff and Gerlach, *Nature* 334:585, 1988); the hairpin ribozyme (for example, as described by Haseloff et al., U.S. Patent No. 5,254,678, issued October 19, 1993 and Hempel et al., European Patent Publication No. 0 360 257, published March 26, 1990); and *Tetrahymena* ribosomal RNA-based ribozymes (see Cech et al., U.S. Patent No. 4,987,071). Ribozymes of the present disclosure typically consist of RNA, but may also be composed of DNA, nucleic acid analogs (e.g., phosphorothioates), or chimerics thereof (e.g., DNA/RNA/RNA).

4. Labels

[0194] The gene product or any of the candidate molecules described above and below, may be labeled with a variety of compounds, including for example, fluorescent molecules, toxins, and radionuclides. Representative examples of fluorescent molecules include fluorescein, *Phycobilli* proteins, such as phycoerythrin, rhodamine, Texas red and luciferase. Representative examples of toxins include ricin, abrin diphtheria toxin, cholera toxin, gelonin, pokeweed antiviral protein, tritin, *Shigella* toxin, and *Pseudomonas* exotoxin A. Representative examples of radionuclides include Cu-64, Ga-67, Ga-68, Zr-89, Ru-97, Tc-99m, Rh-105, Pd-109, In-111, I-123, I-125, I-131, Re-186, Re-188, Au-198, Au-199, Pb-203, At-211, Pb-212 and Bi-212. In addition, the antibodies described above may also be labeled or conjugated to one partner of a ligand binding pair. Representative examples include avidin-biotin, and riboflavin-riboflavin binding protein.

[0195] Methods for conjugating or labeling the molecules described herein with the representative labels set forth above may be readily accomplished by one of ordinary skill in the art (see Trichothecene Antibody Conjugate, U.S. Patent No. 4,744,981; Antibody Conjugate, U.S. Patent No. 5,106,951; Fluorogenic Materials and Labeling Techniques, U.S.

Patent No. 4,018,884; Metal Radionuclide Labeled Proteins for Diagnosis and Therapy, U.S. Patent No. 4,897,255; and Metal Radionuclide Chelating Compounds for Improved Chelation Kinetics, U.S. Patent No. 4,988,496; *see also* Inman, Methods In Enzymology, Vol. 34, Affinity Techniques, Enzyme Purification: Part B, Jakoby and Wilchek (eds.), Academic Press, New York, p. 30, 1974; *see also* Wilchek and Bayer, "The Avidin-Biotin Complex in Bioanalytical Applications," Anal. Biochem. 171:1-32, 1988).

PHARMACEUTICAL COMPOSITIONS

[0196] As noted above, the present disclosure also provides a variety of pharmaceutical compositions, comprising one of the above-described molecules which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents. Generally, such carriers should be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents.

[0197] In addition, the pharmaceutical compositions of the present disclosure may be prepared for administration by a variety of different routes. In addition, pharmaceutical compositions may be placed within containers, along with packaging material which provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients or diluents (*e.g.*, water, saline or PBS) which may be necessary to reconstitute the pharmaceutical composition.

TREATMENT

[0198] The present invention also provides for increasing the mineral content and mineral density of bone. Briefly, numerous conditions result in the loss of bone mineral content, including for example, disease, genetic predisposition, accidents which result in the lack of use of bone (*e.g.*, due to fracture), therapeutics which effect bone resorption, or which kill bone forming cells and normal aging. Through use of the molecules described herein which inhibit the TGF-beta binding-protein binding to a TGF-beta family member such conditions may be treated or prevented. As utilized herein, it should be understood that bone mineral content has been increased, if bone mineral content has been increased in a statistically significant manner (*e.g.*, greater than one-half standard deviation), at a selected site.

[0199] A wide variety of conditions which result in loss of bone mineral content may be treated

with the molecules described herein. Patients with such conditions may be identified through clinical diagnosis utilizing well known techniques (see, e.g., Harrison's Principles of Internal Medicine, McGraw-Hill, Inc.). Representative examples of diseases that may be treated included dysplasias, wherein there is abnormal growth or development of bone. Representative examples of such conditions include achondroplasia, cleidocranial dysostosis, enchondromatosis, fibrous dysplasia, Gaucher's, hypophosphatemic rickets, Marfan's, multiple hereditary exostoses, neurofibromatosis, osteogenesis imperfecta, osteopetrosis, osteopoikilosis, sclerotic lesions, fractures, periodontal disease, pseudoarthrosis and pyogenic osteomyelitis.

[0200] Other conditions which may be treated or prevented include a wide variety of causes of osteopenia (*i.e.*, a condition that causes greater than one standard deviation of bone mineral content or density below peak skeletal mineral content at youth). Representative examples of such conditions include anemic states, conditions caused steroids, conditions caused by heparin, bone marrow disorders, scurvy, malnutrition, calcium deficiency, idiopathic osteoporosis, congenital osteopenia or osteoporosis, alcoholism, chronic liver disease, senility, postmenopausal state, oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, hyperthyroidism, Cushing's disease, acromegaly, hypogonadism, immobilization or disuse, reflex sympathetic dystrophy syndrome, transient regional osteoporosis and osteomalacia.

[0201] Within one aspect of the present disclosure, bone mineral content or density may be increased by administering to a warm-blooded animal a therapeutically effective amount of a molecule which inhibits the TGF-beta binding-protein binding to a TGF-beta family member. Examples of warm-blooded animals that may be treated include both vertebrates and mammals, including for example horses, cows, pigs, sheep, dogs, cats, rats and mice. Representative examples of therapeutic molecules include ribozymes, ribozyme genes, antisense oligonucleotides and antibodies (e.g., humanized antibodies).

[0202] Within other aspects of the present disclosure, methods are provided for increasing bone density, comprising the step of introducing into cells which home to bone a vector which directs the expression of a molecule which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family, and administering the vector containing cells to a warm-blooded animal. Briefly, cells which home to bone may be obtained directly from the bone of patients (e.g., cells obtained from the bone marrow such as CD34+, osteoblasts, osteocytes, and the like), from peripheral blood, or from cultures.

[0203] A vector which directs the expression of a molecule that inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family is introduced into the cells. Representative examples of suitable vectors include viral vectors such as herpes viral vectors (e.g., U.S. Patent No. 5,288,641), adenoviral vectors (e.g., WO 94/26914, WO 93/9191; Kolls et al., PNAS 91(1):215-219, 1994; Kass-Eisler et al., PNAS 90(24):11498-502, 1993; Guzman et al., Circulation 88(6):2838-48, 1993; Guzman et al., Cir. Res. 73(6):1202-1207, 1993; Zabner et al., Cell 75(2):207-216, 1993; Li et al., Hum Gene Ther. 4(4):403-409, 1993; Caillaud et al., Eur. J. Neurosci. 5(10):1287-1291, 1993; Vincent et al., Nat. Genet. 5(2):130-134, 1993; Jaffe

et al., Nat. Genet. 1(5):372-378, 1992; and Levrero et al., Gene 101(2):195-202, 1991), adeno-associated viral vectors (WO 95/13365; Flotte et al., PNAS 90(22):10613-10617, 1993), baculovirus vectors, parvovirus vectors (Koering et al., Hum. Gene Therap. 5:457-463, 1994), pox virus vectors (Panicali and Paoletti, PNAS 79:4927-4931, 1982; and Ozaki et al., Biochem. Biophys. Res. Comm. 193(2):653-660, 1993), and retroviruses (e.g., EP 0,415,731; WO 90/07936; WO 91/0285; WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 93/11230; WO 93/10218). Viral vectors may likewise be constructed which contain a mixture of different elements (e.g., promoters, envelope sequences and the like) from different viruses, or non-viral sources. Within various embodiments, either the viral vector itself, or a viral particle which contains the viral vector may be utilized in the methods and compositions described below.

[0204] Within other embodiments of the disclosure, nucleic acid molecules which encode a molecule which inhibits the TGF-beta binding-protein binding to a member of the TGF-beta family themselves may be administered by a variety of techniques, including, for example, administration of asialosomucoid (ASOR) conjugated with poly-L-lysine DNA complexes (Cristano et al., PNAS 92:122-126, 1993), DNA linked to killed adenovirus (Curiel et al., Hum. Gene Ther. 3(2):147-154, 1992), cytofectin-mediated introduction (DMRIE-DOPE, Vical, California), direct DNA injection (Acsadi et al., Nature 352:815-818, 1991); DNA ligand (Wu et al., J. of Biol. Chem. 264:16985-16987, 1989); lipofection (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, 1989); liposomes (Pickering et al., Circ. 89(1):13-21, 1994; and Wang et al., PNAS 84:7851-7855, 1987); microprojectile bombardment (Williams et al., PNAS 88:2726-2730, 1991); and direct delivery of nucleic acids which encode the protein itself either alone (Vile and Hart, Cancer Res. 53: 3860-3864, 1993), or utilizing PEG-nucleic acid complexes.

[0205] Representative examples of molecules which may be expressed by the vectors of present disclosure include ribozymes and antisense molecules, each of which are discussed in more detail above.

[0206] Determination of increased bone mineral content may be determined directly through the use of X-rays (e.g., Dual Energy X-ray Absorptometry or "DEXA"), or by inference through bone turnover markers (osteoblast specific alkaline phosphatase, osteocalcin, type 1 procollagen C' propeptide (PICP), and total alkaline phosphatase; see Comier, C., Curr. Opin. in Rheu. 7:243, 1995), or markers of bone resorption (pyridinoline, deoxypyridinoline, N-telopeptide, urinary hydroxyproline, plasma tartrate-resistant acid phosphatases and galactosyl hydroxylysine; see Comier, *supra*). The amount of bone mass may also be calculated from body weights, or utilizing other methods (see Guinness-Hey, Metab. Bone Dis. and Rel. Res. 5:177-181, 1984).

[0207] As will be evident to one of skill in the art, the amount and frequency of administration will depend, of course, on such factors as the nature and severity of the indication being treated, the desired response, the condition of the patient, and so forth. Typically, the compositions may be administered by a variety of techniques, as noted above.

[0208] The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

EXAMPLE I

SCLEROSTEOSIS MAPS TO THE LONG ARM OF HUMAN CHROMOSOME 17

[0209] Genetic mapping of the defect responsible for sclerosteosis in humans localized the gene responsible for this disorder to the region of human chromosome 17 that encodes a novel TGF-beta binding-protein family member. In sclerosteosis, skeletal bone displays a substantial increase in mineral density relative to that of unaffected individuals. Bone in the head displays overgrowth as well. Sclerosteosis patients are generally healthy although they may exhibit variable degrees of syndactyly at birth and variable degrees of cranial compression and nerve compression in the skull.

[0210] Linkage analysis of the gene defect associated with sclerosteosis was conducted by applying the homozygosity mapping method to DNA samples collected from 24 South African Afrikaaner families in which the disease occurred. (Sheffield et al., 1994, Human Molecular Genetics 3:1331-1335. "Identification of a Bardet-Biedl syndrome locus on chromosome 3 and evaluation of an efficient approach to homozygosity mapping"). The Afrikaaner population of South Africa is genetically homogeneous; the population is descended from a small number of founders who colonized the area several centuries ago, and it has been isolated by geographic and social barriers since the founding. Sclerosteosis is rare everywhere in the world outside the Afrikaaner community, which suggests that a mutation in the gene was present in the founding population and has since increased in numbers along with the increase in the population. The use of homozygosity mapping is based on the assumption that DNA mapping markers adjacent to a recessive mutation are likely to be homozygous in affected individuals from consanguineous families and isolated populations.

[0211] A set of 371 microsatellite markers (Research Genetics, Set 6) from the autosomal chromosomes was selected to type pools of DNA from sclerosteosis patient samples. The DNA samples for this analysis came from 29 sclerosteosis patients in 24 families, 59 unaffected family members and a set of unrelated control individuals from the same population. The pools consisted of 4-6 individuals, either affected individuals, affected individuals from consanguineous families, parents and unaffected siblings, or unrelated controls. In the pools of unrelated individuals and in most of the pools with affected individuals or family members analysis of the markers showed several allele sizes for each marker. One marker, D17S1299, showed an indication of homozygosity: one band in several of the pools of affected individuals.

[0212] All 24 sclerosteosis families were typed with a total of 19 markers in the region of D17S1299 (at 17q12-q21). Affected individuals from every family were shown to be homozygous in this region, and 25 of the 29 individuals were homozygous for a core haplotype; they each had the same alleles between D17S1787 and D17S930. The other four individuals had one chromosome which matched this haplotype and a second which did not. In sum, the data compellingly suggested that this 3 megabase region contained the sclerosteosis mutation. Sequence analysis of most of the exons in this 3 megabase region identified a nonsense mutation in the novel TGF-beta binding-protein coding sequence (C>T mutation at position 117 of Sequence ID No. 1 results in a stop codon). This mutation was shown to be unique to sclerosteosis patients and carriers of Afrikaaner descent. The identity of the gene was further confirmed by identifying a mutation in its intron (A>T mutation at position +3 of the intron) which results in improper mRNA processing in a single, unrelated patient with diagnosed sclerosteosis.

EXAMPLE 2

TISSUE-SPECIFICITY OF TGF-BETA BINDING-PROTEIN GENE EXPRESSION

A. Human Beer Gene Expression by RT-PCR:

[0213] First-strand cDNA was prepared from the following total RNA samples using a commercially available kit ("Superscript Preamplification System for First-Strand cDNA Synthesis", Life Technologies, Rockville, MD): human brain, human liver, human spleen, human thymus, human placenta, human skeletal muscle, human thyroid, human pituitary, human osteoblast (NHOst from Clonetics Corp., San Diego, CA), human osteosarcoma cell line (Saos-2, ATCC# HTB-85), human bone, human bone marrow, human cartilage, vervet monkey bone, *saccharomyces cerevisiae*, and human peripheral blood monocytes. All RNA samples were purchased from a commercial source (Clontech, Palo Alto, CA), except the following which were prepared in-house: human osteoblast, human osteosarcoma cell line, human bone, human cartilage and vervet monkey bone. These in-house RNA samples were prepared using a commercially available kit ("TRI Reagent", Molecular Research Center, Inc., Cincinnati, OH).

[0214] PCR was performed on these samples, and additionally on a human genomic sample as a control. The sense Beer oligonucleotide primer had the sequence 5'-CCGGAGCTGGAGAACAACAAG-3' (SEQ ID NO:19). The antisense Beer oligonucleotide primer had the sequence 5'-GCACTGGCCGGAGCACACC-3' (SEQ ID NO:20). In addition, PCR was performed using primers for the human beta-actin gene, as a control. The sense beta-actin oligonucleotide primer had the sequence 5'-AGGCCAACC GCGAGAAGATGA CC -3' (SEQ ID NO:21). The antisense beta-actin oligonucleotide primer had the sequence 5'-GAAGT

CCAGGGCGACGTAGCA-3' (SEQ ID NO:22). PCR was performed using standard conditions in 25 ul reactions, with an annealing temperature of 61 degrees Celsius. Thirty-two cycles of PCR were performed with the Beer primers and twenty-four cycles were performed with the beta-actin primers.

[0215] Following amplification, 12 ul from each reaction were analyzed by agarose gel electrophoresis and ethidium bromide staining. See Figure 2A.

B. RNA In-situ Hybridization of Mouse Embryo Sections:

[0216] The full length mouse *Beer* cDNA (Sequence ID No. 11) was cloned into the pCR2.1 vector (Invitrogen, Carlsbad, CA) in the antisense and sense direction using the manufacturer's protocol. ³⁵S-alpha-GTP-labeled cRNA sense and antisense transcripts were synthesized using in-vitro transcription reagents supplied by Ambion, Inc (Austin, TX). In-situ hybridization was performed according to the protocols of Lyons et al. (J. Cell Biol. 111:2427-2436, 1990).

[0217] The mouse *Beer* cRNA probe detected a specific message expressed in the neural tube, limb buds, blood vessels and ossifying cartilages of developing mouse embryos. Panel A in Figure 3 shows expression in the apical ectodermal ridge (aer) of the limb (1) bud, blood vessels (bv) and the neural tube (nt). Panel B shows expression in the 4th ventricle of the brain (4). Panel C shows expression in the mandible (ma) cervical vertebrae (cv), occipital bone (oc), palate (pa) and a blood vessel (bv). Panel D shows expression in the ribs (r) and a heart valve (va). Panel A is a transverse section of 10.5 dpc embryo. Panel B is a sagittal section of 12.5 dpc embryo and panels C and D are sagittal sections of 15.5 dpc embryos. ba=branchial arch, h=heart, te=telencephalon (forebrain), b=brain, f=frontonasal mass, g=gut, h=heart, j=jaw, li=liver, lu=lung, ot=otic vesicle, ao=, sc=spinal cord, skm=skeletal muscle, ns=nasal sinus, th=thymus, to=tongue, fl=forelimb, di=diaphragm

EXAMPLE 3

EXPRESSION AND PURIFICATION OF RECOMBINANT BEER PROTEIN

A. Expression in COS-1 Cells:

[0218] The DNA sequence encoding the full length human Beer protein was amplified using the following PCR oligonucleotide primers: The 5' oligonucleotide primer had the sequence 5'-**AAGCTTGGTACCATGCAGCTCCCAC**-3' (SEQ ID NO:23) and contained a HindIII restriction enzyme site (in bold) followed by 19 nucleotides of the *Beer* gene starting 6 base pairs prior to

the presumed amino terminal start codon (ATG). The 3' oligonucleotide primer had the sequence 5'-**AAGCTTCTACTTGTTCATCGTCGTCCT** TGTAGTCGTAGGCGTTCTCCAGCT-3' (SEQ ID NO:24) and contained a HindIII restriction enzyme site (in bold) followed by a reverse complement stop codon (CTA) followed by the reverse complement of the FLAG epitope (underlined, Sigma-Aldrich Co., St. Louis, MO) flanked by the reverse complement of nucleotides coding for the carboxy terminal 5 amino acids of the Beer. The PCR product was TA cloned ("Original TA Cloning Kit", Invitrogen, Carlsbad, CA) and individual clones were screened by DNA sequencing. A sequence-verified clone was then digested by HindIII and purified on a 1.5% agarose gel using a commercially available reagents ("QIAquick Gel Extraction Kit", Qiagen Inc., Valencia, CA). This fragment was then ligated to HindIII digested, phosphatase-treated pcDNA3.1 (Invitrogen, Carlsbad, CA) plasmid with T4 DNA ligase. DH10B *E. coli* were transformed and plated on LB, 100 µg/ml ampicillin plates. Colonies bearing the desired recombinant in the proper orientation were identified by a PCR-based screen, using a 5' primer corresponding to the T7 promoter/priming site in pcDNA3.1 and a 3' primer with the sequence 5'- GCACTGGCCGGAGCACACC-3' (SEQ ID NO:25) that corresponds to the reverse complement of internal BEER sequence. The sequence of the cloned fragment was confirmed by DNA sequencing.

[0219] COS-1 cells (ATCC# CRL-1650) were used for transfection. 50 µg of the expression plasmid pcDNA-Beer-Flag was transfected using a commercially available kit following protocols supplied by the manufacturer ("DEAE-Dextran Transfection Kit", Sigma Chemical Co., St. Louis, MO). The final media following transfection was DMEM (Life Technologies, Rockville, MD) containing 0.1% Fetal Bovine Serum. After 4 days in culture, the media was removed. Expression of recombinant BEER was analyzed by SDS-PAGE and Western Blot using anti-FLAG M2 monoclonal antibody (Sigma-Aldrich Co., St. Louis, MO). Purification of recombinant BEER protein was performed using an anti-FLAG M2 affinity column ("Mammalian Transient Expression System", Sigma-Aldrich Co., St. Louis, MO). The column profile was analyzed via SDS-PAGE and Western Blot using anti-FLAG M2 monoclonal antibody.

B. Expression in SF9 insect cells:

[0220] The human *Beer* gene sequence was amplified using PCR with standard conditions and the following primers:

Sense primer: 5'-GTCGTCGGATCCATGGGGTGGCAGGCGTTCAAGAATGAT-3' (SEQ ID NO:26)

Antisense primer: 5'-GTCGTCAAGCTTCTACTTGTTCATCGTCCTTGTAGTCGTA GGCGTTCTCCAGCTCGGC-3' (SEQ ID NO:27)

[0221] The resulting cDNA contained the coding region of Beer with two modifications. The N-terminal secretion signal was removed and a FLAG epitope tag (Sigma) was fused in frame to

the C-terminal end of the insert. BamH1 and HindIII cloning sites were added and the gene was subcloned into pMelBac vector (Invitrogen) for transfer into a baculoviral expression vector using standard methods.

[0222] Recombinant baculoviruses expressing Beer protein were made using the Bac-N-Blue transfection kit (Invitrogen) and purified according to the manufacturers instructions.

[0223] SF9 cells (Invitrogen) were maintained in TNM_FH media (Invitrogen) containing 10% fetal calf serum. For protein expression, SF9 cultures in spinner flasks were infected at an MOI of greater than 10. Samples of the media and cells were taken daily for five days, and Beer expression monitored by western blot using an anti-FLAG M2 monoclonal antibody (Sigma) or an anti-Beer rabbit polyclonal antiserum.

[0224] After five days the baculovirus-infected SF9 cells were harvested by centrifugation and cell associated protein was extracted from the cell pellet using a high salt extraction buffer (1.5 M NaCl, 50 mM Tris pH 7.5). The extract (20 ml per 300 ml culture) was clarified by centrifugation, dialyzed three times against four liters of Tris buffered saline (150 mM NaCl, 50 mM Tris pH 7.5), and clarified by centrifugation again. This high salt fraction was applied to Hitrap Heparin (Pharmacia; 5 ml bed volume), washed extensively with HEPES buffered saline (25 mM HEPES 7.5, 150 mM NaCl) and bound proteins were eluted with a gradient from 150 mM NaCl to 1200 mM NaCl. Beer elution was observed at approximately 800 mM NaCl. Beer containing fractions were supplemented to 10% glycerol and 1 mM DTT and frozen at -80 degrees C.

EXAMPLE 4

PREPARATION AND TESTING OF POLYCLONAL ANTIBODIES TO BEER, GREMLIN, AND DAN

A. Preparation of antigen:

[0225] The DNA sequences of Human *Beer*, Human *Gremlin*, and Human *Dan* were amplified using standard PCR methods with the following oligonucleotide primers:

H. Beer

Sense: 5' -GACTTGGATCCCAGGGGTGGCAGGCGTTC- 3' (SEQ ID NO:28)

Antisense 5' -AGCATAAGCTTCTAGTAGGCGTTCTCCAG- 3' (SEQ ID NO:29)

H. Gremlin

Sense: 5' -GACTTGGATCCGAAGGGAAAAAGAAAGGG- 3' (SEQ ID NO:30)

Antisense: 5' -AGCATAAGCTTTTAATCCAAATCGATGGA- 3' (SEQ ID NO:31)

H. Dan

Sense: 5' -ACTACGAGCTCGGCCCCACCAACCATCAACAAG- 3' (SEQ ID NO:32)

Antisense: 5' -ACTTAGAAGCTTTCAGTCCTCAGCCCCCTCTTCC-3' (SEQ ID NO:33)

[0226] In each case the listed primers amplified the entire coding region minus the secretion signal sequence. These include restriction sites for subcloning into the bacterial expression vector pQE-30 (Qiagen Inc., Valencia, CA) at sites BamHI/HindIII for Beer and Gremlin, and sites SacI/HindIII for Dan. pQE30 contains a coding sequence for a 6x His tag at the 5' end of the cloning region. The completed constructs were transformed into *E. coli* strain M-15/pRep (Qiagen Inc) and individual clones verified by sequencing. Protein expression in M-15/pRep and purification (6xHis affinity tag binding to Ni-NTA coupled to Sepharose) were performed as described by the manufacturer (Qiagen, The QIAexpressionist).

[0227] The *E. coli*-derived Beer protein was recovered in significant quantity using solubilization in 6M guanidine and dialyzed to 2-4M to prevent precipitation during storage. Gremlin and Dan protein were recovered in higher quantity with solubilization in 6M guanidine and a post purification guanidine concentration of 0.5M.

B. Production and testing of polyclonal antibodies:

[0228] Polyclonal antibodies to each of the three antigens were produced in rabbit and in chicken hosts using standard protocols (R & R Antibody, Stanwood, WA; standard protocol for rabbit immunization and antisera recovery; Short Protocols in Molecular Biology. 2nd edition. 1992. 11.37- 11.41. Contributors Helen M. Cooper and Yvonne Paterson; chicken antisera was generated with Strategic Biosolutions, Ramona, CA).

[0229] Rabbit antisera and chicken egg IgY fraction were screened for activity via Western blot. Each of the three antigens was separated by PAGE and transferred to 0.45um nitrocellulose (Novex, San Diego, CA). The membrane was cut into strips with each strip containing approximately 75 ng of antigen. The strips were blocked in 3% Blotting Grade Block (Bio-Rad Laboratories, Hercules, CA) and washed 3 times in 1X Tris buffer saline (TBS) /0.02% TWEEN buffer. The primary antibody (preimmunization bleeds, rabbit antisera or chicken egg IgY in dilutions ranging from 1:100 to 1:10,000 in blocking buffer) was incubated with the strips for one hour with gentle rocking. A second series of three washes 1X TBS/0.02%TWEEN was followed by an one hour incubation with the secondary antibody (peroxidase conjugated donkey anti-rabbit, Amersham Life Science, Piscataway, NJ; or

peroxidase conjugated donkey anti-chicken, Jackson ImmunoResearch, West Grove, PA). A final cycle of 3X washes of 1X TBS/0.02%TWEEN was performed and the strips were developed with Lumi-Light Western Blotting Substrate (Roche Molecular Biochemicals, Mannheim, Germany).

C. Antibody cross-reactivity test:

[0230] Following the protocol described in the previous section, nitrocellulose strips of Beer, Gremlin or Dan were incubated with dilutions (1:5000 and 1:10,000) of their respective rabbit antisera or chicken egg IgY as well as to antisera or chicken egg IgY (dilutions 1:1000 and 1:5000) made to the remaining two antigens. The increased levels of nonmatching antibodies was performed to detect low affinity binding by those antibodies that may be seen only at increased concentration. The protocol and duration of development is the same for all three binding events using the protocol described above. There was no antigen cross-reactivity observed for any of the antigens tested.

EXAMPLE 5**INTERACTION OF BEER WITH TGF-BETA SUPER-FAMILY PROTEINS**

[0231] The interaction of Beer with proteins from different phylogenetic arms of the TGF- β superfamily were studied using immunoprecipitation methods. Purified TGF β -1, TGF β -2, TGF β -3, BMP-4, BMP-5, BMP-6 and GDNF were obtained from commercial sources (R&D systems; Minneapolis, MN). A representative protocol is as follows. Partially purified Beer was dialyzed into HEPES buffered saline (25 mM HEPES 7.5, 150 mM NaCl). Immunoprecipitations were done in 300 μ l of IP buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1mM EDTA, 1.4 mM β -mercaptoethanol, 0.5 % triton X 100, and 10% glycerol). 30 ng recombinant human BMP-5 protein (R&D systems) was applied to 15 μ l of FLAG affinity matrix (Sigma; St Louis MO)) in the presence and absence of 500 ng FLAG epitope-tagged Beer. The proteins were incubated for 4 hours @ 4°C and then the affinity matrix-associated proteins were washed 5 times in IP buffer (1 ml per wash). The bound proteins were eluted from the affinity matrix in 60 microliters of 1X SDS PAGE sample buffer. The proteins were resolved by SDS PAGE and Beer associated BMP-5 was detected by western blot using anti-BMP-5 antiserum (Research Diagnostics, Inc) (see Figure 5).

BEER Ligand Binding Assay:

[0232] FLAG-Beer protein (20 ng) is added to 100 μ l PBS/0.2% BSA and adsorbed into each well of 96 well microtiter plate previously coated with anti-FLAG monoclonal antibody (Sigma;

St Louis MO) and blocked with 10% BSA in PBS. This is conducted at room temperature for 60 minutes. This protein solution is removed and the wells are washed to remove unbound protein. BMP-5 is added to each well in concentrations ranging from 10 pM to 500 nM in PBS/0.2% BSA and incubated for 2 hours at room temperature. The binding solution is removed and the plate washed with three times with 200ul volumes of PBS/0.2% BSA. BMP-5 levels are then detected using BMP-5 anti-serum via ELISA (F.M. Ausubel et al (1998) Current Protocols in Mol Biol. Vol 2 11.2.1-11.2.22). Specific binding is calculated by subtracting nonspecific binding from total binding and analyzed by the LIGAND program (Munson and Podbard, Anal. Biochem., 107, p220-239, (1980).

[0233] In a variation of this method, Beer is engineered and expressed as a human Fc fusion protein. Likewise the ligand BMP is engineered and expressed as mouse Fc fusion. These proteins are incubated together and the assay conducted as described by Mellor et al using homogeneous time resolved fluorescence detection (G.W. Mellor et al., J of Biomol Screening, 3(2) 91-99, 1998).

EXAMPLE 6

SCREENING ASSAY FOR INHIBITION OF TGF-BETA BINDING-PROTEIN BINDING TO TGF-BETA FAMILY MEMBERS

[0234] The assay described above is replicated with two exceptions. First, BMP concentration is held fixed at the Kd determined previously. Second, a collection of antagonist candidates is added at a fixed concentration (20 uM in the case of the small organic molecule collections and 1 uM in antibody studies). These candidate molecules (antagonists) of TGF-beta binding-protein binding include organic compounds derived from commercial or internal collections representing diverse chemical structures. These compounds are prepared as stock solutions in DMSO and are added to assay wells at $\leq 1\%$ of final volume under the standard assay conditions. These are incubated for 2 hours at room temperature with the BMP and Beer, the solution removed and the bound BMP is quantitated as described. Agents that inhibit 40% of the BMP binding observed in the absence of compound or antibody are considered antagonists of this interaction. These are further evaluated as potential inhibitors based on titration studies to determine their inhibition constants and their influence on TGF-beta binding-protein binding affinity. Comparable specificity control assays may also be conducted to establish the selectivity profile for the identified antagonist through studies using assays dependent on the BMP ligand action (e.g. BMP/BMP receptor competition study).

EXAMPLE 7

INHIBITION OF TGF-BETA BINDING-PROTEIN LOCALIZATION TO BONE MATRIX

[0235] Evaluation of inhibition of localization to bone matrix (hydroxyapatite) is conducted using modifications to the method of Nicolas (Nicolas, V. *Calcif Tissue Int* 57:206, 1995). Briefly, ¹²⁵I-labelled TGF-beta binding-protein is prepared as described by Nicolas (*supra*). Hydroxyapatite is added to each well of a 96 well microtiter plate equipped with a polypropylene filtration membrane (Polyfiltroninc, Weymouth MA). TGF-beta binding-protein is added to 0.2% albumin in PBS buffer. The wells containing matrix are washed 3 times with this buffer. Adsorbed TGF-beta binding-protein is eluted using 0.3M NaOH and quantitated.

[0236] Inhibitor identification is conducted via incubation of TGF-beta binding-protein with test molecules and applying the mixture to the matrix as described above. The matrix is washed 3 times with 0.2% albumin in PBS buffer. Adsorbed TGF-beta binding-protein is eluted using 0.3 M NaOH and quantitated. Agents that inhibit 40% of the TGF-beta binding-protein binding observed in the absence of compound or antibody are considered bone localization inhibitors. These inhibitors are further characterized through dose response studies to determine their inhibition constants and their influence on TGF-beta binding-protein binding affinity.

EXAMPLE 8

CONSTRUCTION OF TGF-BETA BINDING-PROTEIN MUTANT

A. Mutagenesis:

[0237] A full-length TGF-beta binding-protein cDNA in pBluescript SK serves as a template for mutagenesis. Briefly, appropriate primers (see the discussion provided above) are utilized to generate the DNA fragment by polymerase chain reaction using Vent DNA polymerase (New England Biolabs, Beverly, MA). The polymerase chain reaction is run for 23 cycles in buffers provided by the manufacturer using a 57°C annealing temperature. The product is then exposed to two restriction enzymes and after isolation using agarose gel electrophoresis, ligated back into pRBP4-503 from which the matching sequence has been removed by enzymatic digestion. Integrity of the mutant is verified by DNA sequencing.

B. Mammalian Cell Expression and Isolation of Mutant TGF-beta binding-protein:

[0238] The mutant TGF-beta binding-protein cDNAs are transferred into the pcDNA3.1 mammalian expression vector described in EXAMPLE 3. After verifying the sequence, the resultant constructs are transfected into COS-1 cells, and secreted protein is purified as

described in EXAMPLE 3.

EXAMPLE 9

ANIMAL MODELS -I

GENERATION OF TRANSGENIC MICE OVEREXPRESSING THE *BEER* GENE

[0239] The ~200 kilobase (kb) BAC clone 15G5, isolated from the CITB mouse genomic DNA library (distributed by Research Genetics, Huntsville, AL) was used to determine the complete sequence of the mouse *Beer* gene and its 5' and 3' flanking regions. A 41 kb *Sall* fragment, containing the entire gene body, plus ~17 kb of 5' flanking and ~20 kb of 3' flanking sequence was sub-cloned into the *Bam*HI site of the SuperCosI cosmid vector (Stratagene, La Jolla, CA) and propagated in the *E. coli* strain DH10B. From this cosmid construct, a 35 kb *Mlu*I - *Avi*I restriction fragment (Sequence No. 6), including the entire mouse *Beer* gene, as well as 17 kb and 14 kb of 5' and 3' flanking sequence, respectively, was then gel purified, using conventional means, and used for microinjection of mouse zygotes (DNX Transgenics; US Patent No. 4,873,191). Founder animals in which the cloned DNA fragment was integrated randomly into the genome were obtained at a frequency of 5-30% of live-born pups. The presence of the transgene was ascertained by performing Southern blot analysis of genomic DNA extracted from a small amount of mouse tissue, such as the tip of a tail. DNA was extracted using the following protocol: tissue was digested overnight at 55° C in a lysis buffer containing 200 mM NaCl, 100 mM Tris pH8.5, 5 mM EDTA, 0.2% SDS and 0.5 mg/ml Proteinase K. The following day, the DNA was extracted once with phenol/chloroform (50:50), once with chloroform/isoamylalcohol (24:1) and precipitated with ethanol. Upon resuspension in TE (10mM Tris pH7.5, 1 mM EDTA) 8-10 ug of each DNA sample were digested with a restriction endonuclease, such as *Eco*RI, subjected to gel electrophoresis and transferred to a charged nylon membrane, such as HyBondN+ (Amersham, Arlington Heights, IL). The resulting filter was then hybridized with a radioactively labelled fragment of DNA deriving from the mouse *Beer* gene locus, and able to recognize both a fragment from the endogenous gene locus and a fragment of a different size deriving from the transgene. Founder animals were bred to normal non-transgenic mice to generate sufficient numbers of transgenic and non-transgenic progeny in which to determine the effects of *Beer* gene overexpression. For these studies, animals at various ages (for example, 1 day, 3 weeks, 6 weeks, 4 months) are subjected to a number of different assays designed to ascertain gross skeletal formation, bone mineral density, bone mineral content, osteoclast and osteoblast activity, extent of endochondral ossification, cartilage formation, etc. The transcriptional activity from the transgene may be determined by extracting RNA from various tissues, and using an RT-PCR assay which takes advantage of single nucleotide polymorphisms between the mouse strain from which the transgene is derived (129Sv/J) and the strain of mice used for DNA

microinjection [(C57BL5/J x SJL/J)F2].

ANIMAL MODELS - II

DISRUPTION OF THE MOUSE BEER GENE BY HOMOLOGOUS RECOMBINATION

[0240] Homologous recombination in embryonic stem (ES) cells can be used to inactivate the endogenous mouse *Beer* gene and subsequently generate animals carrying the loss-of-function mutation. A reporter gene, such as the *E. coli* β -galactosidase gene, was engineered into the targeting vector so that its expression is controlled by the endogenous *Beer* gene's promoter and translational initiation signal. In this way, the spatial and temporal patterns of *Beer* gene expression can be determined in animals carrying a targeted allele.

[0241] The targeting vector was constructed by first cloning the drug-selectable phosphoglycerate kinase (PGK) promoter driven *neomycin-resistance* gene (*neo*) cassette from pGT-N29 (New England Biolabs, Beverly, MA) into the cloning vector pSP72 (Promega, Madison, WI). PCR was used to flank the PGK*neo* cassette with bacteriophage PI loxP sites, which are recognition sites for the PI Cre recombinase (Hoess et al., PNAS USA, 79:3398, 1982). This allows subsequent removal of the neo-resistance marker in targeted ES cells or ES cell-derived animals (US Patent 4,959,317). The PCR primers were comprised of the 34 nucleotide (ntd) loxP sequence, 15-25 ntd complementary to the 5' and 3' ends of the PGK*neo* cassette, as well as restriction enzyme recognition sites (BamHI in the sense primer and EcoRI in the anti-sense primer) for cloning into pSP72. The sequence of the sense primer was 5'-AATCTGGATCCATAACTTCGTATAGCATACATTATACGAAGTTATCTGCAG GATTCGAGGGCCCT-3' (SEQ ID NO:34); sequence of the anti-sense primer was 5'-AATCTGAATTCCACCGGTGTTAATTAAATAACTTCGT ATAATGTATGCTATACGAAGTTATAGATCTAGAG TCAGCTTCTGA-3' (SEQ ID NO:35).

[0242] The next step was to clone a 3.6 kb XhoI-HindIII fragment, containing the *E. coli* β -galactosidase gene and SV40 polyadenylation signal from pSV β (Clontech, Palo Alto, CA) into the pSP72-PGK*neo* plasmid. The "short arm" of homology from the mouse *Beer* gene locus was generated by amplifying a 2.4 kb fragment from the BAC clone 15G5. The 3' end of the fragment coincided with the translational initiation site of the *Beer* gene, and the anti-sense primer used in the PCR also included 30 ntd complementary to the 5' end of the β -galactosidase gene so that its coding region could be fused to the *Beer* initiation site in-frame. The approach taken for introducing the "short arm" into the pSP72- β gal-PGK*neo* plasmid was to linearize the plasmid at a site upstream of the β -gal gene and then to co-transform this fragment with the "short arm" PCR product and to select for plasmids in which the PCR product was integrated by homologous recombination. The sense primer for the "short arm" amplification included 30 ntd complementary to the pSP72 vector to allow for this recombination event. The sequence of the sense primer was 5'-ATTAGGTGACACT

ATAGAACTCGAGCAGCTGAAGCTTAACCACATGGTGGCTCACAACCAT-3' (SEQ ID NO:36) and the sequence of the anti-sense primer was 5'-AACGACGGCCAGTGAATCCGTAATCATGGTCATGCTGCCAGGTGGAGGAGGGCA-3' (SEQ ID NO:37).

[0243] The "long arm" from the *Beer* gene locus was generated by amplifying a 6.1 kb fragment from BAC clone 15G5 with primers which also introduce the rare-cutting restriction enzyme sites SgrAI, FseI, Ascl and PacI. Specifically, the sequence of the sense primer was 5'-ATTACCACCGGTGACACCCGCTTCCTGACAG-3' (SEQ ID NO:38); the sequence of the anti-sense primer was 5'-ATTACTTAATTAAACATGGCGCGCCATATGGCCGGCCCCTAATTGCGGCGCATCGTTAATT-3' (SEQ ID NO:39). The resulting PCR product was cloned into the TA vector (Invitrogen, Carlsbad, CA) as an intermediate step.

[0244] The mouse *Beer* gene targeting construct also included a second selectable marker, the *herpes simplex virus 1 thymidine kinase* gene (HSVTK) under the control of rous sarcoma virus long terminal repeat element (RSV LTR). Expression of this gene renders mammalian cells sensitive (and inviable) to gancyclovir; it is therefore a convenient way to select against neomycin-resistant cells in which the construct has integrated by a non-homologous event (US Patent 5,464,764). The RSVLTR-HSVTK cassette was amplified from pPS1337 using primers that allow subsequent cloning into the FseI and Ascl sites of the "long arm"-TA vector plasmid. For this PCR, the sequence of the sense primer was 5'-ATTACGGCCGGCCGCAAAGGAATTCAAGA TCTGA-3' (SEQ ID NO:40); the sequence of the anti-sense primer was 5'-ATTACGGCGCGCCCCCTC ACAGGCCGCACCCAGCT-3' (SEQ ID NO:41).

[0245] The final step in the construction of the targeting vector involved cloning the 8.8 kb SgrAI-Ascl fragment containing the "long arm" and RSVLTR-HSVTK gene into the SgrAI and Ascl sites of the pSP72-"short arm"-βgal-PGKneo plasmid. This targeting vector was linearized by digestion with either Ascl or PacI before electroporation into ES cells.

EXAMPLE 10

ANTISENSE-MEDIATED BEER INACTIVATION

[0246] 17-nucleotide antisense oligonucleotides are prepared in an overlapping format, in such a way that the 5' end of the first oligonucleotide overlaps the translation initiating AUG of the *Beer* transcript, and the 5' ends of successive oligonucleotides occur in 5 nucleotide increments moving in the 5' direction (up to 50 nucleotides away), relative to the *Beer* AUG. Corresponding control oligonucleotides are designed and prepared using equivalent base composition but redistributed in sequence to inhibit any significant hybridization to the coding mRNA. Reagent delivery to the test cellular system is conducted through cationic lipid delivery (P.L. Felgner, Proc. Natl. Acad. Sci. USA 84:7413, 1987). 2 ug of antisense oligonucleotide is

added to 100 ul of reduced serum media (Opti-MEM I reduced serum media; Life Technologies, Gaithersburg MD) and this is mixed with Lipofectin reagent (6 ul) (Life Technologies, Gaithersburg MD) in the 100 ul of reduced serum media. These are mixed, allowed to complex for 30 minutes at room temperature and the mixture is added to previously seeded MC3T3E1 or KS483 cells. These cells are cultured and the mRNA recovered. Beer mRNA is monitored using RT-PCR in conjunction with Beer specific primers. In addition, separate experimental wells are collected and protein levels characterized through western blot methods described in Example 4. The cells are harvested, resuspended in lysis buffer (50 mM Tris pH 7.5, 20 mM NaCl, 1mM EDTA, 1% SDS) and the soluble protein collected. This material is applied to 10-20 % gradient denaturing SDS PAGE. The separated proteins are transferred to nitrocellulose and the western blot conducted as above using the antibody reagents described. In parallel, the control oligonucleotides are added to identical cultures and experimental operations are repeated. Decrease in Beer mRNA or protein levels are considered significant if the treatment with the antisense oligonucleotide results in a 50% change in either instance compared to the control scrambled oligonucleotide. This methodology enables selective gene inactivation and subsequent phenotype characterization of the mineralized nodules in the tissue culture model.

SEQUENCES

[0247]

Sequence ID No. 1: Human BEER cDNA (complete coding region plus 5' and 3' UTRs)

```

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTGCTCTGC
CTGCTGGTACACACAGCCTTCCGTGTAGTGGAGGGCCAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGAAATCATCCC
CGASCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACAAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACACACCCCTTTGAGAGCCAAAGACGTGTCCGAGTACAGCTGCCCGAGCTGCACCTTCAACCGCTACGTGACCGAT
GGGCCGTGCGCAGGGCCAGCCGGTCAACCGAGCTGGTGTGCTCCGGCCAGTGGCGCCCGGCGCGCTGCTGCCCAACGC
CATCGGCCCGGCAAGTGTGGCGACCTAGTGGGCCGACTTCCGCTGCATCCCGAACCGCTACCGCGCGCAACGCGTGC
AGCTGCTGTGTCCCGGTGGTGGAGCGCGCGCGCGCGCAAGGTGGCGCTGGTGGCCTGTTGCAAGTGCAAGCGCTCACC
CGCTTCCACAACAGTCCGAGCTCAAGGACTTCGGGACCGAGGCGCGCTCGGCCCGAGAGGGCGGGAAGCGCGGCCCG
CGCCCGGAGCGCAAGCAACAGGCGGAGCTGGAGAACCGCTACTAGAGCCCGCCCGCGCCCTCCCAACCGCGCGGC
GCCCCGCGCTGAACCCCGCGCCCAATTTCTGTCTCTGCGCGTGGTTTGAATTGTTTATATTTCATTGTAAATGCTGC
AAGCCAGGGCAGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGCGCGCGCAAGGCCCGCTCAGCCCGCGAGCTG
AGGGGTCCACGGGCGAGGGGAGGAATTGAGAGTACAGACACTGAGCCACGCGCCCGCTCTGGGGCCCGCTACCT
TTGCTGGTCCCACTTCAAGAGAGGAGAAATGGAAGCATTTTACCGCCCTGGGGTTTTAAGGGAGCGGTGGAGTGG
GAAGTCCAGGACTGGTTAAGAAAGTTGGATAAGATTCCCGCTTGACCTCGCTGCCATCAGAAAGCTGAGGCGTGC
CCAGAGCACAGACTGGGGCAACTGTAGATGTGGTTTCTAGTCTGGCTCTGCCACTAATGCTGTGTAACTTGAAC
TACACAAATTCCTCTCGGACCTCAATTTCACTTTGTAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAGAGAGAGAGAGATGATG
CAGTTGCATTGATTAGTGCCAAAGTCACTTCCAGAAATCAGAGTTGTGATGCTCTCTCTGACAGCCAAAGTGAAGAA
CAACAGAAAAAAAGTAAGAGTCTATTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAGCTATGCTG
CTTCCCGACCTGGCTTCCCGGATGTTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
AAAGGAGAGGGTCCGAGGGTGGTGGGAGGATAGAAATCACATCCGCCCACTTCCCAAGAGCAGCATCCCTCCCCCG

```

ACCCATAGCCATGTTTAAAGTCACCTCCGAGAGAGTGAAGGTTCAAGGACACTGGCCTTGCAAGGCCGAGGGAGC
 AGCCATCACAACCTCAGAGACCAGCAGATCCCTTTTGAGACACCGCCTTCTGCCACCACTCAGGACACATTTCTGCCT
 AGAAAACAGCTTCTTACTGCTCTTACATGTSATGGCATATCTTACACTAAAAGAATATTATTGGGGGAAAACTACAAGT
 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAATCTTTTGAAATCATTTCAGACACCTC
 TTACTTTCTGTAGTTTAAATGTTAAAAAAAAGTTTAAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
 GGTGTTTTTTTGGCAATTCTTCCAGTGGGACTTGTCCACAAGATGAAGTAGTGGTTTTTAAGAGTTAAGTTACAT
 ATTTATTTTCTCACTTAAGTTATTTATGCAAAAGTTTTCTTGTAGAGAATGACAATGTTAATATTGCTTTATGAATTAA
 CAGTCTGTCTTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 2: Human BEER protein (complete sequence)

MQLFLALCLVLLVHTAFRVVEGQSWQAFKNDTEIIPELGEYFEPFPELENNKTMNRAENGGRFFHHFFETKDVSEYSC
 RELHFTRYVTDGFCRSAPVTELVCSGQCFARLLPNAIGRGKWWRFSGDFRCIFDRYRAQRVQLLCPGGEAFPRARKVR
 LVASCKCKRLTRFHNQSELKDFGTEAARPQKGRKPRPRARSAKANQAELENAY

Sequence ID No. 3: Human Beer cDNA containing Sclerosteosis nonsense mutation

AGAGCCTGTGCTACTGGAGGTGGCGTSCCCTCCTCTGGCTGGTACCCTGCAGCTCCCACTGGCCTGTGTCTCTCTSC
 CTGCTGTGTACACAGCCTTCCGTGTAGTGGAGGGCTAGGGGTGGCAGGCGTTCAAGAATGATGCCACGGPAATCATCC
 CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGAACACAAAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
 CTCCCCACCAACCCCTTTGAGACCAAGAGCTGTCCGAGTACAGCTGCCGGGAGCTGCACTTCAACCGCTACGTGACCGAT
 GGGCCGTGCCGAGCGCCAGCCGGTCAACGAGCTGGTGTCTCCGGCCAGTGGCGCCCGCGCGCCTGCTGCCCAACGC
 CATCGGCCCGCGCAAGTGGTGGCGACCTAGTGGGCCCGACTTCCGCTGCATCCCGACCGCTACCGCGCGCAGCGCTGC
 AAGTGTGTCTCCCGGTGGTGAAGCGCCGCGCGCGCGCGCAGGTGGCGCTGCTGGCCTGTGCAGTGCAGCGCCTCACC
 CGCTTCCACAACCACTCGGAGCTCAAGGACTTCCGGACCGAGGCGCTCGGCCGAGAGGGCCGGAAGCCGCGGCCCCG
 CGCCCGGAGCGCCAAAGCCPACCAAGSCGAGCTGGAGAACGCGCTACTAGAGCCCGCCCGCGCCCTCCCCACCGCGGGC
 GCCCGGCCCCGAACCCCGCGCCACATTTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTCATTGTAAATGCCTGC
 AACCCAGGGCGGGGGCTGAGACCTTCCAGGCCCTGAGGAATCCCGGGCGCGGCAAGGCCCCCTCAGCCCGCCAGCTG
 AGGGGTCCCACGGGGCAGGGGAGGGAATTGAGAGTACAGACACTGAGCCACGCGCCCGCCTCTGGGGCGCCTACCT
 TTGCTGTCTCCACTTCAGAGGAGGCAAPATGGAGCATTTTCAACGCCCTGGGTTTTAAGGAGCGGTGTGGAGTGG
 GAAAGTCCAGGACTGGTTAAGAAAGTTGGATAAGATTCCCGCTTGCACTCTGCTGCCATCAGAAAGCCTGAGGCGTGC
 CCAGAGCACAAAGACTGGGGGCACTGTAGATGTGGTTTCTAGTCTGGCTCTGCCACTAATTGCTGTGTAACTTGAAC
 TACACAAATCTCCTTCGGGACCTCAATTTCCACTTTGTAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
 TGGCATATGATTCCAAGGACTCCAGTGCCTTTGAATGGGCAGAGGTGAGAGAGAGAGAGAGAAAGAGAGAGATGAATG
 CAGTTGCATTGATTCAAGGAGTCACTTCCAGAAATCAGAGTTGTGATGCTCTCTTCTGACAGCCAAAGATGAAPAA
 CAAACAGAAAAAAAGTAAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAGAGAGCTATGCTG
 CTTCACAGCCTGGCTTCCCGGATGTTGGCTACCTCCACCCCTCCATCTCAAAGAAATACATCATCCATTGGGGTAGA
 AAAGGAGAGGGTCCGAGGGTGGTGGGAGGATAGAAATCACATCCGCCCACTTCCCAAGAGCAGCATCCCTCCCCG
 ACCCATAGCCATGTTTAAAGTCACCTTCCGAAGAGAGTGAAGGTTCAAGGACACTGGCCTTGCAAGGCCGAGGGAGC
 AGCCATCACAACCTCAGAGACCAGCAGATCCCTTTTGAGACACCGCCTTCTGCCACCACTCAGGACACATTTCTGCCT
 AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAAGAATATTATTGGGGGAAAACTACAAGT
 GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCCAAAATCTTTTGAAATCATTTCAGACACCTC
 TTACTTTCTGTAGTTTAAATGTTAAAAAAAAGTTTAAACAGAAGCACATGACATATGAAAGCCTGCAGGACT
 GGTGTTTTTTTGGCAATTCTTCCAGTGGGACTTGTCCACAAGATGAAGTAGTGGTTTTTAAGAGTTAAGTTACAT
 ATTTATTTTCTCACTTAAGTTATTTATGCAAAAGTTTTCTTGTAGAGAATGACAATGTTAATATTGCTTTATGAATTAA
 CAGTCTGTCTTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 4: Truncated Human Beer protein from Sclerosteosis

MLPLALCLVCLLVHTAFRVVEG*

Sequence ID No. 5: Human BEER cDNA encoding protein variant (V10I)

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCATCTGC
CTGCTGGTACACACAGCCTTCCTGTAGTGGAGGGCCAGGGGTGGCAGGCGTTCAAGAAATGATGCCACGGAAATCATCCG
CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGGAAACAACAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACCTTACCCCGCTACGTGACCGAT
GGGCCGTGCCGAGCGCAAGCCGGTCACCGAGCTGGTGTGCTCCGCGCAGTGGCGCCGGCGCGCTGCTGCCCAACGC
CATCGGCCGCGCAAGTGGTGGCGACCTAGTGGGCCGACTTCCGCTGCATCCCGACCGCTACCGCGCGCAGCGCGTGC
AGCTGCTGTGTCCCGTGGTGGAGCGCGCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACC
CGCTTCCACAAACAGTCCGAGCTCAAGGACTTCGGGACCGAGGCGCTCGGCCGAGAAAGGGCCGGAAGCGCGGCCCG
CGCCCGGAGCGCAAGCCAAACAGCGGAGCTGGAGAACGCTACTAGAGCCCGCGCGCGCTCCCGACCGCGCGG
GCCCGGCCCTGAACCGCGCGCCACATTTCTGTCTCTGCGCTGGTTGATTGTTTATATTTTCATTGTAATGCCTGC
AACCAGGGCAGGGGCTGAGACCTTCAGGCCCTGAGGAATCCCGGGCGCGGCAAGGCCCGCTCAGCCCGCAGCTG
AGGGGTCCTCCGGGCGAGGGAGGGAATTGAGAGTCAAGACACTGAGCCACGAGCGCCCGCTCTGGGGCGCCTACCT
TTGCTGCTCCACTTCAGAGGAGGAGAAATGGAAGCATTTTACCGCCCTGGGGTTTTTAAGGGAGCGGTGTGGAGTGG
GAAAGTCCAGGAGCTGGTTAAGAAAGTTGGATAAGATTCCCGCTTGCACTCGCTGCCATCAGAAAGCTGAGGCGTGC
CCAGAGCACAGACTGGGGGCACTGTAGATGTGGTTTCTAGTCTGGCTCTGCCACTAATTGCTGTGTAACTTGAAC
TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAAATGAGGGTGGAGGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAGGACTCCAGTGCCTTTGAATGGGCGAGGTGAGAGAGAGAGAGAAAGAGAGAAATGAATG
CAGTTGCATTGATTAGTGCCAGGTCACTTCCAGAAATCAGAGTTGTGATGCTCTTCTGACAGCCAAAGATGAAAA
CAACAGAAAAAAGTAAGAGTCTATTTATGGCTGACATATTTACGGCTGACAACTCCTGGAAGAGCTATGCTG
CTTCCAGCCTGGCTCCCCGGATGTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAACATCATCCATTGGGGTAGA
AAAGGAGAGGGTCCGAGGGTGGTGGGAGGATAGAAATCACATCCGCCCACTTCCCAAAGAGCAGCATCCCTCCCCG
ACCCATAGCCATGTTTAAAGTCACTTCCGAAGAGAGTGAAAGGTTCAAGGACACTGGCCTTGCAAGGCCGAGGGAGC

AGCCATCAGAACTCAGAGACAGCACATCCCTTTGAGACACCGCCTTCTGCCACCACTCAGGACACATTTCTGCCT
AGAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAGAAATATTATTGGGGAAAACTACAAGT
GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCAAAATCTTTTGAATCATTTCCAGACACCTC
TTACTTTCTGTAGTTTTTAATGTTAAAAAAGTTTAAACAGAGGCATGACATATGAAGCCTGCAGGACT
GGTCGTTTTTTGGCAATCTTCCAGTGGGACTTGTCCACAAGAAATGAAAGTAGTGGTTTTTAAAGAGTTAAGTTACAT
ATTTATTTCTCACTTAAGTTATTTATGCAAAAGTTTTCTTGTAGAGAAATGACAAATGTTAATATTGCTTTATGAATTAA
CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAGACAATGAATCATGACCGAAAG

Sequence ID No. 6: Human BEER protein variant (V10I)

MLPLALCLVCLLVHTAFRVVEGQWQAFKNDATETIIRLGEYFEFFEELENNKTMNRAENGGRPPHHFEETKDVSEYSC
RELHETRYVTDGEFRSAKFVTELVCSGQCGEARLLFNAIGRGKWWRESGFDFRCIFDRIYRQVRVQLLCPGGEAFRARKVR
LVASCKCKRLTRFHNQSELKDFGTEAARFQGRKFRFRANSAKANQAELENAY

Sequence ID No. 7: Human Beer cDNA encoding protein variant (P38R)

AGAGCCTGTGCTACTGGAAGGTGGCGTGCCTCCTCTGGCTGGTACCATGCAGCTCCCACTGGCCCTGTGTCTCGTCTGC
CTGCTGGTACACACAGCCTTCCTGTAGTGGAGGGCCAGGGGTGGCAGGCGTTCAAGAAATGATGCCACGGAAATCATCCG
CGAGCTCGGAGAGTACCCCGAGCCTCCACCGGAGCTGGAGGAAACAACAGACCATGAACCGGGCGGAGAACGGAGGGCGGC
CTCCCCACACCCCTTTGAGACCAAGACGTGTCCGAGTACAGCTGCCGCGAGCTGCACCTTACCCCGCTACGTGACCGAT
GGGCCGTGCCGAGCGCAAGCCGGTCACCGAGCTGGTGTGCTCCGGCCAGTGGCGCCGGCGCGCTGCTGCCCAACGC
CATCGGCCGCGCAAGTGGTGGCGACCTAGTGGGCCGACTTCCGCTGCATCCCGACCGCTACCGCGCGCAGCGCGTGC
AGCTGCTGTGTCCCGTGGTGGAGCGCGCGCGCGCGCAAGGTGCGCCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACC

CGCTTCCACAACCAGTCCGAGCTCAAGGACTTCGGGACCGAGGCCGCTCGGCCGAGAGGGCCGGAAGCCGCGGCCCGG
CGCCCGGAGCGCCAAAGCCCAACCGAGGCGAGCTGGAGAACGCCCTACTAGAGCCCGCCGCGCCCTCCCCACCGCGGGG
GCCCGGCCCTGAACCGCGCCCCACATTTCTGTCTCTGCGCGTGGTTTGATTGTTTATATTTTCATTGTAAATGCGCTG
AACCAGGGCAGGGGCTGAGACCTTCAGGCCCTGAGGAATCCCGGCGCGCGCAAGGCCCCCTCAGCCCGCAGCTG
AGGGGTCCACGGGGCAGGGGAGGGAATTGAGAGTCACAGACACTGAGCCACGCAAGCCCGCCCTCTGGGGCCGCTACCT
TTGCTGGTCCCACTTCAGAGGAGGCGAGAAATGGAAGCATTTTCACCGCCCTGGGGTTTAAAGGAGCGGTGTGGAGTGG
GAAAGTCCAGGGACTGGTTAAGAAAGTTGGATAAGATTCCCCCTTGACCTCGCTGCCATCAGAAAGCCTGAGGCGTGC
CCAGAGCACAAGACTGGGGCAACTGTAGATGTGGTTTCTAGTCTGGCTCTGCCACTAATTGCTGTGAACCTTGAAC
TACACAATTCTCCTTCGGGACCTCAATTTCCACTTTGTAAATGAGGGTGGAGTGGGAATAGGATCTCGAGGAGACTAT
TGGCATATGATTCCAAGGACTCCAGTGCCCTTTGAATGGGCGAGGTTGAGAGAGAGAGAGAGAAAGAGAGAGAATGAATG

CAGTTGCATTGATTCACTGCCAAGGCTCACTTCAGAAATTCAGAGTTGTGATGCTCTCTCTGACAGCCAAAGATGAAAA
CAACACAGAAAAAAAGTAAGAGTCTATTATTTAGGCTGACATATTTACGGCTGACAPACTCTGGAGAAGCTATGCTG
CTTCCACGCTGGCTTCCCCGCTTGGCTACCTCCACCCCTCCATCTCAAAGAAATAAGATCATCATTTGGGGTAGA
AAGGAGAGGGTCCGAGGGTGGTGGAGGGATAGAAATCAGATCCGCCCAACTTCCCAAGAGCAGCATCCCTCCCCG
ACCCATAGCCATGTTTAAAGTCACTTCCGAAGAGAGTGAAGGTTCAAGGACACTGGCCTTGCAAGGCCGAGGGAGC
AGCCATCACAACACTCAGAGACAGCAGATCCCTTTTGAAGCAGCCCTCTGCCACCACTCAGGACACATTTCTGCCT
AGAAAACAGCTTCTTACTGCTCTTACATGTGATGGCATATCTTACACTAAAGGATATTTATGGGGGAAAACTACAAGT
GCTGTACATATGCTGAGAACTGCAGAGCATAATAGCTGCCACCAAAATCTTTTGAATCATTTCCAGACACCTC
TTACTTTCTGTGTAGTTTTTAATGTTTAAAGGTTTAAACAGAGCAGCATGACATATGAAGCCTGCAGGACT
GGTGGTTTTTTTGGCAATCTTCCAGTGGGACTTGTCCAGAGGAATGAAGTATGGTTTTTAAAGAGTTAAGTTACAT
ATTTATTTCTCACTTAAGTTATTTTGCAAAAGTTTTCTTGTAGAGAAATGACAATGTTAATATTGCTTTATGAATTA
CAGTCTGTTCTTCCAGAGTCCAGAGACATTGTTAATAAAGACAATGAATCATGACCGAAAG

Sequence ID No. 8: Human Beer protein variant (P38R)

MQFLALCLVCLLVHTAFRVVGGQWQAFKNDATETIIRELGEYPEFFPELENNKTMNRAENGGRPFHHPFETKDVSEYSC
RELHETRYVTDSGCRSAKFVTELVCSGQCGFARLLFNAIGRSKWWRFSGFDRCIFDORYRAQRVQLLCFGEAFRARKVR
LVASCKCKRLTRFHNQSELKDFGTEAARFQKGRKFRPRARSAKANQAELENAY

Sequence ID No. 9: Vervet BEER cDNA (complete coding region)

ATGCAGCTCCCACTGGCCCTGTGTCTGTCTGCTGCTGGTACACGCGAGCCTCCGTGTAGTGGAGGGCCAGGGGTGGCA
GGCCTTCAAGAAATGATGCCACGGAATCATCCCGAGCTCGGAGAGTACCCGAGCCTCCACCGAGCTGGAGAACAA
AGACCATGTAACGGGCGGAGAATGGAGGGCGGCTCCCAACCACTCTTGAGACCAAGACGTGTCGAGTACAGCTGC
CGAGAGCTGCACTTACCCGCTACGTGACCGATGGGCCGTGCCGAGCGCAAGCCAGTACCGAGTTGGTGTGCTCCGG
CCAGTGGGCGCCGCAAGCCTGTGCTGCAACGCAATCGGCGCGGCAAGTGGTGGCGCCGAGTGGGCCGACTTCCGCT
GCATCCCCGACCGCTACCGCGCGCAGCGTGTGAGCTGCTGTGCTCCCGTGGTGGCGCGCGCGCGCAAGGTGCGC
CTGGTGGCTCGTGCAAGTGAAGCGCTCACCCGCTTCCACAACAGTCGGAGCTCAAGGACTTCGGTCCCGAGGCCGC
TCGGCGCAGAGGGGCCGAAGCGCGGCCCGCGCCCGGGGGCCAAAGCCATCAGGCCAGCTGGAGAACGCCCTACT
AG

Sequence ID No. 10: Vervet BEER protein (complete sequence)

MQFLALCLVCLLVHAAFRVVGGQWQAFKNDATETIIRELGEYPEFFPELENNKTMNRAENGGRPFHHPFETKDVSEYSC
RELHETRYVTDSGCRSAKFVTELVCSGQCGFARLLFNAIGRSKWWRFSGFDRCIFDORYRAQRVQLLCFGEAFRARKVR
LVASCKCKRLTRFHNQSELKDFGTEAARFQKGRKFRPRARGAKANQAELENAY

Sequence ID No. 11: Mouse BEER cDNA (coding region only)

ATGCAGCCCTCACTAGCCCGTGGCTCATCTGCCTACTGTGCAAGCTTCCTTCTGTGCTGTGGAGGGCCAGGGGTGGCA

AGCCTTCAGGAATGATGCCACAGAGGTATCCCAGGGCTTGGAGAGTACCCGAGCCTCCTCCTGAGAACACCAGACCA
 TGAACCGGSCGGAGATGGAGGCAGACCTCCCAACATCCCTATGACGCCAAGGTGTGTCCGAGTACAGCTGCCGCGAG
 CTGCACTACACCGCTTCCTGACAGACGGCCCATGCCGACGCGCAAGCGGTACCGAGTTGGTGTGCTCCGGCCAGTG
 CGGCCCGCGCGGCTGCTGCCCAACGCCATCGGGCGCTGAAAGTGGTGGCGCCGAACGGACCGGATTTCCGCTGCATCC
 CGGATCGCTACCGCGCGCAGCGGTGCAGCTGCTGTGCCCGGGGCGCGCGCCGCGCTCGCGCAAGGTGCGTCTGGTG
 GCCTCGTGCAAGTSCAAGCGCTCACCCGCTTCCACAACAGTCCGAGCTCAAGGACTTCGGGCGGAGACCGCGCGGCC
 GCAGAAGGCTCGCAAGCGCGGCCCGCGCCCGGGGAGCCAAAGCCACCAGCGGAGCTGGAGAACGCCTACTAGAG

Sequence ID No. 12: Mouse BEER protein (complete sequence)

MQSLAPCLICLLVHAFAVEGQGWQAFRNDATEVIEGLGEYFEPPFENNQTMMNRAENGGRFFHHFYDAKDVSEYSCRE
 LHYTRFLTDFGCRSAKFVTELVCSGQCGPARLLFNALGRVKWWRPNGFDFRCIFDRYRAQRVQLLCFGGAAPRSRKVRLV
 ASCKCKRLTRFHNQSELKDFGFETARFQKGRKPRFARGAKANQAELENAY

Sequence ID No. 13: Rat BEER cDNA (complete coding region plus 5' UTR)

GAGGACCGAGTGCCCTTCCTCCTTCTGGCACCATGCAGCTCTCACTAGCCCTTGCCCTTGCTGCTGTATCATGCA
 GCCTTCGTTGCTGTGGAGAGCCAGGGGTGGCAAGCCTTCAAGAATGATGCCACAGAAATCATCCGGGACTCAGAGAGTA
 CCCAGAGCCTCCTCAGGAAGTAGAGAACCAACAGACCATGAACCGGGCCGAGAACGGAGGCAGACCCCCCACCATCCTT
 ATGACACCAAGACGTGTCCGASTACAGCTGCCGCGAGCTGCACTACACCGCTTCGTGACCGACGGCCGTCGCGAGT
 GCCAAGCCGGTCACCGAGTTGGTGTGCTCGGGCCAGTGCGGCCCGCGCGCTGCTGCCAACGCCATCGGGCGCGTGAA
 GTGGTGGCGCCGAACGGACCCGACTTCGCTGCATCCCGGATCGCTACCGCGCGCAGCGGGTGCAGCTGCTGTGCCCGG
 GCGGCGCGGCGCGCTCGCGCAAGGTGCGTCTGGTGGCCTCGTGCAAGTGCAAGCGCCTCACCCGCTTCCACAACCAG
 TCGGAGCTCAAGGACTTCGGACCTGAGACCGCGCGCCGAGAGGGTCSGAAGCCGCGGCCCGCGCCCGGGGAATCCAA
 AGCCAACCAAGCGGAGCTGGAGAACGCCTACTAG

Sequence ID No. 14: Rat BEER protein (complete sequence)

!!QLSLAPCLICLLVHAFAVAVESQSWQAFKNDATEIIEGLREYFEFPQELNNQTMNRAENGGRFFHHFYDTKDVSEYSC
 RELHYTRFVTDGFCRSAPKFVTELVCSGQCGPARLLFNALGRVKWWRPNGFDFRCIFDRYRAQRVQLLCFGGAAPRSRKVR
 LVSCKCKRLTRFHNQSELKDFGFETARFQKGRKPRFRARGAKANQAELENAY

Sequence ID No. 15: Bovine BEER cDNA (partial coding sequence)

AGATGATGCCACAGAAATCATCCCGAGCTGGGCGAGTACCCGAGCCTCTGCCAGAGCTGAACACAGACCATGAAC
 CGGGCGGAGAACGGAGGAGACCTCCCCACCACCCCTTTGAGACCAAGACGCCTCCGAGTACAGCTGCCGGGAGCTGCA
 CTTCACCCGCTACGTGACCGATGGGCGGTGCCGACGCGCAAGCCGGTACCCGAGCTGGTGTGCTCGGGCCAGTGCAGCC
 CGGCGCGCTGCTGCCAACGCCATCGGCGCGGCAAGTGGTGGCGCCAAAGCGGGCCGACTTCGCTGCATCCCGAC
 CGCTACCGCGCGCAGCGGGTGCAGCTGTTGTCTGCTGGCGCGCGCGCGCGCGCGCAAGTGGCGCTGTTGCTCTC
 GTGCAAGTGCAAGCGCCTCACTCGCTTCCACAACAGTCCGAGCTCAAGGACTTCGGGCGCGAGGCGCGCGGCGCGCAA
 CGGGCGGGAAGCTGCGGCCCCGCGCCCCGGGCAACCAAGCCAGCCGGGCCGA

Sequence ID No. 16: Bovine BEER protein (partial sequence -- missing signal sequence and last 6 residues)

NDATEIIEGLGEYFEFPELNNKTMNRAENGGRFFHHFFETKDAEYSCRELHFTRYVTDGFCRSAPKFVTELVCSGQCGF
 ARLLFNALGRVKWWRPSGDFDFRCIFDRYRAQRVQLLCFGGAAPRARKVRLVASCKCKRLTRFHNQSELKDFGPEALRFQT
 GRKLRPRARGTKASRA

Sequence ID No. 17: MluI - AvilI restriction fragment used to make mouse Beer transgene

CGCGTTTTGGTGAGCAGCAATATTGCGCTTCGATGAGCCTTGGCGTTGAGATTGATACCTCTGCTGCACAAAAGGCAATC

GACCGAGCTGGACCGCGCATTCGTGACACCGTCTCCTTGGAACTTATTCGCAATGGAGTGTCATTCTCPAGGACNGCC
 TGATCGCAATGGTGCTATCCACGACGCGCATCGAAAAACCTCAGCCSGTGACCAATATCTACACATCAGCCTTGGT
 ATCCTGCGTGATGAGCCAGCGCAGACAGGTAACCGTCASTGCCGATAAGTTCAAGTTAAACCTGGTGTTGATACCAA
 CATTGAAACGTTGATCGAAAAACGCGCTGAAAAACGCTGCTGAATGTGCGSCGCTGGATGTCAAAAGCABAATGGCAGCAG
 ACAAGAAAGCGATGGATGAATGGCTTCTATGTCCGCAAGGCCATCATGATGAATGTTTCCCCGGTGGTGTTATCTGG
 CAGCAGTGCCGTCGATAGTATGCAATTGATAATTATTATCATTTGCGGGTCCCTTCCGGCGATCCGCCTTGTACGGGGC
 GGCGACCTCGCGGGTTTTTCGTATTTATGAAATTTTCGGSTTTAAGGCTTTCCGTTCTTCTTCGTCACTTAATGT
 TTTTATTTAAAAACCCCTCTGAAAGAAAGGAAAGCAGAGTGCTGTAAGCAGAGCTTTTGGCTCTGTCGTTTCTTTC
 TCTGTTTTTGTCCGTGGATGAACAATGGAGTCAACAAAAGCAGAGCTTATCGATGATAAGCGGTCAACATGAGAT
 TCGCGGCGCATTAATACGACTCACTATAGGGATCGACGCCCTACTCCCGCGCATGAAGCGGAGGAGCTGGACTCCGCATG
 CCCAGAGAGCCCCCAACCCCAAGTGCCCTGACCTCAGSCTCTACCACTCTGGCTTGGGCTTGGGCGGGGTCAAGGC
 TACCACGTCTCTTAACAGGTGGCTGGGCTGTCTTGGCGCGCGCTCATGTGACAGCTGCCATAGTTCTGCACTGAGGTG
 ACCGTGGATGTCTGCCCTCGTTGCCATGGCAAGGGATGACGTTACATCTGGGTGTGGAGCTTTTCTGTCCGTGTCA
 GGAATCCAAATACCTTAAATACCTTAGAAGAGGAGTAGCTGAGCCAGGCTTCTCTGGCTTCTCCAGATAAAGTTTG
 ACTTAGATGGAATAACAAATGATAAAGACCGAGCCATCTGAAATTCCTCCTAATTGCACCACTAGGAATGTGTA
 TATTATTGAGCTCGTATGTGTTCTTATTTAAAAAGAAACTTTAGTCATGTTATTAATAAGAAATTTCTCAGCAGTGGGA
 GAGAACCAATATTACACCAAGATAAAGTTGGCATGATCCACATTGCAGGAAGATCCAGCTTGGGTTTTCTATGAATGTG
 AAGACCCCTTTATTAAAGTCTTAAGCTCTGTTTTTGACACTAGGAAGCGATGGCGGGATGGCTGAGSGGCTSTAAGG
 ATCTTTCAATGTCTTACATGTGTGTTCTCTGTCTGCACTAGGACCTGCTGCTAGCCTGCAGCAGAGCCAGAGGGGT
 TCACATGATTAGTCTCAGACACTTGGGGGCAGGTTGCATGTACTGCATCGCTTATTTCCATACGGAGACCTACTATGTG
 TCAAAACCATATGGTGTCTACTCTTCAGAACGGTGGTGGTCATCATGGTGCATTTGCTGACGTTGGATTGGTGGTAGA
 GAGCTCAGATATATGGACGCACTCTTCAGCATTCGTCAACGTGGCTGTGCATTCCTTGTCTCTGAGCACTGGCTAAACA
 GACTCAGAGGTGAGCTCCAGCTCAGTCGCTGCATAGTCTTAGGGAACCTCTCCAGTCTCCCTACCTCAACTATCCA
 AGAAGCCAGGGGGCTTGGCGTCTCAGGAGCCTGCTTGTGGGGACAGGTTGTTGAGTTTTATCTGCAGTAGGTTGCCT
 AGGCATAGTGTAGGACTGATGGCTGCTTGGAGAACACATCCTTTGCCCTCTATGCAAACTGACCTTGACATGGGGGC
 GCTGCTCAGCTGGGAGGATCAACTGCATACCTAAAGCCAGCCTAAAGCTTCTTCGTCCACCTGAAACTCCTGGACCAAG
 GGGCTTCCGGCAGATCCTCTCAGGCCAGTGAGGAGTCTGTGTGAGCTGCATTTCCAATCTCAGGGCGTGAGAGGCAGA
 GGGAGGTGGGGCAGAGCCTTGCAGCTCTTCTCCCTCTGGACAGCGCTCTGGCTCAGCAGCCATATGAGCAGGGC
 ACATCCCCACCCACCCACCTTCTCTGCTGCAAGTATTTAGGCTCTGTTACGGGGGGGGGGGGGGGGGGGCACTCC
 TATCCTCTCTTAGGTAGACAGGACTCTGCAGGAGACACTGCTTTGTAAGATACTGCAGTTTAAATTTGGATGTTGTGAGG
 GGAAGCGAGGGCTCTTTGACCATTCAGTCAAGGTACCTTCTAACTCCCATCGTATTGGGGGGCTACTCTAGTGCTAG
 ACATTGCAGAGAGCCTCAGAAGCTAGTTACAGTGTGGTAGGATTGATCCTTCAGGAGCCTGACATGTGACAGTTCCA
 TTCTTACCGAGTCAACCAACATTTATTAGTACCTACCCCGTAACAGGCACCGTAGCAGTACTGAGGACGGACCACT
 CAAAGAACTGACAGACCGAAGCCTTGAATATAACACCAAGCATCAGGCTCTGCCAACAGAACACTCTTTAACACTCA
 GGCCCTTTAACACTCAGGACCCCAACCCCAAGCAGTTGGCACTGCTATCCACATTTTACAGAGAGGAAAACTA
 GGCACAGGACGATATAAGTGGCTTGCTTAAGCTTGTCTGCATGGTAAATGGCAGGGCTGGATTGAGACCCAGACATTCCA
 ACTCTAGGGTCTATTTTTCTTTTTCTCGTTGTTGCAATCTGGGTCTTACTGGGTAACTCAGGCTAGCCTCAGACTCAT
 ATCCTTCTCCCATGGCTTACGAGTGCTAGGATTCCAGGTGTGTGCTACCATGTCTGACTCCCTGTAGCTTGTCTATACCA
 TCCTCAACATAGGAATTTGTATAGCAGCACACACACCGGAAGGAGCTGGGGAATCCACAGAGGGCTCCGAGGATG
 ACAGGGGAATGCTTACACAGAAGGTGGGAAGGGAAGCAGAGGGAACAGCATGGGCTGGGACCAAGTCTATTGGGG
 AAGCTGCCGGTAACCGTATATGGCTGGGTGAGGGGAGAGGTCATGAATGAGGCAGGAAGAGCCACAGCAGGCAGCGGG
 TACGGGCTCCTTATTGCCAAGAGGCTCGGATCTTCTCCTCTTCTCCTTCCGGGGCTGCTGTTCAATTTCCACCACTG
 CCTCCCATCAGGTCTGTGGCTCAGGACATCACCCAGCTGCAGAACTGGGCTACCCACGTCCTGAATGCTGGGAGG

GCAGGTCTCTCATGCACTCAACACCACTGCTAGCTTCTACGAGGATTCTGGCATCACCTACTTGGGCATCAAGGCCAAT
GATACGCGAGAGTTCACCTCAGTGCTTACTTTGAAAGGSCCAGAGATTTCATTGACCAGGCGCTGGCCATATAAATGG
TAAGGAACGTACATTCCGGCACCCATGGAGCGTAAGCCCTCTGGGACCTGCTTCTCCAAAGAGGGCCCCACTTGAAATA
GGTCCAGAAAGATCCCAAAATATGCCACCACTAGGGATTAASTGTCTACATGTGACCGATGGGGGCCACTGCATAT
AGTCTGTGCCATAGACATGACAAATGGATAATAATATTTAGACAGAGAGCAGGAGTTAGGTAGCTGTGCTCCTTTCCCTT
TAATTGAGTGTGCCATTTTTTTATTCATGTATGTATACATGTGTGTSCACACATGCCATAGGTTGATACTGAACACC
GTCTTCAATCGTTCGCCACCCACCTTATTTTTGAGGCAGGGTCTCTTCCCTGATCCTGGGGCTCATTGGTTTATCTAG
GCTGTGGCCAGTGAGCTCTGGAGTTCTGCTTTTCTCTACCTCCCTAGCCCTGGGACTGCAGGGSCATGTGCTGGGCCAG
GCTTTTATGTCGGTGGGGATCTGAACCTTAGGTCCCTAGGCCCTGAGCACCGTAAGACTCTGCCACATCCCGAGCCTGT
TTGAGCAAGTGAACATTCCCCAGAAATCCCCAGTGGGGCTTTCTACCTTTTATTGGCTAGGCATTGATGAGTGGTC
ACCTCGCCAGAGGAATGAGTGGCCAGACTGGCTCAGGGTCAGCAGCCTAGAGATACTGGGTTAAGTCTTCCCTGCCGCTC
GCTCCCTGCAGCGCAGACAGAAAGTAGGACTGAATGAGAGCTGGCTAGTGGTCAGACAGGACAGAGGCTGAGAGGGTC
ACAGGGCAGATGTACAGCAGAGCAGACAGGTTCTCCCTCTGTGGGGAGGGGTGGCCCACTGCAGGTGTATTTGGCCTTCT
TTGTGCTCCATAGAGGCTTCTGGGTACACAGCAGCTTCCCTGTCTGTGATTCCCAAGAGAACTCCCTACCACTGGA
CTTACAGAAAGTCTATTGACTGGTGTAAAGGTTCAACAGCTTTGGCTCTTGGTGGACGGTGCATACTGCTGTATCAGCTC
AAGAGCTCATTACGAATGAACACACACACACACACACACACACACACAAAGCTAATTTTGATATGCCCTTAATA
GCTCAGTGACTGGGCATTTCTGAACATCCCTGAAGTTAGCACACATTTCCCTCTGGTGTCTCTGGCTTAACACCTTCTAA
ATCTATATTTTATCTTTGCTGCCCTGTACCTTCTGAGAAGCCCTAGGGCCACTTCCCTTCGCACCTACATTGCTGGAT
GGTTTCTCTCCTGCAGCTCTTAATCTGATCCCTCTGCCCTCTGAGCCATGGGAACAGCCCAATAACTGAGTTAGACATAA
AAACGTCTCTAGCCAAAACCTCAGCTAAATTTAGACAATAAATCTTACTGGTTGTGGAATCCTTAAGATTCTTCATGACC
TCCTTCACATGGCAGGATATGAAGCTTTATTACAATTGTTTATTGATCAAATAACTCATAAAAAGCCAGTTGTCTTTC
ACCTGCTCAAGGAAGGAACAAATTCATCCTTAACCTGATCTGTGCACCTTGCAATCCATACGAATATCTTAAGAGTAC
TAAGATTTTGGTTGTGAGAGTCACATGTTACAGAATGTACAGCTTGAAGGTCATCCTTGGGATGCCGAAGTGACCT
GCTGTTCCAGCCCCCTACCTTCTGAGGCTGTTTTGGAAGCAATGCTCTGGAAGCACTTTAGGAGGTAGGATGCTGGAAC
AGCGGGTCACTTCAGCATCCCGATGACGAATCCCGTCAAAGCTGTACATTCTGTAACAGACTGGGAAAGCTGCAGACTTT
AAGGCCAGGGCCCTATGTCCTCTTAATCCCTGTACACCCACCCGAGCCCTTCTCCTCCAGCCGTTCTGTGCTTCTC
ACTCTGGATAGATGGAGAACACGGCCCTTGTAGTTAAAGGAGTGGGCTTCAACCTTCTCAGATGGCAGTGGTTGGTCAT
CCTCATTCAGGGAACTCTGGGGCATTTCTGCCCTTACTTCTCTTTTGGACTACAGGGAATATATGCTGACTTGTTTTGA
CCTTGTGTATGGGGAGACTGGATCTTTGGTCTGGAATGTTTCTGCTAGTTTTTCCCATCCTTTGGCAAAACCTATCTA

TATCTTACCACTAGGCATAGTGGCCCTGTTCTGGAAGCCTGCTTCAGGCTGTTCTCGGGGACCATGTCCCTGGTTTCT
CCCCAGCATATGGTGTTCACAGTGTCTACTGCCGGTGGTTGCTGAACAPAGCGGGGATTGCATCCAGAGCTCCGGTGCC
TTGTGGGTACACTGCTAAGATAAAATGGATACTGGCCTCTCTCTGACCACTTGCAAGCTCTGGTGCCTTGTGGGTACAC
TGCTAAGATAAAATGGATACTGGCCTCTCTCTATCCACTTGCAAGACTCTAGGGACAGGAATCCATTACTGAGAAACC
AGGGGCTAGGAGCAGGGAGGTAGCTGGGCAGCTGAAGTGTCTTGGCGACTAACCAATGAATACCAGAGTTTGGATCTCTAG
AATACTCTTAAATCTGGGTGGGCAGAGTGGCCTGCTCTAATCCAGAACTCGGGAGGCGGAGACAGGGAATCATCAGA
GCAACTGGCTAACCAAGATAGCAAAACACTGAGCTCTGGGCTCTGTGAGAGATCCTGCTTAAATATAGAGAGAGAA
TAAACATTGAAGAGACAGTAGATGCCAATTTTAAAGCCCCACATGCACTGGACAGTGTGGGTTTGAACACACATAT
GCCTCATGTGAACAGGCATGCACACTCGGGCTTATCACACACATAATTTGAAGAGAGAGTGAGAGAGGAGAGTGAC
ATTAGAGTTACAGGAAAGTGTGAGTGAACACACCCATGACACAGACATGTGTGCCAGGAGTAGGAAAGGAGCCTGGG
TTTGTGTATAAGAGGAGGCCATCATGTGTTTCTAAGGAGGCGTGTGAAGGAGGCGTTGTGTGGGCTGGGACTGGAGCAT
GGTGTGTAAGTGAAGTGTCTCCTGTGGGAACAGGAGGGTGGCCACCTGACAGAGGGTCCCACTGTCCAGCGGATCAGT
AAAGAGCCCTGCTGAGAACTTTAGGTAAATAGCCAGAGAGGAAAGGTAGGAAAGTGGGGGACTCCCATCTCTGATGTAG
GAGGATCTGGGCAAGTAGAGGTGCTTTGAGGTAGAAAGAGGGTGCAGAGGAGATGCTCTTAATCTGGGTGAGCAGTT
TCTTTCCAAATAATGCTGTGAGGAGGTGTAGGTGGTGGCCATTCACTCACTCAGCAGAGGGATGATGATGCCCGGTGGA

GGCAGCGSTGTGACGCTGCCTGGTGTGGGTGCTGGGGAACCCAACTTGAATCTAAGACCAAGCACTTTTAACTGCTGAAGGACAGG
TCTCAGTACCCCTCTCTCATTTCTCCGCTGGGTTCATTCTATGGACACATGTAGCTAGAAATATCTTGCTTATCTAATTA
TGTACATTGTTTGTGCTAAGAGAGAGTAATGCTCTATAGCCTGAGGCTGGCCTCAACCTTGGCATCCTCCTGCCCTCAGCC
TCCTCCTCCTGAGTGTCTAGGTGACAGGCGAGTGGTAACTTACATGSGTTTCATGTTTGTTCAGAGCTGAAGGATAACAT
TCATACAGAGAGAAGGTCTGGGTACAAAGTGTGACAGTTCACTGAATGGCACACCCCGTGATCAAGAAACAAAACCTCAGGG
CTGGAGAGATGGCACTGACTGCTCTTCCAGAGGTCCGGAGTTCAATTCCGACGACCCACATGGTGGCTCAGAGCCATCTA
TAACGAGATCTGACGCCCTCTTCTGGTGTGTCTGAAGACAGCTACAGTGTACTCAGCATAAATAAATAAATCTTTAAAG
ACACACACACACACAATTACCAACCCAGAPAGCCCACTGCATGTTTCCCTCCAGGTCTCTGCCCTACAGTACTCCAGGTT
ACCACTGTTCAAGCTTCTAACAACCTGGTTTACTTGGGCTCTTTTCTGCTCTGTGGAGCCACACATTTGTGTGCCCTCAT
ACAGCTTCTTTCTAGTAAGTTGCATATTACTCTGCGTTTTTACATGTATTTATTTATGTAGTTGTGTGTGGCTGTGGGC
CCATGCATGGCACAAGTGTGTGGGGATGTACAGATATTGTGAACAGGGGACAGTTCTTTTCTTCAATCATGTGGGTTCCAG
AGGTTGAACCTCAGGTCATCATGTGTGGGACCAATGCCTTTACCCACTGAGACATCTGCATATTCCTTTTTTTTCCCTG
AGGTGGGGCTTGTTCATAGCCCAAACCTGGCTTTGCACCTTGCAAGTTCGAGTGACTCCCTGTCTCCACCTCTTAGAGTA
TTGGAATTACAGATGTGTACTACCACACTGACTGGATCATTAATTCTTTGATGGGGGCGGGGAAGGCGACATGCTGCAGG
TGAAGGGATGACTGGACTGGACRTGAGCGTGGAGGCGAGAGACAGCTTCAGTCTAATGCTCTCCCACTGAGCTATTTC
GGTTTGCCAGAGAACAACTTACAGAAAGTTCTCAGTGCCATGTGGATTGGGGGTTGGAGTTCAACTCATCAGCTTGACAT
TGGCTCCTCTACCCACTGAGCCTTCTCACTACTCTCTACCTAGATCATTAATTCTTTTTTAAAGAGACTATTAGGGGGC
TGGAGAGATGGCTCAGCGGTTAAGAGCACCGAATGCCCTTCCAGAGGTCCTGAGTTCAATTCCAGCATGCCATTGCTGG
GCAGTAGGGGGCGCAGGTGTTCAACGTGAGTAGCTGTTGCCAGTTTTCCGCGGTGGAGAACTCTTGACACCTGCTGTG
CCTGGTCATTCTGGGTGGGTGCATGGTGATATGCTTGTGTATGGAAGACTTTGACTGTTACAGTGAAGTTGGGCTTCCA
CAGTTAACACGTCTCCCTGTTTCTTGAGGCGCGGGTGCTTGTCATTGCCCGAGGGCTACAGCCGCTCCCAACGCTA
GTTATCGCCTACCTCATGATGCGGCGAGAAGATGGACGTCAAGTCTGCTCTGAGTACTGTGAGGCGAGATCGTGAGATCGG
CCCCAACGATGGCTTCTGCCCCAACTCTGCCAGCTCAATGACAGACTAGCCAAAGGAGGCAAGGTGAACTCTAGGGTG

TGGGGTCAATGGGATTCCTTTAAAGGCATCCTTCCAGGGCTGGGTCACTTCAATAGTAGGGTGCCTTGCCAGCAAGC
GTGAGACCCCTAGGTTAGAGTCCCCAGAACTCTGCCCCCAACCCCCCAAAAGGCATCCTTCTSCCTCTGGGTGGGTGGGG
GAGCAAAACCCCTTAACTAAGACCATTAGCTGGCAGGGGTAAACAATGACCTTGGCTAGAGGAATTTGGTCAAGCTGGAT
TCCGCCCTTCTGTAGAAGCCCCACTTGTTCCTTTGTTAAGGTGGCCACAGTTTGTTCGAGAAATGCCTGAGGGGCCAG
GGAGCCAGACATTAAGAGCCAAAGCTCATTTTGATATCTGAATAACACAGCCTGACTGCCCTGCCCGTGGGAGGTACTGG
GAGAGCTGCTGTGTCCCTGCTCACCACGCCCCCCCCCAGACACACTCCTCGGGTCACTCTGGGAGGTGCCAGCAG
CAATTTGGAAGTTTACTGAGCTTGAGAAGTCTTGGGAGGGCTGACGCTAAGCACACCCCTTCTCCACCCCCCCCCACCC
ACCCCGTGAAGAGAGGGTGAAGAAACATGGGACCAAGCCCTGCTCCAGCCCGTCTTATTGCTGGCATGAGGCAGAGG
GGGCTTTAAAGGCAACCGTATCTAGGCTGGACACTGGAGCCTGTGCTACCGAGTGCCCTCTCCACCTGGCAGCATGC
AGCCCTCACTAGCCCCGTGCCCTCATCTGCCCTACTTGTGCAGCTGCCCTTCTGTGCTGTGAAGGGCCAGGGGTGGCAAGCC
TTCAGGAATGATGCCACAGAGGTCACTCCAGGGCTTGGAGAGTACCCCGAGCCTCCTCTGAGAAACACAGACCATGAA
CCGGGCGGGAATGGAGGCAGACCTCCCCACCATCCCTATGACGCCAAAGGTACGGGATGAAGAAAGCATTAGTGGGG
GGGGGTCCTGGGAGGTGACTGGGGTGGTTTAGCATCTTCTTCAGAGGTTTGTGTGGGTGCTAGCCTCTGCTACATCA
GGSCAGGGACACATTTGCTGGAGAATACTAGCACAGCATTAGAACCTGGAGGGCAGCATTTGGGGGGCTGCTAGAGAGC
ACCCAAGCCAGGGTGGAGGCTGAGGTGAGCCGAGGCTGGCATTAAACAGGGCATGGGCTTGTATGATGGTCCAGAGPATC
TCTCTCAAGGATGAGGACACAGGTCCAGATCTAGCTGCTGACCACTGGGGAAGTGATATGCTGAGGCTGGATGCCAGATG
CCATCCATGGCTGTACTATATCCACATGACCACCACATGAGGTAAAGAGGGCCCCAGCTTGAGATGGAGAAACCGAGA
GGCTCCTGAGATAAAGTCACCTGGGAGTAAGAGAGCTGAGACTGGAAGCTGGTTTGATCCAGATGCAAGGCAACCCCTAG
ATTGGGTTGGGTGGGAACCTGAAGCCAGGAGGAATCCCTTAGTTCCCCCTTGGCCAGGCTCTGCTCAATGAGCCAGA
GGGTAGCATTAAGAGAACAGGGTTGTAGGTGGCATGTGACATGAGGGGCAGCTGAGTGAATGTCCCTGTATGAGCA
CAGGTGGACCACTTGCCCTGAGCTTGCAACCTGACCCCACTTTGCCCTCATTCTGAGGACAGCAGAACTGTGGAGGC
AGAGCCAGCAGAGAGATGCCTGGGTGGGGTGGGGTATCACGCACGGAACTAGCAGCAATGAATGGGGTGGGGTGG
CAGCTGGAGGGCACTCCAGAGAAATGACCTTGTGCTGCTCACCATTGTGTGGGAGGAGAGCTCATTTCCAGCTTGCCAC
CACATGCTGTCCCTCCTGTCTCTAGCCAGTAAGGGATGTGGAGGAAAGGGCCACCCCAAGGAGCATGCAATGCAGTCA
CGTTTTTGACAGGGAAGTGCTTGACCTAAGGGCACTATTCTTGGAAAGCCCCAAACTAGTCCCTCCCTGGGCAACAGG
CCTCCCCACATACCACCTCTGAGGGGTGAGTAAATTAAGCCAGCCAAGAGGGTGGCAAGGCCCTACACCTCCCCCT
GTTGTGCCCCCCCCCCCCGTGAAGGTGCATCCTGGCCTCTGCCCTCTGGCTTTGGTACTGGGATTTTTTTTTCCTT
TTATGTCAATTTGATCTGACACCATGGAATTTTGGAGGTAGACAGGACCCACATGGAATTAGTTAAAGCCTCCCAT
CCATCTAAGCTCATGGTAGGAGATAGAGCATGTCCAAGAGAGGAGGGCAGGCATCAGACCTAGAAGATATGGCTGGCAT
CCAACCAATCTCCTTCCCGGAGAAACAGACTCTAAGTCAGATCCAGCCACCCCTTGAATACCAGCTCAAGGTACACAGA
ACAAGAGAGTCTGGTATACAGCAGGTGCTAAACAAATGCTTGTGGTAGCAAAAGCTATAGGTTTTGGGTGAGAACTCCGA
CCCAAGTCGAGAGTAAGAGCGAAAGGCCCTCTACTGCCACCGCCCCGCCACCTGGGGTCTATAACAGATCACTT
TCACCTTGCGGGAGCCAGAGAGCCCTGGCATCCTAGGTAGCCCCCCCCCCCCCCCCCGCAAGCAGCCAGCCCTGCC
TTTTGGGCAAGTTCTTTCTCAGGCTGGACCTGTGATAATGAGGGGTTGGACGGCCGCTTTGGTGCCTTCAAGTCT
AATGAATTTTATCCCTACCACTGCCCTCTACCCCGCTCCTCCACAGCAGCTGTCTGATTTATTACCTTCAATTAAG
CTCCACTCCTTTCTCCATCTCCTGGATACCGCCCTGTCCAGTGCTGGTAAGGAGCTTAGGAAGGACAGAGCCAG
GTGTGGCTAGAGGCTACCAAGCAGGCTGGGATGAGGAGCTAAACTGGAAGAGTGTGTGTTAGTAGGCACAAAGCCTT
GGGTGGGATCCCTAGTACCGGAGAAAGTGGAGATGGGCGCTGAGAAGTTCAAGAACATCCATCCTTAACTACACAGCCAGT
TTGAGGCCAGCCTGGGCTACATAAACCACATCTCAAGAGCTGCCAATCTGATTTCTGTGCCAGTAGTGCCTGATGTA
ATAGTGGATGAAGTGTGATCCTGGGCAACCTATTTACAGATGTGGGAAAGCACTTTAAGTACCTGCCCCA
GATCAACAAAGTAAGTGAAGAGGCTCCAGTGTTCATCCTGGGTTCCAAAGGACAGGAGAGAGAGCCAGGGTGGG
ATCTCACTGCTCCCGGTGCTCCTTCTATAATCCATACAGATTGCAAGCGCAGGGCAGGTTTGGAAAGAGAGAGG
GTTGGAGGAGCAGACAGTGTGGCTAGGCTGCAGCCCTCACGCATCCCTCTCTCCGAGATGTGTCCGAGTACAGCT
GCCGCGAGCTGCACTACACCGCTTCTEACAGACGGCCATGCCGACAGGCCAAGCCGGTCAACGAGTTGGTGTGCTCC
GSCAGTGGGCCCCGCGGGCTGCTGCCAACGCCATGGGGCGGTGAAGTGGTGGGCCCCGAACGAGCCGGATTCCG

GGTCAGGTTAGAGTTTATTTATGGAAAGTTATTTCTACCTCCATGGGGTCTACAGGGCTGGCGCCCATCAGAAAGAAACA
AACACACAGGCTGATCTGGGAGGGGTGGTACTCTATGGCAGGGAGCAGTGTGCTTGGGGTACAGCCAGACACGGGGCTTG
TATTATACACAGGGCTTGTATTAAATAGGCTGAGAGTCAAGCAGACAGAGAGACAGAAAGAAACACACACACACACACACA
CACACACACACACACACACACATGCACACACCCACTCACTTCTCACTCGAAGAGCCCTACTTACATTCTAAGAACAAACC
ATTCTCTCTCATAAAGGAGACAAAGTTGCAGAAACCCAAAGAGGCCACAGGGTCCCCACTCTCTTTGAAATGACTTGGAC
TTGTTGCAGGGAAGACAGAGGGGTCTGCAGAGGCTTCCTGGGTGACCCAGAGCCACAGACACTGAAATCTGGTGCTGAGA
CCTGTATAAACCTCTTCCACAGGTTCCCTGAAAGGAGCCACATTCCCCAACCTGTCTCTGACCCTGAGGATGAGA
GCCTTGGGCCTTCCCCATTCTTGGAGTGCACCCTGGTTCCCCATCTGAGGGCACATGAGGTCTCAGGTCTTGGGAAAG
TTCCACAAGTATTGAAGTGTCTTGTGTTTGTGTTTGTGATTAAATTTAGGTGTATGAGTGCTTTTGCTTGAATATATGCCT
GTGTAGCATTACAAGCCTGGTGCTGAGGAGATCAGAGATGGCATCAGATACCCTGGAAGTGGACTTGCAGACAGTTA
TGAGCCACTGTGTGGGTGCTAGGAACAGAACCTGGATCCTCCGGAAGAGCAGACAGCCAGCGCTCTTAGCCACTAAGCCA
TCACTGAGGTTCTTCTGTGGCTAAAGAGACAGGAGACAAAGGAGAGTTTCTTTTAGTCAATAGGACCATGAATGTTCTCT
CGTAACGTGAGACTAGGGCAGGGTGATCCCCAGTGACACCGATGGCCCTGTGTAGTTATTAGCAGCTCTAGTCTTATTC
CTTAATAAGTCCAGTTTGGGGCAGGAGATATGTATTCCTGCTTTGAAGTGGCTGAGGTCAGTTATCTACTTCCAAGT
ACTTGTCTTCTTCTTGGAGTTGGGGAAGCTCCCTGCCTGCCTGTAAATGTGTCCATTCTTCAACCTTAGACAAGATCAC
TTTCCCTGAGCAGTCAGGCCAGTCCAAGCCCTTCAATTTAGCTTTCATAAGGAACACCCCTTTTGTGGGTGGAGGTAG

CACTTGCTTGAATCCCAGCATTAAGAAGGCAGAGAGAGTCCGATCTCTGTGAGTTCCAGCCAGCCTGCTCTACGGAGT
GAGTTCCAGACAGCCAGGCCCTACACAGAGAAACCCTGTCTCGAAAAAACAACAAACAAAGAAATAAGGAAAAAGAAAA
CAAAAAACGAACAAACAGAAAAACAGCCAGAGTGTGTTGTCCCGTATTTTATTATCATATTTTGTCCCTTTGCCATTT
TAGACTAAAGACTCGGGAAGCAGGTCTCTCTCTGTTTCTCATCGGACACACCCAGAACCCAGATGTATGGAAGATGGC
TAATGTGCTGCACTTGCACATCTGGGGCTGGGTGGATTGGTTAGATGGCTGGGCTGGGTGTGGTTACGATCACTGCAAG
AGCAGGAGTATGTGGTGATAGCAACGAGGAAGTTTGACAGAGACAACTCTGTGTACTGATGTGCAGGTATGGGCA
CATECAAGCAGAGCCAGGGGACAGCCTTAGGGTAGTGTTCACAGACCCCTCCCCCTTTTAAACATGGGCATCTCTCA
TTGGCTGGAGCTTGCCACTGGGCTGGGCTGGCTAGCTTGTAGGTCCAGGGATCTGCATATCTCTGCCTCCCTAGTGC
TGGGATTACAGTCATATATGACACACCTGGCTTTTATGTGGTTCTGGGCTTTGACCCAGATCTGAGTGTCTGCAA
GGCAATCGGTTGAATGACTGCTTCTATCTCCCCAGACCCCTGGGATTCTACTTTCTATTAAAGTATTTCTATTAAATCAATG
AGCCCCCTGCCCTGCCTCAGCAGTCTTAGGCCCTGCTGAGAGTCAAGTGGGGAGTGAGGCAAGCCTCGAGACCCCATC
AGCGAAGCAGAGGACAAAGAAATGAAACTTGGGRTTCGAGGCTCGGGATATGAGATACAGAAAGGGTCAGGGAGAGAA
ATGAACCGAGATGAATAGAGGCAGGAAGGTAGGGCCCTGCATACATGGACCTGGTGATCATGTTATCTGCATGGGGTTT
GCATTGCAATGGCTCTTACAGAGGTTCAACCACTGGGAACAGAGCCAAAGAGAGAGTAGGTGGTGTGTTGAGTCAGA
TACTGTCACTCATGCTGAAGAAATGGAAGCAATTAACGATGCGCCGCAATTAGGATATTAGCTCCCTGAAGAAAGGCAA
GAAGCTGGGCTGTGGGCACTGAAGGGAGCTTTGAATGATGTACATTTCTGTATGCTTACAGGGCAGTATTGGAGACT
GAGACTTGACTTGTGTGTCATATGATTCCTCTTTTCTACAGTCATCTGGGGCTCCTGAGCTTCGTCTTGTCCAAGA
ACCTGAGCTGGCAGTGGGAGCTGCAGTATAGATGTCTGCAAGAAAGATCTGAAAGAGGGAGGAAGATGAAGGACCC
AGAGGACCAACCCACTCTGCTGCTGACAAAGCTGCAGGACCACTCTCTACAGATGGGAGACAGAGGCGAGAGATGA
ATGGTCAGGGGAGGAGTCAGAGAAAGGAGAGGGTGAGGCAGAGACCAAGGAGGGAAACACTTGTGCTCTACAGCTACTG
ACTEAGTACCAGCTGCGTGGCAGACAGCCAATGCCAAGGCTCGGCTGATCATGGCACCTCGTGGGACTCCTAGCCAGTG
CTGGCAGAGGGGAGTGTGAATGGTGATGGTTGGATATGATCTGAATGTGGTCCAGCCCTAGTTTCTTCCAGTTGCT
GGGATAAAGCACCCCTGACCAAGCTACTTTTTGTTTGTGTTTGGTTTGGTTTGTGTTTGGTTTTCGAGGCAGGGTT
TCTCTGTATCACTTACCTGTCTTGAACCTCACTCTGTAGACCAAGGCTGGCCTCGAACTCAGAAATCCCCCTGCTCTGC
CTCCTAAGTGTGGAATTAAGGCTGCGCCACCACTGCGGGCCCAAGCTACTTTAAGAGAGAGAGAGGAATGTATAAG
TATTATAATTCCAGGTTATAGTTCAATGTCTGTAGAATTGGAGTCTTCATATTCAGGTAATCTCCACAGACATGCCACA
AAACAACCTGTTCTACGAATCTCTCATGGACTCCCTCCCCAGTAATCTAAACTGTGTCAAATCTACAAGAAATAGTG
ACAGTCACAGTCTCTAACGTTTGGGCATGAGTCTGAAGTCTCATTGCTAAGTACTGGGAAGATGAAAACCTTACCTAGT
GTCAGCATTTGGAGCAGAGCCTTTGGGATTTGAGATGGTCTTTGACAGCTCCTAATGGCTACATGGAGAGAGGGGGCC

AGGATATCTGATATTGACTTCTGSCCAACACAGCCCTCTCTGCACATCTGTAGTTGCAAGCCTTTTGCACCTAAGTTTG
GCCAGAGTCAGAGTTTGCAAGTGTGTTGGACTGAATGCACGTGTGCTGATCTACAAAGTCACCCCTCTTCTCAAG
CTAGCAGCACTGGCTTCGGCCAGCTGCTCATTCAAGCCTCTTTGCAGAGTCATCACGGGATGGGGGAGCAGGGCCCTC
CCTAGAACACCAAGCCTGTGGTTGTTTATTGAGGACATTATTGAGGGCCAGATGACAGATACTCTATCACTTGGCCAA
CAGTCGGGTGTGCGGTGTAGGTTATTTCTGTCTGTCAGAAAACAGTSCAACCTGGACAAAAGAAATAAATGATATCA
TTTTTCATTGAGGCAACTAGATTCCGTGGTACAAAAGCTCCCTGGGGAAGGAGCCGGGACAGCGCGGCTCCTGAGTCA
CTATTTCCGTCTGTCAATCTCTAATCTCTTGTATTCCTCCCTCTGTCTGTTTCCTTCTCTGTGCGGGCCAGTGA
GTCTGTGTACTCACAGGAGGAGGGTGGCAAGCCCTGGTCTCTACGGGCTGGGGGAAGGGGGGAAGCTGTGCGGCCAG
TGACTTTTTCCCTTTCTCTTTTCTTAGAAACAGTCTCAATTTAAGATAATGAGTCTCCTCATTCAGTGTGCTCACT
ATTCATAGGACTTATCCACCCCGCCCTGTCAATCTGGCTAAGTAAGACAGTCAAAATTTAAAGGGAACGTTTTCTA
AAATGTGGCTGGACCGTGTGCGGCAAGAAACAGGCTATGGCGGTCTAAGTTACATGCTCTCTGCCAGCCCGGTGCT
TTTTCTTTGGGAAGGAGACCCGGAGGTAAACGAATTTGCCAACTTTTGTGATGGTGTGCGCGGGGTGACTCTTTAA
ATGTCATCCATACCTGGGATAGGGAAAGCTCTTCAGGAGTCTCTAGCCCTCCCTTCAGGAAAGATTCACCTTCGGT
TTAGTTAGCTTCCACCTGGTCCCTTATCCGCTGTCTCTGCCACTAGTCTCATCCATCCGGTTTCGCGCCTCATCCACC
TTGCCCTTTTAGTTCCTAGAAAGCAGCCGTAGTCTTGGCAGGTGGGCCATTGGTCACTCCGCTACCACTGTTACCATG
GCCACCAAGGTGTCAATTAATATGAGCTCACTGAGTCTGCGGGATGGCTTGGTTGGTAATATGCTTCTGCAAAATCG
TGAGAACTGGAGTCAATTCACGACATGGATGATTTCCAGCAGCTGGAAAGCAGGAGCAGAGATCTTAAGGCTCCT
GGCCAGACAGCCAGCCTAATTAGTATCAGTGAGAGACCTGTCTCAAGGAACAAGATGGAACATCAAGGTCACCTC
TTGTCTCCACACACAAATACACACATGCACATACATCCACACACAGGCTAACACATGACACACCTGAACACCTCCA
CAATATACATACATAAAATAAATAACATACACACATACATACATACACACATTCCTCTCTTASTCTCCTGGCTAC
GCTCTGTGACCCCACTAAGGCTCAACTTCTTCTATTCTTCATCTTGACTCCTGTACTTTGCATGCCTTTTCCAG
CAAGGCTTTTCTTTAAATCTCCGTCAATTCATAAACTCCCTCTAAATTTCTTCCCTGCCCCTTTCTTCTCTAGGGA
GATAAGACACACACTACAAAGTCAACGTGGGACCACTTATTCACCCACCCAGCCCTGCTTCTGTTCATCCGGCCAGCT
AAGTAGTCAACCTCTCTGGTGTGTACCCCTGGACCTGGCTTACCACAGCTCCTCCATGCTACCCAGCCCTGCAAAAC
TTCAGCCTAGCCTCTGGTTCTCAACACAGCAGGCCCCAGTCTGGCTTCTATGTCCTAGAAATCTCCTTCATTTCTCTCA
TTTCCCTCTGAATCTACACCTTCTTTCTCCCTTCTCCTGACCTCTAATGTCTTGGTCAAACGATTACAAGGAAGCCAA
TGAAATTAGCAGTTTGGGTAACCTCAGAGTCAGCAGGGAGCTGGGATGAATTCACATTTCCAGGCTTTGCTTTGCTCC
CCGGATTCTGACAGGAGTTCGGAGGCTGAGTCCAGGAAGCTGAATTTAAATACACTCCAGCTGGGTTCTGAGGCAAGC
CCTACCACATCAGCTGGCCCTGACTGAGCTGTGTCTGGGTGGCAGTGGTGTGGTGTGGTGTGGTGTGGTGTGGTGTGGT
GTGGT
GACAAATCTGCCCTATATAGGCAAGATGACTTATGCCTATATAAGATATAAGATGACTTATGCCACTTATTAGCA
ATAGTTACTGTCAAAGTAATCTATTATACACCCCTTATACATGGTATTGCTTTTGTGGAGACTCTAAATCCAGATT
ATGTATTTAAAAAAATTCCTCAGTCTTAAAGGTGAAGATGGACCCAGATAGAAGGTACGGCACAGTATGGAGT
CGGAGTGTGGAGTCTGCCAATGGTCTGGACAGAAGCATCCAGAGAGGGTCCAAGACAAATGCCCTCGCCTCCTAAGGAAC
ACTGGCAGCCCTGATGAGGTACAGAGATTGCTAAGTGGAGGAATACAGGATCAGACCCATGGAGGGGCTTAAAGCGTGA

CTGTAGCAACCCCTCCGCTGAGGGGCTCCAGGTGGGCGCCCAAGGTGCTGCAGTGGGAGCCACATGAGAGGTGATGTCTG
GAGTCACCTCGGGTACCAATTGTTTAGGGAGGTGGGGATTGTGTGTGTGGAGACAGGCAGCCTCAAGGATGCTTTTCAACA
ATGGTGTAGTGGTTGGAATAAAACAGGGGCCATCACACTGGCTCCCATAGCTCTGGGCTTGCCAGCTTCCACATCTGCC
CCGACCCCTCTGTCTGGCACCAGCTCAAGCTCTGTGATTCTACACATCCAAAGAGGAAGATAGCCTACTGGCATGCC
ACCTCTTCTGGACCATCAGGTGAGAGTGTGGCAAGCCCTAGGCTCCTGTCCAGGATGCAAGGCTGCCAGATAGGATGCTC
AGCTATCTCCTGAGCTGGAACTATTTTAGGAATAAGGATTATGCCCGCCGGGGTTGGCCAGCAGCCCAAGCAGCCTGTGC
TTGCGTAAAGCAAGTGTGTTGATTATCTTAAACAGAGCCGTGGACCCACCCACAGGACAAGTATGATGCATCTGT
TTCATGTATCTGAAAGCGACACACCACTTTTACACATCATGGCATCTTCTAACCCTCATCTTTTGTGTTTGTGTTT
TTSAGACAGGGTTTCTCTGTGTAGTCTGTGGTCTCTGGAACCTCACTTTGTAGACAGGCTGGGCTCGAATCAGAAATC

CTGGGATTAAAGGTGTGTGCCACCACGCCCGGCCCTAACCCCATTTCTTAATGGTGATCCAGTGGTTGPAATTTGGGGCC
ACACACATGTCCATTAGGATTAGCTGCTGTCTTCTGAGCTACCTGGTACAATCTTTATCCCCTGGGGCCTGGGCTCCTG
ATCCCTGACTCGGGCCCGATCAAGTCCAGTTCTGGGCCCGATCAAGTCCAGTTCTGGGCCCGAACAAAGTCCAGTCCCT
AGCTCGATTAGCTCATCTGGCTCCCTGGCCTGTTCTTACTTACACTCTTCCCTTGCTCTGGACTTGTTCCTTTCTTTA
CTCAAGTTGTCTGCCACAGTCCCTAAGCCACCTCTGTAAACAACTAAGATATACTTCCCTCAAGCCGGAAGTCCCTG
AGTCACACACCCCTCTGGAGGTGTGTGGACACATGTTGATGCGTGTGGTTGCGCTTACGTACGTGTGC

Sequence ID No. 18: Human Beer Genomic Sequence (This gene has two exons, at positions 161-427 abd 3186-5219).

tagaggagaa gtctttgggg agggtttgcct ctgagcacac ccctttccct. ccctccgggg 60

ctgagggaaa catgggacca gccctgcccc agcctgtcct cattggctgg catgaagcag 120

agaggggctt taaaaaggcg accgtgtctc ggctggagac cagagcctgt gctactggaa 180

ggtggcgtgc cctcctctgg ctggtaccat gcagctccca ctggccctgt gtctcgtctg 240

cctgctggta cacaCagcct tccgtgtagt ggagggccag gggtaggcagg cgttcaagaa 300

tgatgccacg gaaatcatcc ccgagctcgg agagtacccc gagcctccac cggagctgga 360

gaacaacaag accatgaacc gggcggagaa cggagggcgg cctccccacc acccctttga 420

gaccaaaggt atgggggtgga ggagagaatt cttagtaaaa gatcctgggg aggtttttaga 480

aacttctctt tgggaggctt ggaagactgg ggtagacca gtgaagattg ctggcctctg 540

ccagcactgg tcgaggaaca gtcttgccctg gaggtggggg aagaatggct cgctggtgca 600

gccttcaaatt tcaggtgcag aggcctgagg caacagacgc tggtagagac ccagggcagg 660

gaggacgctg gggtagtgag ggtatggcat cagggcatca gaacaggctc aggggctcag 720

aaaagaaaag gtttcaaaga atctcctcct gggaatatag gagccacgctc cagctgctgg 780

taccactggg aagggaaaca ggtaaggagg cctcccatcc acagaacagc acctgtgggg 840

caccggacac tctatgctgg tggtagctgt cccaccaca cagaccaca tcatggaatc 900

cccaggaggt gaacccccag ctgaagggg aagaaacagg ttccaggcac tcagtaactt 960

ggtagtgaga agagctgagg tgtgaacctg gtttgatcca actgcaagat agccctgggt 1020

tgtggggggg tgtgggggac agatctccac aaagcagtgg ggaggaaggc cagagaggca 1080

ccctgcagt gtgcattgcc catggcctgc ccagggagct ggcacttgaa ggaatgggag 1140

ttttcggcac agtttttagcc cctgacatgg gtgcagctga gtccaggccc tggaggggag 1200
agcagcatcc tctgtgcagg agtagggaca tctgtcctca gcagccaccc cagtcccaac 1260
cttgccctcat tccaggggag ggagaaggaa gaggaaccct gggttcctgg tcaggcctgc 1320
acagagaagc ccaggtgaca gtgtgcatct ggcctctataa ttggcaggaa tcctgaggcc 1380
atgggggagt ctgaaatgac acttcagact aagagcttcc ctgtcctctg gccattatcc 1440
aggtggcaga gaagtccact gccagggctc ctggacccca gccctccccg cctcacaacc 1500
tgttgggact atgggggtgt aaaaaggga actgcatggg aggccagcca ggaccctccg 1560
tcttcaaaat ggaggacaag ggcgcctccc ccacagctc cccttctagg caaggtcagc 1620
tgggtccag cgactgcctg aagggctgta aggaacccaa acacaaaatg tccacctgc 1680
tggaactcca cgagaggcca cagccccga ggaagccaca tgctcaaaac aaagtcatga 1740
tctgcagagg aagtgcctgg cctaggggag ctattctcga aaagccgcaa aatgccccct 1800
tcccctggga aatgcccccc tgaccacaca cacattccag ccctgcagag gtgaggatgc 1860
aaaccagccc acagaccaga aagcagcccc agacgatggc agtggccaca tctccctgc 1920
tgtgcttgct cttcagagtg ggggtggggg gtggccttct ctgtccctc tctggtttgg 1980
tcttaagact atttttcatt ctttcttgtc acattggaac tatcccatg aaacctttgg 2040
gggtggactg gtactcacac gacgaccagc tatttaaaaa gtcccaccc atctaagtc 2100
accataggag acatggtaaa ggtgtgtgca ggggatcagg ccaggcctcg gagcccaatc 2160
tctgcctgcc cagggagtat caccatgagg cgccattca gataacacag aacaagaaat 2220
gtgcccgca gagagccagg tcaatgtttg tggcagctga acctgtagg tttgggtcag 2280
agctcagggc ccctatggta ggaaagtaac gacagtaaaa agcagccctc agctccatcc 2340
cccagcccag cctcccatgg atgctcgaac gcagagcctc cactcttgcc ggagccaaaa 2400
ggtgctggga cccagggaa gtggagtccg gagatgcagc ccagcctttt gggcaagtcc 2460

ttttctctgg ctggggcctca gtattctcat tgataatgag ggggttgag acactgcctt 2520

tgattccttt caagtctaata gaattcctgt cctgatcacc tccccttcag tccctcgctt 2580

ccacagcagc tgccctgatt tattaccttc aattaacctc tactcctttc tccatccctt 2640

gtccacccct cccaagtggc tggaaaagga atttgggaga agccagagcc aggcagaagg 2700

tgtgctgagt acttaccctg cccaggccag ggaccctgag gcacaagtgt ggcttaaate 2760

ataagaagac cccagaagag aaatgataat aataatacat aacagccgac gctttcagct 2820

atatgtgcca aatggatatt tctgcattgc gtgtgtaatg gattaactcg caatgcttgg 2880

ggcggcccat ttgcagaca ggaagaagag agagggttaag gaacttgccc aagatgacac 2940

ctgcagttag cgatggagcc ctggtgtttg aacccagca gtcatttggc tccgagggga 3000

cagggtgagc aggagagctt tccaccagct ctgagagcgc tgggaccttc ctgcaataga 3060

tgttcagggg caaaagcctc tggagacagg ctgggcaaaa gcagggtggtt ggtggagaga 3120

gacgggcccg tccagggcag ggggtggccag gcggggcgcc acctcacgc gcgcctctct 3180

ccacagacgt gtccgagtag agctgcccgc agctgcactt caccgctac gtgaccgatg 3240

ggcgtgccc cagcgccaag ccggtcaccg agctggtgtg ctccggccag tgcggcccgg 3300

cgcgcctgct gcccaacgac atcggccgag gcaagtgggt gcgacctagt gggcccgact 3360

tccgctgcat ccccgaccgc taccgcgcgc agcgcgtgca gctgctgtgt cccggtggtg 3420

aggcgcgcgc cgcgcgcaag gtgcgcctgg tggcctcgtg caagtgcaag cgcctcacc 3480

gcttcacaaa ccagtcggag ctcaaggact tcgggaccga ggccgctcgg ccgcagaagg 3540

ggcgggaagc ggggccccgc gccgggagcg ccaaagccaa ccaggccgag ctggagaacg 3600

cctactagag cccgcccgcg cccctcccca ccggcgggcg ccccgccctt gaaccgcgc 3660

cccacatttc tgcctctgc gcgtggtttg attgtttata tttcattgta aatgcctgca 3720

accaggggca gggggctgag acctccagg ccctgaggaa tcccgggcgc cggaaggcc 3780

cccctcagcc cgccagctga ggggtccac ggggcagggg aggggaattga ggtcacaga 3840

cactgagcca cgcagccccc cctctggggc cgcctacett tgctgggtccc acttcagagg 3900

aggcagaaat ggaagcattt tcaccgccct ggggttttaa gggagcgggtg tgggagtggg 3960

aaagtccagg gactgggttaa gaaagtggga taagattccc ccttgccact cgctgcccac 4020

cagaaagcct gaggcgtgcc cagagcacia gactgggggc aactgtagat gtggtttcta 4080

gtcctggctc tgccactaac ttgctgtgta acctgaact acacaattct ccttcgggac 4140

ctcaatttcc actttgtaaa atgagggtgg aggtgggaat aggatctcga ggagactatt 4200

ggcatatgat tccaaggact ccagtgcctt ttgaatgggc agagggtgaga gagagagaga 4260

gaaagagaga gaatgaatgc agttgcattg attcagtgcc aaggtcactt ccagaattca 4320

gagttgtgat gctctcttct gacagccaaa gatgaaaaac aaacagaaaa aaaaaagtaa 4380

agagtctatt tatggctgac atatttacgg ctgacaaaact cctggaagaa gctatgctgc 4440

ttcccagcct ggcttcccgc gatgtttggc tacctccacc cctccatctc aaagaaataa 4500

catcatccat tggggtagaa aaggagaggg tccgaggggtg gtgggagggga tagaaatcac 4560

atccgcccc aactcccaaa gacgagcatc cctccccga cccatagcca tgttttaag 4620

tcaccttccg aagagaagtg aaaggttcaa ggacactggc cttgcaggcc cgaggagca 4680

gccatcacia actcacagac cagcacatcc cttttgagac accgccttct gccaccact 4740

cacggacaca tttctgccta gaaaacagct tcttactgct cttacatgtg atggcatatc 4800

ttacactaaa agaataattat tgggggaaaa actacaagtg ctgtacatat gctgagaaac 4860

tcgagagcat aatagctgcc acccaaaaat ctttttgaaa atcatttcca gacaacctct 4920

tactttctgt gtagttttta attgttaaaa aaaaaaagtt ttaaacagaa gcacatgaca 4980

tatgaaagcc tgcaggactg gtcgtttttt tggcaattct tccacgtggg acttgtccac 5040

aagaatgaaa gtagtgggtt ttaaagagtt aagttacata tttattttct cacttaagtt 5100

atztatgcaa aagtttttct tgtagagaat gacaatgtta atattgcttt atgaattaac 5160

agtctgttct tccagagtcc agagacattg ttaataaaga caatgaatca tgaccgaaag 5220

gatgtggtct cattttgtca accacacatg acgtcatttc tgtcaaagtt gacacccttc 5280

tcttggteac tagagctcca accttggaac cacctttgac tgctctctgg tggcccttgt 5340

ggcaattatg tcttcctttg aaaagtcatg ttatccctt cctttccaaa ccagaccgc 5400

atttcttcac ccagggcacg gtaataacct cagccttgta tctttttagc agcctccct 5460

ccatgctggc ttccaaaatg ctgttctcat tgtatcactc cctgctcaa aagccttcca 5520

tagtccccc ttgccagga tcaagtgcag ttccctatc tgacatggga ggccttctct 5580

gcttgactcc cactccccc tccaccaagc ttctactga ctccaaatgg tcatgcagat 5640

cctgcttcc ttagtttgcc atccacactt agcaccacca ataactaatc ctctttctt 5700

aggattcaca ttacttgta tcttttccc taacctcca gagatgtcc aatctccat 5760

gatccctctc tctctgagg ttccagccc tttgtctac accactactt tggttctaa 5820

ttctgtttc catttgacag tcattcatgg aggaccagcc tggccaagtc ctgcttagta 5880

ctggcataga caacacaaag ccaagtacaa ttcaggacca gctcacagga aacttcact 5940

tcttogaagt gtggatttga tgcctcctgg gtagaaatgt aggatcttca aaagtgggcc 6000

agcctcctgc acttctctca aagtctgcgc tcccaagggt gtcttaatag tctgggatgc 6060

tagctgagtt agcatcttca gatgaagagt aacctaaag ttactcttca gttgcctaa 6120

ggtgggatgg tcaactggaa agctttaaat taagtccagc ctaccttggg ggaaccacc 6180

cccacaaaga aagctgaggt cctcctgat gacttgtagc tttaactacc aataaccac 6240

ttgaattaat catcatcatc aagtcttga taggtgtgag tgggtatcag tggccgtcc 6300

cttctgggg ctccagccc cgaggaggcc tcagttagcc cctgcagaaa atccatgcat 6360

catgagtgtc tcagggccca gaatatgaga gcaggtagga aacagagaca tcttccatcc 6420

ctgagaggca gtgcggtcca gtgggtgggg acacgggctc tgggtcaggt ttgtgtgtt 6480

tgtttgttg ttttgagaca gagtctcgt ctattgccc ggctggagtg cagtgtcaca 6540

atctcgggctt actgcaactt ctgccttccc ggattcaagt gattctcctg cctcagcctc 6600
cagagtagct gggattacag gtgcgtgcc aacgcctgg ctaatttttg tatttttgat 6660
agagacgggg tttcaccatg ttggccaggc tagtctcgaa ctcttgacct caagtgatct 6720
gcctgcctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccaca cccagcccca 6780
ggttggtgtt tgaatctgag gagactgaag caccaagggg ttaaattgtt tgcccacagc 6840
catacttggg ctgagttcct tgcctaccc ctcacttgag ctgcttagaa cctgggtgggc 6900
acatgggcaa taaccaggtc aactgtttt gtaccaagtg ttatgggaat ccaagatagg 6960
agtaatttgc tctgtggagg ggaatgagga tagtgggttag ggaaagcttc acaaagtggg 7020
tgttgcttag agattttcca ggtggagaag ggggcttcta ggcagaaggc atagcccaag 7080
caaagactgc aagtgcattg ctgctcatgg gtagaagaga atccaccatt cctcaacatg 7140
taccgagtc ttgccatgtg caaggcaaca tgggggtacc aggaattcca agcaatgtcc 7200
aaacctaggg tctgctttct gggacctgaa gatacaggat ggatcagccc aggctgcaat 7260
cccattacca cgagggggaa aaaaacctga aggcctaaat gtaggtcggg ttagaggtta 7320
tttatggaaa gttatattct acctacatgg ggtctataag cctggcgcca atcagaaaag 7380
gaacaaacaa cagacctagc tgggaggggc agcattttgt ttagaggggc ggggcacatg 7440
ttctgggggt acagccagac tcagggttg tattaatagt ctgagagtaa gacagacaga 7500
gggtagaag gaaataggtc cttttctctc tctctctctc tctctctctc actctctctc 7560
tctctcacac acacacacag acacacacac acgctctgta ggggtctact tatgctccaa 7620
gtacaaatca ggccacattt acacaaggag gtaaaggaaa agaacgttgg aggagccaca 7680
ggaccccaaa attccctgtt ttccttgaat caggcaggac ttacgcagct gggaggggtg 7740
agagcctgca gaagccacct gcgagtaagc caagttcaga gtcacagaca ccaaagctg 7800
tgcccatgtc ccacaccgc ccacctcca cctgtctctt gacacagccc tgtgctccac 7860
aaccacactc ccaatcatt gattataact ctacacactc caccctctct cctaccacat 7920

cccccccca ttcttggaac ctgccctctg tcttctccct tgtccaaggg caggcaaggg 7980
 ctcaagctatt gggcagcttt gaccaacagc tgaggctcct tttgtggctg gagatgcagg 8040
 aggcagggga atattccctct tagtcaatgc gaccatgtgc ctggtttgcc caggggtggc 8100
 tcgtttacac ctgtaggcca agcgttaatta ttaacagctc ccacttctac tctaaaaaat 8160
 gacccaatct gggcagtaaa ttatatgggtg cccatgctat taagagctgc aacttgctgg 8220
 gcgtgggtggc tcacacctgt aatcccagta ctttgggacg tcaaggcggg tggatcacct 8280
 gaggtcacga gttagagact ggcctggcca gcatggcaaa accccatctt tactaaaaat 8340
 aaaaaatta gcaaggcatg gtggcatgca cctgtaatcc caggtactcg ggaggtgag 8400
 acaggagaat ggcttgaacc caggaggcag aggttgcatg gagccaagat tgtgccactg 8460
 cctccagcc ctggcaacag agcaagactt catctcaaaa gaaaaggat actgtcaatc 8520
 actgcaggaa gaaccagggt aatgaatgag gagaagagag gggctgagtc accatagtgg 8580
 cagcaccgac tctgcagga aaggcgagac actgggtcat gggtagtgaa gggtgccctg 8640
 aatgacgttc tgctttagag accgaacctg agccctgaaa gtgcatgcct gttcatgggt 8700
 gagagactaa attcatcatt ccttggcagg tactgaatcc tttcttacgg ctgccctcca 8760
 atgccaatt tccctacaat tgtctggggt gcctaagctt ctgccacca agagggccag 8820
 agctggcagc gagcagctgc aggtaggaga gataggtagc cataaggagag gtgggaaaga 8880
 gagatggaag gagaggggtg cagagcacac acctccctg cctgacaact tctgagggc 8940
 tggatcatgcc agcagattta aggcggaggc aggggagatg gggcgggaga ggaagtgaag 9000
 aaggagaggg tgggatgga gaggaagaga gggatcatc tcattcattc cattgctact 9060
 gactggatgc cagctgtgag ccaggcacca cctagctct gggcatgtgg ttgtaatctt 9120
 ggagcctcat ggagctcaca gggagtgtg gcaaggagat ggataatgga cggataacaa 9180
 ataaacattt agtacaatgt ccgggaatgg aaagtctctg aaagaaaaat aaagctgggt 9240
 aacatataaa caccctcaa acccccaga caggaattt ctgaagatg agatttcaa 9300

c

9301

SEQUENCE LISTING

[0248]

<110> Brunkow, Mary E.

Galas, David J.

Kovacevich, Brian

Mulligan, John T.

Paeper, Bryan W.

Van Ness, Jeffrey

Winkler, David G.

<120> COMPOSITIONS AND METHODS FOR INCREASING
BONE MINERALIZATION

<130> 240083.508

<140> US

<141> 1999-11-24

<160> 41

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2301

<212> DNA

<213> Homo sapien

<400> 1

agagcctgtg ctactggaag gtggcgtgcc ctctctctggc tggtagcatg cagctccac	60
tggccctgtg tctcgtctgc ctgctggtac acacagcctt ccgtgtagtg gagggccagg	120
ggtggcaggc gttcaagaat gatgccacgg aaatcatccc cgagctcgga gagtaccccg	180
agcctccacc ggagctggag aacaacaaga ccatgaaccg ggcggagAAC ggagggcggc	240
ctccccacca cccctttgag accaaagacg tgtccgagta cagctgccgc gagctgcact	300
tcacccgcta cgtgaccgat gggccgtgcc gcagcgccaa gccggtcacc gagctggtgt	360
gctccggcca gtgcggcccg gcgcgcctgc tgcccaacgc ctcgggccgc ggcaagtggc	420
ggcgacctag tgggcccgcac ttccgctgca tccccgaccg ctaccggcgc cagcgcgtgc	480
agctgctgtg tcccggtggc gagggcgcgc gcgcgcgcaa ggtgcgcctg gtggcctcgt	540
gcaagtgcAA ggcctccacc cgcttcacaa accagtcgga gctcaaggac ttccgggaccg	600
agggcctcga acccagaaag gccccgaaac ccccccacaa cccccgaaac cccaaaccca	660

```

accaggccga gctggagaac gcctactaga gcccgcccgc gccctccccc accggcgggc 720
gcccgccccc tgaacccgcg cccacattt ctgtcctctg cgcgtgggtt gattgtttat 780
atcttcattgt aaatgcctgc aacccagggc aggggggtga gacctccag gccctgagga 840
atcccgggcg ccggcaaggc cccctcagc ccgccagctg aggggtccca cggggcaggg 900
gaggggaattg agagtcacag aactgagcc acgcagcccc gccctctgggg ccgcctacct 960
ttgctggtcc cacttcagag gaggcagaaa tggagcatt ttcaccgcc tgggggttta 1020
agggagcggg gtgggagtgg gaaagtccag ggactgggta agaaagtggg ataagattcc 1080
cccttgacc togctgcccc tcagaaagcc tgaggcgtgc ccagagcaca agactggggg 1140
caactgtaga tgtgggtttct agtcctggct ctgccactaa ctgctgtgt aacctgaac 1200
tacacaattc tcttcggga cctcaatttc cactttgtaa aatgaggggt gaggtgggaa 1260
taggatctcg aggagactat tggcatatga ttccaaggac tccagtgcct tttgaatggg 1320
cagaggtgag agagagagag agaaagagag agaatgaatg cagttgcatt gattcagtgc 1380
caaggtcact tccagaattc agagttgtga tgctctcttc tgacagccaa agatgaaaaa 1440
caaacagaaa aaaaaaagta aagagtctat ttatggctga catatttacg gctgacaaac 1500
tcttgaaga agctatgtg ctcccagcc tggcttcccc ggatgtttgg ctacctcac 1560
ccctccatct caaagaaata acatcatcca ttggggtaga aaaggagagg gtccgagggt 1620
gggtgggggg atagaaatca catccgcccc aacttcccaa agagcagcat cctcccccg 1680
acccatagcc atgttttaaa gtcaccttc gaagagaagt gaaagggttc aggacactgg 1740
ccttcgagcg ccgagggagc agccatcaca aactcacaga ccagcacatc ccttttgaga 1800
caccgccttc tgcccaccac tcacggacac atttctgcct agaaaacagc ttcttactgc 1860
tcttacatgt gatggcatat cttacactaa aagaatatta ttgggggaaa aactacaagt 1920
gctgtacata tgctgagaaa ctgcagagca taatagctgc caccacaaaa tctttttgaa 1980
aatcatttcc agacaacctc ttactttctg tgtagttttt aattgttaaa aaaaaaagt 2040
tttaaacaga agcacatgac atatgaaagc ctgcaggact ggtcgttttt ttggcaattc 2100
ttccacgtgg gacttgtcca caagaatgaa agtagtggtt tttaaagagt taagttacat 2160
atattatttc tcacttaagt tatttatgca aaagtttttc ttgtagagaa tgacaatgtt 2220
aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
acaatgaatc atgaccgaaa g 2301

```

<210> 2

<211> 213

<212> PRT

<213> Homo sapien

<400> 2

```

Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr
  1             5             10             15
Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
      20             25             30
Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
      35             40             45
Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
      50             55             60
Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
      65             70             75             80
Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser

```

```

      85              90              95
Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
      100              105              110
Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
      115              120              125
Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
      130              135              140
Gln Leu Leu Cys Pro Gly Gly Glu Ala Pro Arg Ala Arg Lys Val Arg
      145              150              155              160
Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
      165              170              175
Ser Glu Leu Lys Asp Phe Gly Thr Glu Ala Ala Arg Pro Gln Lys Gly
      180              185              190
Arg Lys Pro Arg Pro Arg Ala Arg Ser Ala Lys Ala Asn Gln Ala Glu
      195              200              205
Leu Glu Asn Ala Tyr
      210

```

<210> 3

<211> 2301

<212> DNA

<213> Homo sapien

<400> 3

```

agagcctgtg ctactggaag gtggcgtgcc ctccctctggc tgggtaccatg cagctcccac      60
tggccctgtg tctcgtctgc ctgctggtac acacagcctt ccgtgtagtg gagggctagg      120
ggtggcaggc gttcaagaat gatgccacgg aatcatccc cgagctcggg gagtaccacc      180
agcctccacc ggagctggag aacaacaaga ccatgaaccg ggcggagaac ggagggcggc      240
ctccccacca cccctttgag accaaagacg tgtccgagta cagctgccgc gagctgcact      300
tcaccgcgta cgtgaccgat gggcgcgtgc gcagcgccaa gccggtcacc gagctggtgt      360
gctccggcca gtgcggcccg gcgcgcctgc tgcccaacgc catcggccgc ggcaagtggg      420
ggcgacctag tgggcccagc ttccgctgca tccccgaccg ctaccgcgcg cagcgcgtgc      480
agctgctgtg tcccgggtgg gaggcgcgcg gcgcgcgcaa ggtgcgcctg gtggcctcgt      540
gcaagtgcaa gcgcctcacc cgcttcaca accagtcgga gctcaaggac ttcgggaccg      600
aggccgctcg gccgcagaag ggccggaagc cgcggccccc cgcccggagc gccaaagcca      660
accaggccga gctggagaac gcctactaga gcccgccgc gccctccccc accgcggggc      720
gccccggccc tgaaccgcg cccacattt ctgtcctctg cgcgtgggtt gattgtttat      780
atttcattgt aaatgcctgc aaccagggc agggggctga gaccttcag gccctgagga      840
atccccggcg ccggcaaggc cccctcagc ccgccagctg aggggtccca cggggcaggg      900
gagggaaatt agagtcacag aactgagcc acgcagcccc gcctctgggg ccgcctacct      960
ttgctggtcc cacttcagag gaggcagaaa tggaaagcatt ttcaccgcc tgggggttta      1020
agggagcggg gtgggagtg gaaagtccag ggactgggta agaaagtggg ataagattcc      1080
cccttgacc tcgctgccc tcagaaagcc tgaggcgtgc ccagagcaca agactggggg      1140
caactgtaga tgtggtttct agtcctggct ctgccactaa cttgctgtgt aacctgaac      1200
tacacaattc tccttcggga cctcaatttc cactttgtaa aatgaggggt gaggtgggaa      1260
taqatctc aqaaactat tqqcatatqa ttccaaqqac tccaqtccct tttqaatqqq      1320

```

```

cagaggtgag agagagagag agaaagagag agaatgaatg cagttgcatt gattcagtgc 1380
caaggctact tccagaattc agagttgtga tgctctcttc tgacagccaa agatgaaaaa 1440
caaacagaaa aaaaaaagta aagagtctat ttatggctga catatttacg gctgacaaac 1500
tcttgaaga agctatgctg ctcccagcc ttgcttcccc ggatgtttgg ctacctccac 1560
ccctccatct caaagaaata acatcatcca ttggggtaga aaaggagagg gtccgagggg 1620
gggtgggagg atagaaatca catccgccc aacttccaa agagcagcat ccctcccccg 1680
acccatagcc atgttttaaa gtcaaccttc gaagagaagt gaaaggttca aggacactgg 1740
ccttgaggc ccgagggagc agccatcaca aactcacaga ccagcacatc ccttttgaga 1800
cacgccttc tgcccaccac tcacggacac atttctgcct agaaaacagc ttcttactgc 1860
tcttacatgt gatggcatat cttacactaa aagaatatta ttgggggaaa aactacaagt 1920
gctgtacata tgctgagaaa ctgcagagca taatagctgc cacccaaaaa tctttttgaa 1980

aatcatttcc agacaacctc ttactttctg ttagtttttt aattgttaaa aaaaaaagt 2040
tttaaacaga agcacatgac atatgaaagc ctgcaggact ggtcgttttt ttggcaattc 2100
ttccacgtgg gacttgcca caagaatgaa agtagtggtt tttaagagt taagttaacat 2160
atttatttcc tcaacttaagt tatttatgca aaagttttcc ttgtagagaa tgacaatggt 2220
aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
acaatgaatc atgaccgaaa g 2301

```

<210> 4

<211> 23

<212> PRT

<213> Homo sapien

<400> 4

```

Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr
  1             5             10             15
Ala Phe Arg Val Val Glu Gly
      20

```

<210> 5

<211> 2301

<212> DNA

<213> Homo sapien

<400> 5

```

agagcctgtg ctactggaag gtggcggtgcc ctctctctggc tggtaccatg cagctccac 60
tgccctgtg tctcatctgc ctgctgttac acacagcctt ccgtgtagtg gagggccagg 120
gggtggcaggc gttcaagaat gatgccacgg aaatcatccg cgagctcggg gagtaccacc 180
agcctccacc ggagctggag aacaacaaga ccatgaaccg ggcggagaaac ggagggcggc 240
ctccccacca cccctttgag accaaagacg tgtccgagta cagctgccgc gagctgcact 300
tcacccgcta cgtgacgat gggccgtgcc gcagcgccaa gccggtcacc gagctggtgt 360
gctccggcca gtgcggcccc gcgcgcctgc tgcccaacgc catcggccgc ggcaagtggg 420
ggcgacctag tgggcccagc ttccgctgca tccccgaccg ctaccgcgcg cagcgcgtgc 480
agctgctgtg tcccggtggt gagggcgcgc gcgcgcgcaa ggtgcgcctg gtggcctcgt 540
gcaagtgcaa gcgcctcacc cgcttcaca accagtcgga gctcaaggac ttccggaccg 600
agggcctcga agcagagaaa agccagaaac cagcgcgcgc cagccagaaac accaaagcca 660

```

```

gggctggctg ggggagggg gggggggg- gg-gggctgg gg-gggggg- g-gggggg- 720
accagggcca gctgggagaac gcctactaga gcccgcccg gccctcccc accggcgggc

gccccggccc tgaaccgcgg cccacattt ctgtcctctg cgcgtgggtt gattgtttat 780
atttcattgt aaatgcctgc aacccagggc agggggctga gaccttccag gccctgagga 840
atcccgggcg ccggcaaggc cccctcagc ccgccagctg aggggtccca cggggcaggg 900
gaggggaattg agagtcacag acaactgagc acgcagcccc gcctctgggg ccgcctacct 960
ttgctgggtcc cacttcagag gaggcagaaa tggagcatt ttcaccgcc tggggtttta 1020
aggggagcgtg gtgggagtg gaaagtccag ggactgggtt agaaagttgg ataagattcc 1080
cccttgccac tcgctgcccc tcagaaagcc tgaggcgtgc ccagagcaca agactggggg 1140
caactgtaga tgtggtttct agtcctggct ctgccactaa cttgctgtgt aacctgaac 1200
tacacaattc tccttcggga cctcaatttc cactttgtta atgaggggtg gaggtgggaa 1260
taggatctcg aggagactat tggcatatga ttccaaggac tccagtgcct tttgaatggg 1320
cagaggtgag agagagagag agaaagagag agaatgaatg cagttgcatt gattcagtgc 1380
caaggtcact tccagaattc agagttgtga tgctctcttc tgacagccaa agatgaaaa 1440
caaacagaaa aaaaaaagta aagagtctat ttatggctga catatttacg gctgacaaac 1500
tcctggaaga agctatgctg ctcccagcc tggcttcccc ggatgtttgg ctacctccac 1560
ccctccatct caaagaaata acatcatcca ttggggtaga aaaggagagg gtccgagggg 1620
gggtgggagg atagaaatca catccgcccc aacttcccaa agagcagcat cctcccccg 1680
acccatagcc atgtttttaa gtcaccttc gaagagaagt gaaaggttca aggacactgg 1740
ccttgcaggc ccgagggagc agccatcaca aactcacaga ccagcacatc ccttttgaga 1800
caccgccttc tgcccaccac tcacggacac atttctgcct agaaaacagc ttcttactgc 1860
tcttacatgt gatggcatat ctactactaa aagaatatta ttgggggaaa aactacaagt 1920
gctgtacata tgctgagaaa ctgcagagca taatagctgc caccacaaaa tctttttgaa 1980
aatcatttcc agacaacctc ttactttctg ttagtgtttt aattgttaaa aaaaaaagt 2040
tttaaacaga agcacatgac atatgaaagc ctgcaggact ggtcgttttt ttggcaattc 2100
ttccacgtgg gacttgcca caagaatgaa agtagtggtt tttaaagat taagttacat 2160
atatttttcc tcaacttaagt tatttatgca aaagttttcc ttgtagagaa tgacaatgtt 2220
aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
acaatgaatc atgaccgaaa g 2301

```

<210> 6

<211> 213

<212> PRT

<213> Homo sapien

<400> 6

Met Gln Leu Pro Leu Ala Leu Cys Leu Ile Cys Leu Leu Val His Thr

1 5 10 15

Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp

20 25 30

Ala Thr Glu Ile Ile Arg Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro

35 40 45

Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg

50 55 60

Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys

65 70 75 80
 Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
 85 90 95
 Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
 100 105 110
 Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
 115 120 125
 Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
 130 135 140
 Gln Leu Leu Cys Pro Gly Gly Glu Ala Pro Arg Ala Arg Lys Val Arg
 145 150 155 160
 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 165 170 175
 Ser Glu Leu Lys Asp Phe Gly Thr Glu Ala Ala Arg Pro Gln Lys Gly
 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Ser Ala Lys Ala Asn Gln Ala Glu
 195 200 205
 Leu Glu Asn Ala Tyr
 210

<210> 7

<211> 2301

<212> DNA

<213> Homo sapien

<400> 7

agagcctgtg ctactggaag gtggcgtgcc ctccctctggc tggtagcatg cagctcccac 60
 tggccctgtg tctcgtctgc ctgctggtac acacagcctt ccgtgtagtg gagggccagg 120
 ggtggcaggc gttcaagaat gatgccacgg aaatcatccg cgagctcgga gagtaccccg 180

 agcctccacc ggagctggag aacaacaaga ccatgaaccg ggaggagaac ggagggcggc 240
 ctccccacca cccctttgag accaaagacg tgtccgagta cagctgccgc gagctgcact 300
 tcaccgcgta cgtgaccgat gggccgtgcc gcagcgccaa gcgggtcacc gagctggtgt 360
 gctccggcca gtgcggcccc gcgcgcctgc tgcccaacgc catcgccgcg ggcaagtggg 420
 ggcgacctag tgggccccgc ttccgctgca tccccgaccg ctaccgcgcg cagcgcgtgc 480
 agctgctgtg tcccgggtgt gaggcgcgcg gcgcgcgcaa ggtgcgcctg gtggcctcgt 540
 gcaagtgcaa gcgcctcacc cgcttccaca accagtcgga gctcaaggac ttcgggaccg 600
 aggcgcgtcg gccgcagaag ggccggaagc cgcggccccc cgcccggagc gccaaagcca 660
 accaggccga gctggagaac gcctactaga gcccgcgcgc gccctcccc accggcgggc 720
 gccccggccc tgaacccgcg ccccacattt ctgtcctctg cgcgtggttt gattgtttat 780
 atttcattgt aaatgcctgc aaccagggc agggggctga gaccttcag gccctgagga 840
 atcccgggcg ccggcaaggc cccctcagc ccgcagctg aggggtccca cggggcaggg 900
 gagggaattg agagtacag aactgagcc acgcagcccc gcctctgggg ccgcctacct 960
 ttgctggtcc cacttcagag gaggcagaaa tggaagcatt ttcaccgccc tgggggttta 1020

```

agggagcgggt gtgggagtggt gaaagtccag ggactgggtta agaaagttgg ataagattcc 1080
cccttgccacc tcgctgcccc tcagaaagcc tgaggcgtgc ccagagcaca agactggggg 1140
caactgtaga tgtggtttct agtccctggct ctgccactaa cttgctgtgt aaccttgaac 1200
tacacaattc tccttcggga cctcaatttc cactttgtaa aatgaggggtg gaggtgggaa 1260
taggatctcg aggagactat tggcatatga ttccaaggac tccagtgcct tttgaatggg 1320
cagaggtgag agagagagag agaaagagag agaatgaatg cagttgcatt gattcagtg 1380
caaggtcact tccagaattc agagttgtga tgctctcttc tgacagccaa agatgaaaaa 1440
caaacagaaa aaaaaaagta aagagtctat ttatggctga catatttacg gctgacaaac 1500
tcctggaaga agctatgctg ctccccagcc tggcttcccc ggatgtttgg ctacctccac 1560
ccctccatct caaagaaata acatcatcca ttggggtaga aaaggagagg gtccgagggg 1620
gggtgggaggg atagaaatca catecgcccc aacttcccaa agagcagcat ccttcccccg 1680
accatagcc atgttttaaa gtcaccttcc gaagagaagt gaaaggttca aggacactgg 1740
ccttgccaggc ccgagggagc agccatcaca aactcacaga ccagcacatc ccttttgaga 1800
caccgccttc tgcccaccac tcacggacac atttctgcct agaaaacagc ttcttactgc 1860
tcttacatgt gatggcatat cttacactaa aagaatatta ttgggggaaa aactacaagt 1920
gctgtacata tgctgagaaa ctgcagagca taatagctgc cacccaaaaa tctttttgaa 1980
aatcatttcc agacaacctc ttactttctg tgtagttttt aattgttaaa aaaaaaagt 2040
tttaaacaga agcacatgac atatgaaagc ctgcaggact ggctcgttttt ttggcaattc 2100
ttccacgtgg gacttgtcca caagaatgaa agtagtggtt tttaaagagt taagttacat 2160
atattatttc tcaacttaagt tatttatgca aaagtttttc ttgtagagaa tgacaatgtt 2220
aatattgctt tatgaattaa cagtctgttc ttccagagtc cagagacatt gttaataaag 2280
acaatgaatc atgaccgaaa g 2301

```

<210> 8

<211> 213

<212> PRT

<213> Homo sapien

<400> 8

```

Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Thr
  1             5             10             15
Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
      20             25             30
Ala Thr Glu Ile Ile Arg Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
      35             40             45
Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
      50             55             60
Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
      65             70             75             80
Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg Ser
      85             90             95
Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
      100            105            110
Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
      115            120            125
Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val

```

130 135 140
 Gln Leu Leu Cys Pro Gly Gly Glu Ala Pro Arg Ala Arg Lys Val Arg
 145 150 155 160
 Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
 165 170 175
 Ser Glu Leu Lys Asp Phe Gly Thr Glu Ala Ala Arg Pro Gln Lys Gly
 180 185 190
 Arg Lys Pro Arg Pro Arg Ala Arg Ser Ala Lys Ala Asn Gln Ala Glu
 195 200 205
 Leu Glu Asn Ala Tyr
 210

<210> 9

<211> 642

<212> DNA

<213> Cercopithecus pygerythrus

<400> 9

```

atgcagctcc cactggccct gtgtcttgtc tgcctgctgg tacacgcagc cttccgtgta      60
gtggaggggc aggggtggca ggccttcaag aatgatgcc a cgaaatcat ccccgagctc      120
ggagagtacc ccgagcctcc accggagctg gagaacaaca agaccatgaa ccgggcggag      180
aatggagggc ggcctcccca ccacccttt gagaccaaag acgtgtccga gtacagctgc      240
cgagagctgc acttcaccgc ctacgtgacc gatgggccgt gccgcagcgc caagccagtc      300
accgagttgg tgtgtctccg ccagtgcggc ccggcacgcc tgctgccc aa cgccatcggc      360
cgcggcaagt ggtggcgccc gaggggccc gaettccgct gcattcccga ccgctaccgc      420
gcgacgcgtg tgcagctgct gtgtcccggg ggtgccgcgc cgcgcgcgcg caaggtgcgc      480
ctggtggcct cgtgcaagtg caagcgctc acccgcttc acaaccagtc ggagctcaag      540
gacttcggtc ccgaggccgc tcggccgcag aagggccgga agccgcggcc ccgcgcccg      600
ggggccaaag ccaatcaggc cgagctggag aacgcctact ag                          642

```

<210> 10

<211> 213

<212> PRT

<213> Cercopithecus pygerythrus

<400> 10

Met Gln Leu Pro Leu Ala Leu Cys Leu Val Cys Leu Leu Val His Ala
 1 5 10 15
 Ala Phe Arg Val Val Glu Gly Gln Gly Trp Gln Ala Phe Lys Asn Asp
 20 25 30
 Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 35 40 45
 Glu Leu Glu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
 50 55 60
 Pro Pro His His Pro Phe Glu Thr Lys Asp Val Ser Glu Tyr Ser Cys
 65 70 75 80
 Arg Glu Leu His Phe Thr Arg Thr Val Thr Asn Gly Pro Cys Arg Ser

Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Phe Cys Arg Ser
85 90 95

Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
100 105 110

Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro Ser
115 120 125

Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
130 135 140

Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ala Arg Lys Val Arg
145 150 155 160

Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
165 170 175

Ser Glu Leu Lys Asp Phe Gly Pro Glu Ala Ala Arg Pro Gln Lys Gly
180 185 190

Arg Lys Pro Arg Pro Arg Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu
195 200 205

Leu Glu Asn Ala Tyr
210

<210> 11

<211> 638

<212> DNA

<213> Mus musculus

<400> 11

atgcagccct cactagcccc gtgcctcattg tgcctacttg tgcacgctgc cttctgtgct	60
gtggagggcc aggggtggca agccttcagg aatgatgccca cagaggcatat cccagggctt	120
ggagagtacc ccgagcctcc tccctgagaac aaccagacca tgaaccgggc ggagaatgga	180
ggcagacctc cccaccatcc ctatgacgcc aaagggtgtgt ccgagtacag ctgccgcgag	240
ctgcactaca cccgcttccct gacagacggc ccattgccga gcgccaagcc ggtcaccgag	300
ttggtgtgct ccggccagtg cggccccgcg cggtctgtgc ccaacgccat cgggcgcgtg	360
aagtgggtggc gcccgaaagg accggatttc cgtgcacatc cggatcgcta ccgcgcgcag	420
cgggtgcagc tgctgtgccc cggggggcgc gcgccgcgct cgcgcaaggt gcgtctggtg	480
gcctcgtgca agtgcaagcg cctcaccgcg ttccacaacc agtcggagct caaggatttc	540
gggccggaga ccgcgcggcc gcagaagggt cgcgaagccgc ggcccggcgc ccggggagcc	600
aaagccaacc aggcggagct ggagaacgcc tactagag	638

<210> 12

<211> 211

<212> PRT

<213> Mus musculus

<400> 12

Met Gln Pro Ser Leu Ala Pro Cys Leu Ile Cys Leu Leu Val His Ala
1 5 10 15
Ala Phe Cys Ala Val Glu Gly Gln Gly Trp Gln Ala Phe Arg Asn Asp

20 25 30
 Ala Thr Glu Val Ile Pro Gly Leu Gly Glu Tyr Pro Glu Pro Pro Pro
 35 40 45
 Glu Asn Asn Gln Thr Met Asn Arg Ala Glu Asn Gly Gly Arg Pro Pro
 50 55 60
 His His Pro Tyr Asp Ala Lys Asp Val Ser Glu Tyr Ser Cys Arg Glu
 65 70 75 80
 Leu His Tyr Thr Arg Phe Leu Thr Asp Gly Pro Cys Arg Ser Ala Lys
 85 90 95
 Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala Arg Leu
 100 105 110
 Leu Pro Asn Ala Ile Gly Arg Val Lys Trp Trp Arg Pro Asn Gly Pro
 115 120 125
 Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val Gln Leu
 130 135 140
 Leu Cys Pro Gly Gly Ala Ala Pro Arg Ser Arg Lys Val Arg Leu Val
 145 150 155 160
 Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln Ser Glu
 165 170 175
 Leu Lys Asp Phe Gly Pro Glu Thr Ala Arg Pro Gln Lys Gly Arg Lys
 180 185 190
 Pro Arg Pro Gly Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu Leu Glu
 195 200 205
 Asn Ala Tyr
 210

<210> 13

<211> 674

<212> DNA

<213> Rattus norvegicus

<400> 13

gaggaccgag tgcccttcct ccttctggca ccatgcagct ctactagcc ccttgccctg 60
 cctgcctgct tgtacatgca gccttcgttg ctgtggagag ccaggggtgg caagccttca 120
 agaatgatgc cacagaaatc atcccgggac tcagagagta cccagagcct cctcaggaac 180
 tagagaacaa ccagaccatg aaccggggccg agaacggagg cagaccccc caccatcctt 240
 atgacaccaa agacgtgtcc gagtacagct gccgcgagct gactacacc cgcttcgtga 300
 ccgacggccc gtgccgcagt gccaagccgg tcaccgagtt ggtgtgctcg ggccagtgcg 360
 gccccgcgcg gctgctgccc aacgccatcg ggcgcgtgaa gtggtggcgc ccgaacggac 420
 ccgacttcgg ctgcatcccg gatcgctacc gcgcgcagcg ggtgcagctg ctgtgccccg 480
 gcggcgcgcc gccgcgctcg cgcaagggtg gtctgggtggc ctctgcaag tgcaagcgcc 540
 tcaccgcgtt ccacaaccag tcggagctca aggaactcgg acctgagacc gcgcggccgc 600
 agaagggtcg caagccgcgg ccccgcgccc ggggagccaa agccaaccag gcggagctgg 660
 agaacgccta ctag 674

<210> 14

<211> 213

<212> PRT

<213> Rattus norvegicus

<400> 14

```

Met Gln Leu Ser Leu Ala Pro Cys Leu Ala Cys Leu Leu Val His Ala
  1             5             10             15
Ala Phe Val Ala Val Glu Ser Gln Gly Trp Gln Ala Phe Lys Asn Asp
      20             25             30
Ala Thr Glu Ile Ile Pro Gly Leu Arg Glu Tyr Pro Glu Pro Pro Gln
      35             40             45
Glu Leu Glu Asn Asn Gln Thr Met Asn Arg Ala Glu Asn Gly Gly Arg
      50             55             60
Pro Pro His His Pro Tyr Asp Thr Lys Asp Val Ser Glu Tyr Ser Cys
      65             70             75             80
Arg Glu Leu His Tyr Thr Arg Phe Val Thr Asp Gly Pro Cys Arg Ser
      85             90             95
Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro Ala
      100            105            110
Arg Leu Leu Pro Asn Ala Ile Gly Arg Val Lys Trp Trp Arg Pro Asn
      115            120            125
Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg Val
      130            135            140
Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ser Arg Lys Val Arg
      145            150            155            160
Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn Gln
      165            170            175
Ser Glu Leu Lys Asp Phe Gly Pro Glu Thr Ala Arg Pro Gln Lys Gly
      180            185            190
Arg Lys Pro Arg Pro Arg Ala Arg Gly Ala Lys Ala Asn Gln Ala Glu
      195            200            205
Leu Glu Asn Ala Tyr
      210

```

<210> 15

<211> 532

<212> DNA

<213> Bos torus

<400> 15

```

agaatgatgc cacagaaatc atccccgagc tgggagagta ccccgagcct ctgccagagc      60
tgaacaacaa gaccatgaac cgggaggaga acggaggag acctccccac caccctttg      120
agaccaaaga cgcctccgag tacagctgcc gggagctgca cttcaccgc tacgtgaccg      180
atgggcccgtg ccgcagcgcc aagccggtca ccgagctggt gtgctcgggc cagtgcggcc      240
cggcgcgccct gctgccaac gccatcgcc gcggcaagtg gtggcgcca agcgggccc      300
acttcgctg catccccgac cgctaccgc cgcagcgggt gcagctgttg tgtcctggcg      360

```

```

gcgcggcgcc gcgcgcgcgc aaggtgcgcc tgggtggcctc gtgcaagtgc aagcgccctca 420
ctcgctttcca caaccagtcg gagctcaagg acttcggggcc cgaggccgcg cggccgcaaa 480
cgggcccggaa gctgcggccc cgcgcccggg gcaccaaagc cagccggggcc ga 532

```

<210> 16

<211> 176

<212> PRT

<213> Bos torus

<400> 16

```

Asn Asp Ala Thr Glu Ile Ile Pro Glu Leu Gly Glu Tyr Pro Glu Pro
 1           5           10           15
Leu Pro Glu Leu Asn Asn Lys Thr Met Asn Arg Ala Glu Asn Gly Gly
      20           25           30
Arg Pro Pro His His Pro Phe Glu Thr Lys Asp Ala Ser Glu Tyr Ser
      35           40           45
Cys Arg Glu Leu His Phe Thr Arg Tyr Val Thr Asp Gly Pro Cys Arg
      50           55           60
Ser Ala Lys Pro Val Thr Glu Leu Val Cys Ser Gly Gln Cys Gly Pro
      65           70           75           80
Ala Arg Leu Leu Pro Asn Ala Ile Gly Arg Gly Lys Trp Trp Arg Pro
      85           90           95
Ser Gly Pro Asp Phe Arg Cys Ile Pro Asp Arg Tyr Arg Ala Gln Arg
      100          105          110
Val Gln Leu Leu Cys Pro Gly Gly Ala Ala Pro Arg Ala Arg Lys Val
      115          120          125
Arg Leu Val Ala Ser Cys Lys Cys Lys Arg Leu Thr Arg Phe His Asn
      130          135          140
Gln Ser Glu Leu Lys Asp Phe Gly Pro Glu Ala Ala Arg Pro Gln Thr
      145          150          155          160
Gly Arg Lys Leu Arg Pro Arg Ala Arg Gly Thr Lys Ala Ser Arg Ala
      165          170          175

```

<210> 17

<211> 35828

<212> DNA

<213> Mus musculus

<220>

<221> misc_feature

<222> (1)...(35828)

<223> n = A,T,C or G

<400> 17

```

cgcgcttttg tgagcagcaa tattgcgctt cgatgagcct tggcggttgag attgatacct 60
ctgctgcaca aaaggcaatc gaccgagctg gaccagcgca ttcgtgacac cgtctccttc 120
gaacttattc gcaatggagt gtcattcatt aaggacngcc tgatcgcaaa tgggtgctatc 180

```

cacgcagcgg caatcgaaaa ccctcagccg gtgaccaata tctacaacat cagccttggt	240
atcctgcgtg atgagccagc gcagaacaag gtaaccgtca gtgccgataa gttcaaagtt	300
aaacctgggtg ttgataccaa cattgaaacg ttgatcgaaa acgcgctgaa aaacgctgct	360
gaatgtgcgg cgctggatgt cacaaagcaa atggcagcag acaagaaagc gatggatgaa	420
ctggcttcct atgtccgcac ggccatcatg atggaatgt tccccgggtg tgttatctgg	480
cagcagtgcc gtcgatagta tgcaattgat aattattatc atttgcgggt cctttccggc	540
gatccgcctt gttacggggc ggcgacctcg cgggttttcg ctatttatga aaattttccg	600
gtttaaggcg tttccgttct tcttcgtcat aacttaatgt ttttatttaa aataccctct	660
gaaaagaaag gaaacgacag gtgctgaaag cgagcttttt ggctctgtc gtttcctttc	720
tctgtttttg tccgtggaat gaacaatgga agtcaacaaa aagcagagct tatcgatgat	780
aagcggctca acatgagaat tcgcggccgc ataatacgac tcactatagg gatcgacgcc	840
tactccccgc gcataagcg gaggagctgg actccgcag cccagagacg ccccccaacc	900
cccaaagtgc ctgacctcag cctctaccag ctctggcttg ggcttgggcg ggggtcaaggc	960
taccacgttc tcttaacagg tggtgggct gtctcttggc cgcgcgtcat gtgacagctg	1020
cctagtctcg cagtgaaggc accgtggaat gtctgccttc gttgccatgg caacgggatg	1080
acgttacaat ctgggtgtgg agcttttcct gtccgtgtca ggaaatccaa ataccctaaa	1140
ataccctaga agaggaagta gctgagccaa ggctttccctg gcttctccag ataaagtgtg	1200
acttagatgg aaaaaaacia aatgataaag acccgagcca tctgaaaatt cctcctaatt	1260
gcaccactag gaaatgtgta tattattgag ctcgatgtg ttcttatttt aaaaagaaaa	1320
ctttagtcat gttattaata agaattttctc agcagtggga gagaaccaat attaacacca	1380
agataaaagt tggcatgac cacattgcag gaagatccac gttgggtttt catgaatgtg	1440
aagaccccat ttattaaagt cctaagctct gtttttgac actaggaagc gatggccggg	1500
atggctgagg ggctgtaagg atctttcaat gtcttacatg tgtgtttcct gtccctgcacc	1560
taggacctgc tgcctagcct gcagcagagc cagaggggtt tcacatgatt agtctcagac	1620
acttgggggc aggttgcatg tactgcatcg ctattttcca tacggagcac ctactatgtg	1680
tcaaacacca tatggtgttc actcttcaga acgggtgggtg tcatcatggt gcatttgctg	1740
acgggtggat tgggtgtaga gagctgagat atatggagcg actcttcagc attctgtcaa	1800
cgtggctgtg cattcttgc cctgagcaag tggctaaca gactcacagg gtcagcctcc	1860
agctcagtc ctgcatagtc ttagggaacc tctcccagtc ctccctacct caactatcca	1920
agaagccagg gggcttggcg gtctcaggag cctgcttgcg gggggacagg ttgttgagtt	1980
ttatctgcag taggttgctt aggcatagtg tcaggactga tggctgcctt ggagaacaca	2040
tcctttgccc tctatgcaaa tctgaccttg acatgggggc gctgctcagc tgggaggatc	2100
aactgcatac ctaaagccaa gcctaaagct tcttcgtcca cctgaaactc ctggaccaag	2160
gggcttccgg cacatcctct caggccagtg agggagtctg tgtgagctgc actttccaat	2220
ctcagggcgt gagaggcaga gggaggtggg ggcagagcct tgcagctctt tctctccatc	2280
tggacagcgc tctggctcag cagcccatat gagcacaggc acatccccac cccaccccca	2340
cctttcctgt cctgcagaat ttaggctctg ttcacggggg gggggggggg ggggcagtc	2400
tatcctctct taggtagaca ggactctgca ggagacactg ctttgaaga tactgcagtt	2460
taaatttgga tgttgtgagg ggaagcgaa gggcctcttt gaccattcag tcaaggtacc	2520
ttctaactcc catcgatttg gggggctact ctagtgttag acattgcaga gagcctcaga	2580
actgtagtta ccagtgtggt aggattgac cttcagggag cctgacatgt gacagttcca	2640
ttcttcaccc agtcaccgaa catttattca gtacctacc cgtaacaggc accgtagcag	2700
gtactgaggg acggaccact caaagaactg acagaccgaa gccttggaat ataaacacca	2760
aagcatcagg ctctgccaac agaacactct ttaacactca ggccctttaa cactcaggac	2820

ccccaccccc	accccaagca	gttggcactg	ctatccacat	tttacagaga	ggaaaaacta	2880
ggcacaggac	gatataagt	gcttgcttaa	gcttgctgc	atggtaaatg	gcagggctgg	2940
attgagaccc	agacattcca	actctaggg	ctatttttct	tttttctcgt	tgttcgaatc	3000
tgggtcttac	tgggtaaaact	caggctagcc	tcacactcat	atccttctcc	catggcttac	3060
gagtgcctagg	attccagggtg	tgtgctacca	tgtctgactc	cctgtagctt	gtctatacca	3120
tcctcacaac	ataggaattg	tgatagcagc	acacacaccg	gaaggagctg	gggaaatccc	3180
acagagggct	ccgcaggatg	acaggcgaat	gcctacacag	aagggtggga	aggggaagcag	3240
agggaaacagc	atggggcgtg	gaccacaagt	ctatttgggg	aagctgccgg	taaccgtata	3300
tggctgggg	gaggggagag	gtcatgagat	gaggcaggaa	gagccacagc	aggcagcggg	3360
tacgggctcc	ttattgcca	gaggctcgga	tcttctctct	cttctctctt	ccggggctgc	3420
ctgttcattt	tccaccactg	cctcccatcc	aggctctgtg	ctcaggacat	caccagctg	3480
cagaaactgg	gcatacccca	cgtcctgaat	gctgccgagg	gcaggtcctt	catgcacgtc	3540
aacaccagtg	ctagcttcta	cgaggattct	ggcatcacct	acttgggcat	caaggccaat	3600
gatacgagg	agttcaacct	cagtgcctac	tttgaaaggg	ccacagattt	cattgaccag	3660
gcgctggccc	ataaaaatgg	taaggaaagt	acattccggc	acccatggag	cgtaagccct	3720
ctgggacctg	cttctcccaa	agaggccccc	acttgaaaaa	ggttccagaa	agatcccaa	3780
atatgccacc	aactagggat	taagtgtcct	acatgtgagc	cgatgggggc	cactgcatat	3840
agtctgtgcc	atagacatga	caatggataa	taatatattca	gacagagagc	aggagttagg	3900
tagctgtgct	cctttccctt	taattgagtg	tgcccatttt	tttattcatg	tatgtgtata	3960
catgtgtgtg	cacacatgcc	ataggttgat	actgaacacc	gtcttcaatc	gttccccacc	4020
ccaccttatt	ttttgaggca	gggtctcttc	cctgatccctg	gggctcattg	gtttatctag	4080
gctgctggcc	agttagctct	ggagtctctc	ttttctctac	ctccctagcc	ctgggactgc	4140
aggggcatgt	gctgggccag	gcttttatgt	cgcgttgggg	atctgaactt	aggctccctag	4200
gcctgagcac	cgtaaagact	ctgccacatc	cccagcctgt	ttgagcaagt	gaaccattcc	4260
ccagaattcc	cccagtgggg	ctttcttacc	cttttatttg	ctaggcattc	atgagtggtc	4320
acctcgccag	aggaatgagt	ggccacgact	ggctcagggt	cagcagccta	gagatactgg	4380
gttaagtctt	cctgccgctc	gctccctgca	gccgcagaca	gaaagtagga	ctgaatgaga	4440
gctggctagt	ggtcagacag	gacagaaggc	tgagagggtc	acagggcaga	tgtcagcaga	4500
gcagacaggt	tctccctctg	tgggggaggg	gtggccact	gcaggtgtaa	ttggccttct	4560
ttgtgctcca	tagaggcttc	ctgggtacac	agcagcttcc	ctgtcctggg	gattcccaaa	4620
gagaactccc	taccactgga	cttacagaag	ttctattgac	tgggtgaacg	gttcaacagc	4680
tttggctctt	ggtaggacgt	gcatactgct	gtatcagctc	aagagctcat	tcacgaatga	4740
acacacacac	acacacacac	acacacacac	acacaagcta	atattgatat	gccttaacta	4800
gctcagtgac	tgggcatttc	tgaacatccc	tgaagttagc	acacatttcc	ctctgggtgt	4860
cctggcttaa	caccttctaa	atctatatatt	tatctttgct	gcctgttac	cttctgagaa	4920
gcccctaggg	ccacttccct	tcgcacctac	attgctggat	ggtttctctc	ctgcagctct	4980
taaatctgat	ccctctgcct	ctgagccatg	ggaacagccc	aataactgag	ttagacataa	5040
aaacgtctct	agccaaaact	tcagctaaat	ttagacaata	aatcttactg	gttgtggaat	5100
ccttaagatt	cttcatgacc	tccttcacat	ggcacgagta	tgaagcttta	ttacaattgt	5160
ttattgatca	aactaactca	taaaaagcca	gttgtctttc	acctgctcaa	ggaaggaaaca	5220
aaattcatcc	ttaactgac	tgtgcacctt	gcacaatcca	tacgaatatc	ttaagagtac	5280
taagattttg	gttgtgagag	tcacatgtta	cagaatgtac	agctttgaca	agggtgatcc	5340
ttgggatgcc	gaagtgcct	gctgttccag	ccccctacct	tctgaggctg	ttttggaagc	5400
aatgctctgg	aagcaacttt	aggaggtagg	atgctggaac	agcgggtcac	ttcagcatcc	5460
cqatqacqaa	tccctcaaaa	qctgtacatt	ctqtaacaa	ctqqgaaac	tqcaqacttt	5520

aaggccaggg ccctatggtc cctcttaatc cctgtcacac ccaacccgag cccctctcct 5580
ccagccgttc tgtgcttctc actctggata gatggagaac acggccttgc tagttaaagg 5640
agtgaggctt cacccttctc acatggcagt ggttgggtcat cctcattcag ggaactctgg 5700
ggcattctgc ctttacttcc tctttttgga ctacagggaa tatatgctga cttgttttga 5760
ccttggtgat ggggagactg gatctttggt ctggaatggt tcctgctagt ttttccccat 5820
cctttggcaa accctatcta tatcttacca ctaggcatag tggccctcgt tctggagcct 5880
gccttcaggc tgggtctcgg ggaccatgtc cctggtttct cccagcata tgggtgtcac 5940
agtggttact gcgggtggtt gctgaacaaa gcggggattg catcccagag ctccggtgcc 6000
ttgtgggtac actgctaaga taaaatggat actggcctct ctctgaccac ttgcagagct 6060
ctggtgcctt gtgggtacac tgctaagata aaatggatac tggcctctct ctatccactt 6120
gcaggactct aggggaacagg aatccattac tgagaaaacc aggggctagg agcagggagg 6180
tagctgggca gctgaagtgc ttggcgacta accaatgaat accagagttt ggatctctag 6240
aatactctta aaatctgggt gggcagagtg gcctgcctgt aatcccagaa ctcgaggagg 6300
ggagacaggg aatcatcaga gcaaaactggc taaccagaat agcaaaacac tgagctctgg 6360
gctctgtgag agatcctgcc ttaacatata agagagagaa taaaacattg aagaagacag 6420
tagatgcaa ttttaagccc ccacatgcac atggacaagt gtgcgtttga acacacatat 6480

gcactcatgt gaaccaggca tgcacactcg ggcttatcac acacataatt tgaaagagag 6540
agtgagagag gagagtgcac attagagttc acaggaaagt gtgagtgagc acacccatgc 6600
acacagacat gtgtgccagg gagtaggaaa ggagcctggg tttgtgtata agagggagcc 6660
atcatgtggt tctaaggagg gcgtgtgaag gaggcgttgt gtgggctggg actggagcat 6720
ggttgtact gagcatgtc cctgtgggaa acaggagggt ggccacctg cagagggtcc 6780
cactgtccag cgggatcagt aaaagccctt gctgagaact ttaggtaata gccagagaga 6840
gaaaggtagg aaagtggggg gactcccatc tctgatgtag gaggatctgg gcaagtagag 6900
gtgcgtttga ggtagaaaaga ggggtgcaga ggagatgctc ttaattctgg gtcagcagtt 6960
tctttccaaa taatgcctgt gaggaggtgt aggtggtggc cattcactca ctacagagag 7020
ggatgatgat gcccggtgga tgctggaaat ggccgagcat caacctggc tctggaagaa 7080
ctccatcttt cagaaggaga gtgatctgt gtatggccag cggggtcaca ggtgcttggg 7140
gccccgggg gactcctagc actgggtgat gtttatcgag tgctcttgtg tgccaggcac 7200
tggcctgggg ctttgtttct gtctctgttt tgtttcgttt tttgagacag actcttgeta 7260
tgtatccgtg tcaatcttgg aatctcactg catagccag gctgcggaga gaggggaggg 7320
caataggcct tgtaagcaag ccacacttca gagactagac tccacctgc gaatgatgac 7380
aggtcagagc tgagttccgg aagatTTTTT ttccagctgc caggtggagt gtggagtggc 7440
agctagcggc aagggtagag ggcgagctcc ctgtgcagga gaaatgcaag caagagatgg 7500
caagccagtg agttaagcat tctgtgtggg gaggaggtgg atgaagagag aggctgggct 7560
ttcgcctctg gggggggggg gaggggtggg gatgaggtga gaggagggca gctccctgca 7620
gtgtgatgag atttttcctg acagtgcct ttggcctctc cctcccccac ttcccttctt 7680
tcctttcttc ccaccattgc ttcccttctc ctgagaaat tctgagtctc cacttactg 7740
gtgatgcaga cggaaacaga agccgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 7800
gtgtgtgtgt ttgtgtgtat gtgtgtgtgt gtgtttgtgt gtatgtgtgt cagtgggaat 7860
ggctcatagt ctgcaggaag gtgggcagga aggaataagc tgtaggctga ggcagtgtgg 7920
gatgcaggga gagaggagag gagggatacc agagaaggaa attaaggag ctacaaggag 7980
gcattgttgg ggtgtgtgtg tgtgtgtgt gtttatatct gtattggaaa tacattcttt 8040
taaaaaatac ttatccattt atttatTTTT atgtgcacgt gtgtgtgcct gcatgagttc 8100
atgtgtgaga cgtgtgtgga ggaaccttg gagggagaa gggggcatct gatccctgg 8160

atgctgctca	cgctgctgcy	ggccccctcy	gagggcaca	gggggcactc	gaccccccyg	8180
aactggagtt	ggaggaggtt	gtgagtcctc	tgacatgttt	gctgggaact	gaacccccgt	8220
cctatgcaag	agcagggaag	gcagttatct	gctgagccat	ctctccagtc	ctgaaatcca	8280
ttctcttaaa	atacacgtgg	cagagacatg	atgggattta	cgtatggatt	taatgtggcg	8340
gtcattaagt	tccggcacag	gcaagcacct	gtaaagccat	caccacaacc	gcaacagtga	8400
atgtgaccat	cacccccatg	ttcttcatgt	ccctgtctcc	ctccatctct	cattctcaag	8460
cacctcttgc	tctgcctctg	tcgtgggaga	acagtgtgca	tctgcacact	cttatgtcag	8520
tgaagtcaca	cagcctgcac	cccttctctg	tctgagttat	tgggttctga	ctctgctatc	8580
acacactact	gtactgcatt	ctctcgctct	ctttttttaa	acatattttt	atttgtttgt	8640
gtgtatgcac	atgtgccaca	tgtgtacaga	tactatggag	gccagaagag	gcatggcccg	8700
tccctggagc	tggagttaca	ggcagcgtgt	gagctgcctg	gtgtgggtgc	tgggaaccaa	8760
acttgaatct	aaagcaagca	cttttaactg	ctgaggcagc	tctcagtaac	cttcttcatt	8820
tctccgcctg	ggttccattg	tatggacaca	tgtagctaga	atatcttgct	tatctaatta	8880
tgtacattgt	tttgtgctaa	gagagagtaa	tgtctatag	cctgagctgg	cctcaacctt	8940
gccatcctcc	tgcctcagcc	tcctcctcct	gagtgtctag	atgacaggcg	agtggtaact	9000
tacatggttt	catgttttgt	tcaagactga	aggataacat	tcatacagag	aaggctctggg	9060
tcacaaagtg	tgcagttcac	tgaatggcac	aacccgtgat	caagaaacaa	aactcagggg	9120
ctgggagagat	ggcactgact	gctcttccag	aggtccggag	ttcaattccc	agcaaccaca	9180
tgggtggctca	cagccatcta	taacgagatc	tgacgcctct	ttctgggtgt	tctgaagaca	9240
gctacagtgt	actcacataa	aataaataaa	tctttaaaac	acacacacac	acacaattac	9300
caccccagaa	agcccactcc	atgttccctc	ccacgtctct	gcctacagta	ctcccaggtt	9360
accactgttc	aggcttctaa	caacctgggt	tacttgggcc	tcttttctgc	tctgtggagc	9420
cacacatttg	tgtgctcat	acacgttctt	tctagtaagt	tgcataattac	tctgcgtttt	9480
tacatgtatt	tatttattgt	agtttgttgt	gcgtgtgggc	ccatgcatgg	cacagtgtgt	9540
gggggatgtca	gagtattgtg	aacaggggac	agttcttttc	ttcaatcatg	tgggttccag	9600
aggttgaact	caggtcatca	tgtgtggcag	caaatgcctt	tacccactga	gacatctcca	9660
tattcttttt	ttttccctcg	aggtgggggc	ttgttccata	gcccacactg	gctttgcact	9720
tgcagttcaa	agtgaactcc	tgtctccacc	tcttagagta	ttggaattac	gatgtgtact	9780
accacacctg	actggatcat	taattctttg	atggggggcg	ggaagcgcac	atgctgcagg	9840
tgaagggatg	actggactgg	acatgagcgt	ggaagccaga	gaacagcttc	agtctaattgc	9900
tctcccaact	gagctatttc	ggtttgccag	agaacaactt	acagaaagtt	ctcagtgccca	9960
tgtggattcg	gggttggagt	tcaactcatc	agcttgacat	tggctcctct	acccactgag	10020
ccttctcact	actctctacc	tagatcatta	attctttttt	aaaaagactt	attagggggc	10080
tggagagatg	gctcagccgt	taagagcacc	gaatgccctt	ccagagggtcc	tgagttcaat	10140
tcccagcatg	ccattgctgg	gcagtagggg	gcgcaggtgt	tcaacgtgag	tagctgttgc	10200
cagttttccg	cggtggagaa	cctcttgaca	ccctgctgtc	cctggtcatt	ctgggtgggt	10260
gcatgggtgat	atgcttgttg	tatggaagac	tttgactgtt	acagtgaagt	tgggttccca	10320
cagttaccac	gtctccctcg	tttcttgtag	gcgggtgtgt	tgtccattgc	cgcgagggtct	10380
acagccgctc	cccaacgcta	gttatcgctt	acctcatgat	gcggcagaag	atggacgtca	10440
agtctgctct	gagtactgtg	aggcagaatc	gtgagatcgg	ccccaacgat	ggcttctctg	10500
cccaactctg	ccagctcaat	gacagactag	ccaaggaggg	caaggtgaaa	ctctagggtg	10560
cccacagcct	cttttgacaga	ggtctgactg	ggagggccct	ggcagccatg	tttaggaaac	10620
acagtatacc	cactccctgc	accaccagac	acgtgcccac	atctgtccca	ctctgggtct	10680
cggggggccac	tccaccctta	gggagcacat	gaagaagctc	cctaagaagt	tctgctcctt	10740
agccatcctt	tctgttaatt	tatgtctctc	cctgaggtga	ggttcaggtt	tatgtccctg	10800

tctgtggcat	agatacatct	cagtgaacca	gggtgggagg	gctatcaggg	tgcattggccc	10860
gggacacggg	cactcttcat	gacccctccc	ccacctgggt	tcttccctgt	tgggtccagaa	10920
ccacgagcct	ggtaaaaggaa	ctatgcaaac	acaggccctg	acctcccat	gtctgttccct	10980
ggtcctcaca	gcccgaacag	ccctgctgag	gcagacgaat	gacattaagt	tctgaagcag	11040
agtggagata	gatttagtac	tagatttcca	aaaagaagga	aaaaaaaggc	tgcatttttaa	11100
aattatttcc	ttagaattaa	agatactaca	tagggggccct	tgggtaagca	aatccattttt	11160
tcccagaggc	tatcttgatt	ctttggaatg	tttaaagtgt	gccttgccag	agagcttacg	11220
atctatatct	gctgcttcag	agccttccct	gaggatggct	ctgttccctt	gcttgctaga	11280
agagcgatgc	cttgggcagg	gtttccccc	tttcagaata	cagggtgtaa	agtccagcct	11340
attacaaaca	aacaaacaaa	caaacaaaca	aaggacctcc	atltggagaa	ttgcaaggat	11400
tttatcctga	attatagtgt	tggtagttc	aagtcacac	gccaagtgt	tgccatcctg	11460
gttgctattc	taagaataat	taggaggagg	aacctagcca	attgcagctc	atgtccgtgg	11520
gtgtgtgcac	gggtgcatat	gttggagggt	gtgcctgtcc	ccttggggac	agaaggaaaa	11580
tgaaggccc	ctctgctcac	cctggccatt	tacgggaggc	tctgctgggt	ccacggtgtc	11640
tgtgcaggat	cctgaaactg	actcgctgga	cagaaacgag	acttggcggc	accatgagaa	11700
tggagagaga	gagagcaaa	aaagaaacag	cctttaaaag	aactttctaa	gggtgggtttt	11760
tgaacctgcg	tggaccttgt	atgtgtgcac	atltgccaga	gattgaacat	aatcctcttg	11820
ggacttcacg	ttctcattat	ttgtatgtct	ccggggtcac	gcagagccgt	cagccaccac	11880
cccagcacc	ggcacatagg	cgtctcataa	aagcccattt	tatgagaacc	agagctgttt	11940
gagtaccccg	tgtatagaga	gagttgttgt	cgtggggcac	ccggatccca	gcagcctgggt	12000
tgcctgcctg	taggatgtct	tacaggagtt	tgcagagaaa	ccttcccttg	agggaaagaa	12060
atatcaggga	tttttgttga	atatttcaaa	ttcagcttta	agtgtgaagac	tcagcagtgt	12120
tcattggttaa	ggtaagggaac	atgccttttc	cagagctgct	gcaagaggca	ggagaagcag	12180
acctgtctta	ggatgtcact	cccagggtaa	agacctctga	tcacagcagg	agcagagctg	12240
tgcagcctgg	atggctcattg	tcccctatct	tgtgtgacca	cagcaaccct	ggtcacatag	12300
ggctggctcat	cctttttttt	tttttttttt	tttttttttg	gccagaatg	aagtgacct	12360
agccaagttg	tgtacctcag	tcttttagttt	ccaagcggct	ctcttgcctc	atacaatgtg	12420
catttcaaaa	taacactgta	gagttgacag	aactgggttc	tgtgttatga	gagaggaaaa	12480
gagaggaaa	aacaaaacaa	aacaaaacac	cacaaaccaa	aaacatctgg	gctagccagg	12540
catgattgca	atgtctacag	gccagttca	tgagaggcag	agacagggaag	accgcccga	12600
ggtaaggat	agcatgggtct	acgtatcgag	actccagcca	gggtacgggt	cccaagatcc	12660
taggtttttg	atlttgggct	ttggtttttg	agacagggtt	tctctgtgta	gccctggctg	12720
tcctgggaact	cgtctgttag	accaggctgg	cctcaaaact	agagatctgc	ctgactctgc	12780
ctttgagggc	tgggacgaat	gccaccactg	cccaactaag	attccattaa	aaaaaaaaaa	12840
agttcaagat	aattaagagt	tgccagctcg	ttaaagctaa	gtagaagcag	tctcaggcct	12900
gctgcttgag	gctgttcttg	gcttggacct	gaaatctgcc	cccaacagtg	tccaagtgca	12960
catgactttg	agccatctcc	agagaaggaa	gtgaaaattg	tggctcccca	gtcgattggg	13020
acacagtctc	tctttgtcta	ggtaacacat	ggtgacacat	agcattgaac	tctccactct	13080
gagggtgggg	ttccctcccc	ctgcctcttc	tgggttggtc	accccatagg	acagccacag	13140
gacagtcaact	agcacctact	ggaaacctct	ttgtgggaac	atgaagaaag	agcctttggg	13200
agattccctg	ctttccatta	gggtgaaaag	tacaacgggt	cttgggtggc	tttgctcgt	13260
gtttataaaa	ctagctacta	ttcttcagggt	aaaataccga	tgtgtgggaa	aagccaacct	13320
cgtggctgcc	cgtgagtagg	gggtgggggt	gggaatccct	gatagtgttc	tatccatgga	13380
actgctgga	ataggaaata	aggggtcttc	gggggggggg	agcctcttgc	tcagcagcag	13440

aagtcgctga ataggaaata agggctgttc ccccccttc aactctcttc ccagaccag 13440
 ccactttcta tgacttataa acatccaggt aaaattaca aacataaaaa tggtttctct 13500
 tctcaatctt ctaaagtctg cctgcctttt ccaggggtag gtctgtttct ttgctgttct 13560
 attgtcttga gagcacagac taacacttac caaatgaggy aactcttggc ccatactaag 13620
 gctcttctgg gctccagcac tcttaagtta ttttaagaat tctcacttgg ccttttagcac 13680
 acccgccacc cccaagtggg tgtggataat gccatggcca gcagggggca ctggttagggc 13740
 ggggtgcctt ccaccttaag ttgcttatag tatttaagat gctaaatgtt ttaatcaaga 13800
 gaagcactga tcttataata caggataag agattttctc acaggaaatt gtctttttca 13860
 taattctttt acaggctttg tcctgatcgt agcatagaga gaatagctgg atatttaact 13920
 tgtattccat tttctctgc cagcgttagg ttaactccgt aaaaagtgat tcagtggacc 13980
 gaagaggctc agagggcagg ggatggtggg gtgaggcaga gcactgtcac ctgccaggca 14040
 tgggaggctc tgccatccgg gaggaaaagg aaagttagc ctctagtcta ccaccagtgt 14100
 taacgcactc taaagtgtga accaaaataa atgtcttaca ttacaaagac gtctgttttg 14160
 tgtttccttt tgtgtgtttg ggctttttat gtgtgcttta taactgctgt ggtggtgctg 14220
 ttgttagttt tgaggttaga tctcaggctg gccttgaact tctgatcgcc tgccctgcc 14280
 cctgccccctg cccctgtccc tgccccaag tgcctaggact aaaagcacat gccaccacac 14340
 cagtacagca tttttctaac atttaaaaat aatcacctag gggctggaga gagggtcca 14400
 gctaagagtg cacactgtc ttgggttaga cctgagttta gttcccagaa cctatactgg 14460
 gtggctccag gtccagagga tccaggacct ctggcctcca tgggcatctg ctcttagcac 14520
 ataccacat acagatacac acataaaaat aaatgaagc ctttaaaaac ctctaaaac 14580
 ctagcccttg gaggtacgac tctggaaagc tggcatactg tgtaagtcca tctcatggtg 14640
 ttctggctaa cgtaagactt acagagacag aaaagaactc aggggtgtgt ggggggtggg 14700
 atggaggaag agggatgagt agggggagca cggggaactt gggcagtga aattctttgc 14760
 aggacactag aggaggataa ataccagtca ttgcacccac tactggacaa ctccagggaa 14820
 ttatgctggg tgaaaagaga agggcccagg tattggctgc attggtgca tttgcgtaac 14880
 atttttttaa attgaaaaga aaaagatgta aatcaagggt agatgagtgg ttgctgtgag 14940
 ctgagagctg ggggtgagtga gacatgtgga caactccatc aaaaagcgac agaaagaacg 15000
 ggctgtgggtg acagctacct ctaatctcca cctccgggag gtgatcaagg ttagccctca 15060
 gctagcctgt ggtgcatgag accctgtttc aaaaacttta ataaagaaat aatgaaaaaa 15120

gacatcaggg cagatccttg gggccaaagg cggacaggcg agtctcgtgg taaggctcgtg 15180
 tagaagcgga tgcattagca cgtgccgcag gcatcatgag agagccctag gtaagtaagg 15240
 atggatgtga gtgtgtcggc gtcggcgcac tgcacgtcct ggctgtggtg ctggactggc 15300
 atctttgggt agctgtggag gggaaatggg tagggagatc ataaaatccc tccgaattat 15360
 ttcaagaact gtctattaca attatctcaa aatattaaaa aaaaagaaga attaaaaaac 15420
 aaaaaaccta tccagggtgtg gtgggtgtgca cctatagcca cgggcacttg gaaagctgga 15480
 gcaagaggat ggcgagtttg aaggatatct gggctgtaca gcaagaccgt cgtccccaaa 15540
 ccaaaccaaa cagcaaaccc attatgtcac acaagagtgt ttatagttag cggcctcgct 15600
 gagagcatgg ggtgggggtg ggggtggggg acagaaatat ctaaactgca gtcaataggg 15660
 atccactgag accctggggc ttgactgcag cttaaccttg ggaaatgata agggttttgt 15720
 gtttagtaaa agcatcgatt actgacttaa cctcaaatga agaaaaagaa aaaaagaaaa 15780
 caacaaaagc caaaccaagg ggctggtgag atggctcagt gggtaagagc acccgactgc 15840
 tcttccgaag gtccagagtt caaatcccag caaccacatg gtggctcaca accatctgta 15900
 acgagatatg atgccctctt ctgggtgtgc tgaagacagc tacagtgtac ttacatataa 15960
 taaataaatc ttaaaaaaaaa aaaaaaaaaa aaaagccaaa ccgagcaaac caggccccc 16020

aacagaaggc	aggcacgacg	gcaggcacca	cgagccatcc	tgtgaaaagg	cagggctacc	16080
catggggcga	ggaggggtcca	gagagatagg	ctggtaagct	cagtttctct	gtataccctt	16140
tttcttggtg	acactacttc	aattacagat	aaaataacaa	ataaacaaaa	tctagagcct	16200
ggccactctc	tgtctgcttg	atttttcctg	ttacgtccag	caggtggcgg	aagtgttcca	16260
aggacagatc	gcattcattaa	ggtggccagc	ataatctccc	atcagcaggt	ggtgctgtga	16320
gaaccattat	ggtgctcaca	gaatcccggg	cccaggagct	gccctctccc	aagtctggag	16380
caataggaaa	gctttctggc	ccagacaggg	ttaacagtcc	acattccaga	gcaggggaaa	16440
aggagactgg	aggtcacaga	caaaaggggc	agcttctaac	aacttcacag	ctctggtagg	16500
agagatagat	cacccccaac	aatggccaca	gctggttttg	tctgccccga	aggaaactga	16560
cttaggaagc	aggtatcaga	gtccccttcc	tgaggggact	tctgtctgcc	ttgtaaagct	16620
gtcagagcag	ctgcattgat	gtgtgggtga	cagaagatga	aaaggaggac	ccaggcagat	16680
cgccacagat	ggaccggcca	cttacaagtc	gaggcaggtg	gcagagcctt	gcagaagctc	16740
tgcaggtgga	cgacactgat	tcattaccca	gttagcatac	cacagcgggc	taggcggacc	16800
acagcctcct	tcccagtctt	cctccagggc	tggggagtc	tccaaccttc	tgtctcagtg	16860
cagcttccgc	cagcccctcc	tccttttgca	cctcaggtgt	gaaccctccc	tcctctcctt	16920
ctcctctgtg	catggccctc	ctgctactgc	aggtgagca	ttggatttct	ttgtgcttag	16980
atagacctga	gatggctttc	tgatttatat	atatatatcc	atcccttgga	tcttacatct	17040
aggaccacga	gctgtttgtg	ataccataag	aggtctggga	gatgatatgg	taagagtgtc	17100
tgctgtacaa	gcataagac	atgagttcga	atccccagca	accatgtgga	aaaataacct	17160
tctaacctca	gagttgaggg	gaaaggcagg	tggattctgg	gggcttactg	gccagctagc	17220
cagcctaacc	taaatgtctc	agtcagagat	cctgtctcag	ggaataactt	gggagaatga	17280

ctgagaaaga	cacctcctca	ggtctcccat	gcaccacac	agacacacgg	ggggggggta	17340
atgtaataag	ctaagaaata	atgagggaaa	tgattttttg	ctaagaaatg	aaattctgtg	17400
ttggccgcaa	gaagcctggc	caggggaagg	actgcctttg	gcacaccagc	ctataagtca	17460
ccatgagttc	cctggctaag	aatcacatgt	aatggagccc	aggtccctct	tgcttggtgg	17520
ttgcctctcc	cactggtttt	gaagagaaat	tcaagagaga	tctccttggt	cagaattgta	17580
ggtgtctgagc	aatgtggagc	tggggccaat	gggattcctt	taaaggcatc	cttcccaggg	17640
ctgggtcata	cttcaaatgt	aggggtgctt	cacagcaagc	gtgagaccct	aggttagagt	17700
ccccagaatc	tgcccccaac	cccccaaaaa	ggcatccttc	tgctctgggg	tgggtggggg	17760
gagcaaacac	ctttaactaa	gaccattagc	tggcaggggt	aacaaatgac	cttggctaga	17820
ggaatttggt	caagctggat	tccgccttct	gtagaagccc	cacttggttc	ctttgttaag	17880
ctggcccaca	gtttgttttg	agaatgcctg	agggggcccag	ggagccagac	aattaaaagc	17940
caagctcatt	ttgatatact	aaaaccacag	cctgactgcc	ctgccctggg	gaggtactgg	18000
gagagctggc	tgtgtccctg	cctcaaccaac	gccccccccc	ccaacacaca	ctcctcgggt	18060
cacctgggag	gtgccagcag	caatttgga	gtttactgag	cttgagaagt	cttgggaggg	18120
ctgacgctaa	gcacaccctc	tctccacccc	ccccccaccc	acccccgtga	ggaggagggg	18180
gaggaaacat	gggaccagcc	ctgctccagc	ccgtccttat	tggctggcat	gaggcagagg	18240
gggcttttaa	aaggcaaccg	tatctaggct	ggacactgga	gcctgtgcta	ccgagtgcc	18300
tctccacact	ggcagcatgc	agccctcact	agccccgtgc	ctcatctgcc	tacttgtgca	18360
cgtgccttcc	tgtgtctgtg	agggccaggg	gtggcaagcc	ttcaggaatg	atgccacaga	18420
ggtcatccca	gggcttgagg	agtaccccca	gcctcctcct	gagaacaacc	agaccatgaa	18480
ccgggcggag	aatggaggca	gacctcccca	ccatccctat	gacgccaaaag	gtacgggatg	18540
aagaagcaca	ttagtggggg	gggggggtcct	gggaggtgac	tgggggtggt	ttagcatctt	18600
cttcagaggt	ttgtgtgggt	ggctagcctc	tgctacatca	gggcagggac	acatttgctt	18660

ggaagaatac tagcacagca ttagaacctg gagggcagca ttggggggct ggtagagagc	18720
acccaaggca ggggtggaggc tgaggctcagc cgaagctggc attaacacgg gcatgggctt	18780
gtatgatggc ccagagaatc tccctctaag gatgaggaca caggtcagat ctagctgctg	18840
accagtgggg aagtgtatg gtgaggctgg atgccagatg ccatccatgg ctgtactata	18900
tcccacatga ccaccacatg aggtaaagaa gggcccagct tgaagatgga gaaaccgaga	18960
ggctcctgag ataaagtcac ctgggagtaa gaagagctga gactggaagc tggtttgatc	19020
cagatgcaag gcaaccctag attgggtttg ggtgggaacc tgaagccagg aggaatccct	19080
ttagttcccc cttgcccagg gtctgctcaa tgagcccaga gggttagcat taaaagaaca	19140
gggtttgtag gtggcatgtg acatgagggg cagctgagtg aaatgtcccc tgtatgagca	19200
cagggtggc accttgccct gagcttgcac cctgacccca gctttgcctc attcctgagg	19260
acagcagaaa ctgtggaggc agagccagca cagagagatg cctgggggtg ggggtgggggt	19320
atcacgcacg gaactagcag caatgaatgg ggtgggggtg cagctggagg gacactccag	19380
agaaatgacc ttgctgggtc ccatttgtgt gggaggagag ctcattttcc agcttgccac	19440
cacatgctgt ccctcctgtc tcctagccag taagggatgt ggaggaaagg gccaccccaa	19500
aggagcatgc aatgcagtca cgtttttgca gaggaagtgc ttgacctaa ggcactattc	19560
ttggaaaagg ccaaaactag tccttcctg ggcaaacagg cctccccac ataccacctc	19620
tgcaggggtg agtaaatata gccagccaca gaagggtggc aaggcctaca cctccccct	19680
gttgtgcccc ccccccccc gtgaagggtc atcctggcct ctgccccctt ggctttggta	19740
ctgggatttt ttttttccct ttatgtcata ttgacctga caccatggaa cttttggagg	19800
tagacaggac ccacacatgg attagttaaa agcctcccat ccatctaagc tcatggtagg	19860
agatagagca tgtccaagag aggagggcag gcatcagacc tagaagatat ggctgggcat	19920
ccaaccaat ctcttcccc ggagaacaga ctctaagtca gatccagcca cccttgagta	19980
accagctcaa ggtacacaga acaagagagt ctggtataca gcagggtgta aacaaatgct	20040
tgtggtagca aaagctatag gttttgggtc agaactccga cccaagtgc gagtgaagag	20100
cgaaggcccc tctactcgc accgccccgc ccccacctgg ggtcctataa cagatcactt	20160
tcacccttgc gggagccaga gagccctggc atcctaggta gcccccccg ccccccccc	20220
gcaagcagcc cagccctgcc tttggggcaa gttcttttct cagcctggac ctgtgataat	20280
gaggggggtg gacgcgcgc ctttgggtgc tttcaagtct aatgaattct tatccctacc	20340
acctgcccc ctacccccgt cctccacagc agctgtcctg atttattacc ttcaattaac	20400
ctccactcct ttctccatct cctgggatac cgccctgtc ccagtggctg gtaaaggagc	20460
ttaggaagga ccagagccag gtgtggctag aggctaccag gcagggtgg ggatgaggag	20520
ctaaactgga agagtgtttg gttagtaggc acaaagcctt ggggtgggac cctagtaccg	20580
gagaagtgga gatgggcgct gagaagttca agaccatcca tccttaacta cacagccagt	20640
ttgaggccag cctgggctac ataaaaacc aatctcaaaa gctgccaatt ctgattctgt	20700
gccacgtagt gcccgatgta atagtggatg aagtcgttga atcctggggc aacctatttt	20760
acagatgtgg ggaaaagcaa ctttaagtac cctgccaca gatcaciaag aaagtaagtg	20820
acagagctcc agtggttcat ccctgggttc caaggacagg gagagagaag ccagggtggg	20880
atctcactgc tcccgggtgc ctcttctcta taatccatac agattcgaaa gcgcagggca	20940
ggtttgga aaagagagaag ggtggaagga gcagaccagt ctggcctagg ctgcagcccc	21000
tcacgcatec ctctctccgc agatgtgtcc gagtacagct gccgcgagct gcactacacc	21060
cgcttctga cagacggccc atgcccagc gccaaagcgg tcaccgagtt ggtgtgctcc	21120
ggccagtgc gccccgcgc gctgctgcc aacgccatcg ggcgcgtgaa gtggtggcgc	21180
ccgaacggac cggatttccg ctgcatccc gatcgctacc gcgcgcagcg ggtgcagctg	21240
ctgtgcccc ggggcgcgc gccgcgctc cgcaagggtc gtctgggtgc ctcgtgcaag	21300

tgcaagegcc	tcacccgctt	ccacaaccag	tggagctca	aggacttcgg	gccggagacc	21360
gcgcggccgc	agaagggtcg	caagccgcgg	cccgcgcgcc	ggggagccaa	agccaaccag	21420
gcggagctgg	agaacgccta	ctagagcgag	ccgcgccta	tgcagcccc	gcgcgatccg	21480
attcgttttc	agtgtaaagc	ctgcagccca	ggccaggggt	gccaaaacttt	ccagaccgtg	21540
tggagttccc	agcccagtag	agaccgcagg	tccttctgcc	cgctgcgggg	gatggggagg	21600
gggtgggggt	cccgcgggcc	aggagaggaa	gcttgagtcc	cagactctgc	ctagccccgg	21660
gtgggatggg	ggtcttttcta	ccctcgccgg	acctatacag	gacaaggcag	tgtttccacc	21720
ttaaagggaa	gggagtgtgg	aacgaaagac	ctgggactgg	ttatggacgt	acagtaagat	21780
ctactccttc	cacccaaatg	taaagcctgc	gtgggctaga	tagggtttct	gacctgacc	21840
tggccactga	gtgtgatgtt	gggtacgtg	gttctctttt	ggtacggctt	tctttgtaaa	21900
atagggaccg	gaactctgct	gagattccaa	ggattgggggt	accccggtga	gactggtgag	21960
agagaggaga	acagggggagg	ggttagggga	gagattgtgg	tgggcaaccg	cctagaagaa	22020
gctgtttgtt	ggctcccagc	ctcgccgcct	cagagggttg	gcttccccca	ctccttcctc	22080
tcaaattctgc	cttcaaatac	atatctggga	tagggaaggc	cagggtccga	gagatggtag	22140
aagggccaga	aatcacactc	ctggccccc	gaagagcagt	gtcccgcccc	caactgcctt	22200
gtcatattgt	aaagggatgt	tctacacaac	agtttaaggt	cgttggaggga	aactgggctt	22260
gccagtcacc	tcccatcctt	gtcccttgcc	aggacaccac	ctcctgcctg	ccaccacagg	22320
acacatttct	gtctagaaac	agagcgtcgt	cgtgctgtcc	tctgagacag	catatcttac	22380
attaaaaaga	ataatacggg	gggggggggc	ggagggcgca	agtgttatac	atatgctgag	22440
aagctgtcag	gcgccacagc	accaccacac	atctttttgt	aaatcatttc	cagacacctc	22500
ttactttctg	tgtagatttt	aattgttaaa	aggggaggag	agagagcgtt	tgtaacagaa	22560
gcacatggag	gggggggtag	gggggttggg	gctggtagt	ttggcgaact	ttccatgtga	22620
gactcatcca	caaagactga	aagccgcgtt	ttttttttta	agagtccagt	gacatattta	22680
ttttctcatt	taagttatgt	atgccaaacat	ttttttcttg	tagagaaagg	cagtgttaat	22740
atcgctttgt	gaagcacaa	gtgtgtgtgt	ttttgttttt	ttgttttttc	cccgaccaga	22800
ggcattgtta	ataaagacaa	tgaatctcga	gcaggaggct	gtggtcttgt	tttgtcaacc	22860
acacacaatg	tctcgccact	gtcatctcac	tccttccct	tggtcacaag	acccaaacct	22920
tgacaacacc	tccgactgct	ctctggtagc	ccttgtggca	atacgtgttt	cctttgaaaa	22980
gtcacattca	tcctttccct	tgcaaacctg	gctctcatte	cccagctggg	tcategtcat	23040
accttcaccc	cagcctccct	ttagctgacc	actctccaca	ctgtcttcca	aaagtgcacg	23100
tttcacggag	ccagttccct	ggtccaggtc	atcccattgc	tcctccttgc	tccagacctt	23160
tctcccacaa	agatgttcat	ctcccactcc	atcaagcccc	agtggccctg	cggctatccc	23220
tgtctcttca	gttagctgaa	tctacttgct	gacaccacat	gaattccttc	ccctgtctta	23280
aggttcattg	aactcttgcc	tgcccctgaa	ccttcagga	ctgtcccagc	gtctgatgtg	23340
tcctctctct	tgtaaagccc	caccccacta	tttgattccc	aattctagat	cttccttctg	23400
tcattccctc	acgggatagt	gtctcatctg	gccaaagcct	gcttgatatt	gggataaatg	23460
caaagccaag	tacaattgag	gaccagtcca	tcattgggcc	aagctttttc	aaaatgtgaa	23520
ttttacacct	atagaagtgt	aaaagccttc	caaagcagag	gcaatgectg	gtcttccctt	23580
caacatcagg	gctcctgctt	tatgggtctg	gtgggtagt	acattcataa	acccaacact	23640
aggggtgtga	aagcaagatg	attgggagtt	cgaggccaat	cttggctatg	aggccctgtc	23700
tcaacctctc	ctccctccct	ccagggtttt	gttttgtttt	gtttttttga	tttgaaactg	23760
caacacttta	aatccagtc	agtgcactct	tgcgtgaggg	gaactctatc	cctaataata	23820
gcttccatct	tgatttgtgt	atgtgcacac	tgggggttga	acctgggcct	ttgtacctgc	23880

cgggcaagct	ctctactgct	ctaaaccag	ccctcactgg	ctttctgttt	caactcccaa	23940
tgaattcccc	taaatgaatt	atcaatatca	tgtctttgaa	aaataccatt	gagtgcctgct	24000
ggtgtccctg	tggttccaga	ttccaggaag	gacttttcag	ggaatccagg	catcctgaag	24060
aatgtcttag	agcaggaggc	catggagacc	ttggccagcc	ccacaaggca	gtgtggtgca	24120
gagggtgagg	atggaggcag	gcttgcaatt	gaagctgaga	cagggctactc	aggattaaaa	24180
agcttcccc	aaaacaattc	caagatcagt	tcctgggtact	tgcacctgtt	cagctatgca	24240
gagcccagtg	ggcataggtg	aagacaccgg	ttgtactgtc	atgtactaac	tgtgcttcag	24300
agccggcaga	gacaaataat	gttatgggtga	ccccagggga	cagtgattcc	agaaggaaca	24360
cagaagagag	tgtctgctaga	ggctgcctga	aggagaaggg	gtcccagact	ctctaagcaa	24420
agactccact	cacataaaga	cacaggctga	gcagagctgg	ccgtggatgc	agggagccca	24480
tcaccatcc	tttagcatgc	ccttgatttc	ccatcacatg	ccagggatga	ggggcatcag	24540
agagtccaag	tgatgcccc	acccaaacac	acctaggact	tgctttctgg	gacagacaga	24600
tgcaggagag	actagggttg	gctgtgatcc	cattaccaca	aagagggaaa	aaacaaaaaa	24660
caaacaacaa	aacaaaaaaa	aacaaaacaa	aacaaaaaaa	aaccaagggt	ccaaattgta	24720
ggtcaggtta	gagtttattt	atggaaagtt	atattctacc	tccatggggg	ctacaaggct	24780
ggcgcccatc	agaaagaaca	aacaacaggc	tgatctggga	ggggtggtac	tctatggcag	24840
ggagcacgtg	tgttggggg	acagccagac	acggggcttg	tattaatcac	agggcttgta	24900
ttaataggct	gagagtcaag	cagacagaga	gacagaagga	aacacacaca	cacacacaca	24960
cacacacaca	cacacacaca	catgcacaca	ccactcactt	ctcactcgaa	gagccctac	25020
ttacattcta	agaacaaacc	attcctcctc	ataaaggaga	caaagttgca	gaaacccaaa	25080
agagccacag	ggtccccact	ctctttgaaa	tgacttggac	ttgttgcagg	gaagacagag	25140
gggtctgcag	aggcttctcg	ggtgaccag	agccacagac	actgaaatct	ggtgctgaga	25200
cctgtataaa	ccctcttcca	caggttccct	gaaaggagcc	cacattcccc	aacctgtct	25260
cctgaccact	gaggatgaga	gcacttgggc	cttccccatt	cttggagtgc	accctggttt	25320
ccccatctga	gggcacatga	ggtctcaggt	cttgggaaag	ttccacaagt	attgaaagtg	25380
ttcttgtttt	gtttgtgatt	taatttaggt	gtatgagtgc	ttttgcttga	atatatgcct	25440
gtgtagcatt	tacaagcctg	gtgctgagg	agatcagaag	atggcatcag	ataccctgga	25500
actggacttg	cagacagtta	tgagccactg	tgtgggtgct	aggaacagaa	cctggatcct	25560
ccggaagagc	agacagccag	cgctcttagc	cactaagcca	tcactgaggt	tctttctgtg	25620
gctaaagaga	caggagacaa	aggagagttt	cttttagtca	ataggaccat	gaatgttctt	25680
cgtaacgtga	gactagggca	gggtgatccc	ccagtgcac	cgatggccct	gtgtagtatt	25740
tagcagctct	agtcttattc	cttaataagt	cccagtttgg	ggcaggagat	atgtattccc	25800
tgctttgaag	tggctgaggt	ccagttatct	acttccaagt	acttgtttct	ctttctggag	25860
ttggggaagc	tcctgcctg	cctgtaaattg	tgtccattct	tcaaccttag	acaagatcac	25920
tttccctgag	cagtcaggcc	agtccaaagc	ccttcaattt	agctttcata	aggaacaccc	25980
cttttgttgg	gtggaggtag	cacttgccct	gaatcccagc	attaagaagg	cagagacagt	26040
cggatctctg	tgagttcaca	gccagcctgg	tctacggagt	gagttccaag	acagccaggc	26100
ctacacagag	aaacctgtc	tcgaaaaaaa	caaaaacaaa	agaaataaag	aaaagaaaaa	26160
caaaaacgaa	caaacagaaa	aacaagccag	agtgtttgtc	cccgattttt	attaatcata	26220
tttttgtccc	tttgccattt	tagactaaaa	gactcgggaa	agcagggtctc	tctctgtttc	26280
tcacccggac	acaccagaaa	ccagatgtat	ggaagatggc	taatgtgctg	cagttgcaca	26340
tctggggctg	ggtggattgg	ttagatggca	tgggctgggt	gtggttacga	tgactgcagg	26400
agcaaggagt	atgtggtgca	tagcaaacga	ggaagtttgc	acagaacaac	actgtgtgta	26460
ctgatgtgca	ggtatgggca	catgcaagca	gaagccaagg	gacagcctta	gggtagtgtt	26520
tcacacaccc	cctccccctt	tttaacatgg	acatctctca	ttqccctqqa	acttqccaac	26580

tgggctgggc	tggctagctt	gtagggtccca	gggatctgca	tatctctgcc	tcctagtgcc	26640
tgggattaca	gtcatatatg	agcacacctg	gcttttttat	gtgggttctg	ggctttgaac	26700
ccagatctga	gtgcttgcaa	ggcaatcggg	tgaatgactg	cttcattctcc	ccagacctg	26760
ggattctact	ttctattaaa	gtattttctat	taaatcaatg	agccctgcc	cctgcaactca	26820
gcagttctta	ggcctgctga	gagtcaagtg	gggagtgaga	gcaagcctcg	agaccccatc	26880
agcgaagcag	aggacaaaaga	aatgaaaact	tgggattcga	ggctcgggat	atggagatac	26940
agaaagggtc	agggaaggaa	atgaaccaga	tgaatagagg	caggaagggt	agggccctgc	27000
atacatggaa	cctgggtgtac	atgttatctg	catgggggtt	gcattgcaat	ggctcttcag	27060
caggttcacc	acactgggaa	acagaagcca	aaaagaagag	taggtggtgt	tggagtcaga	27120
tactgtcagt	catgcctgaa	gaaatggaag	caattaacga	tgcgccgcaa	ttaggatatt	27180
agctccctga	agaaaggcaa	gaagctgggc	tgtgggcact	gaaggagct	ttgaatgatg	27240
tcacattctc	tgtatgccta	gcagggcagt	attggagact	gagacttgac	ttgtgtgtcc	27300
atatgattcc	tccttttctc	acagtcatct	ggggctcctg	agcttcgtcc	ttgtccaaga	27360
acctggagct	ggcagtgggc	agctgcagtg	atagatgtct	gcaagaaaga	tctgaaaaga	27420
gggaggaaga	tgaaggacct	agaggaccac	gcacctctgc	tgctgacaa	agctgcagga	27480
ccagtctctc	ctacagatgg	gagacagagg	cgagagatga	atggtcaggg	gaggagtcag	27540
agaaaggaga	gggtgaggca	gagaccaaag	gagggaaca	cttgtgtctc	acagctactg	27600
actgagtacc	agctgcgtgg	cagacagcca	atgccaaagg	tcggctgac	atggcacctc	27660
gtgggactcc	tagccctagtg	ctggcagagg	ggagtgtctga	atggctgatg	gtttggatat	27720
gatctgaatg	tgggtccagcc	ctagtcttct	tccagttgct	gggataaagc	accctgacca	27780
aagctacttt	tttgtttgtt	tgttttggtt	tggttttgtt	tggttttctg	aggcagggtt	27840
tctctgtatc	accctagctg	tcctggaact	cactctgtag	accaggctgg	cctcgaactc	27900
agaaatcccc	ctgcctctgc	ctcctaagtg	ctggaattaa	aggcctgcgc	caccactgcc	27960
ggcccaaagc	tactttaaga	gagagagagg	aatgtataag	tattataatt	ccagggtata	28020
gttcattgct	gtagaattgg	agtcttcata	ttccaggtaa	tctccacag	acatgccaca	28080
aaacaacctg	ttctacgaaa	tctctcatgg	actcccttcc	ccagtaattc	taaactgtgt	28140
caaactctaca	agaaatagtg	acagtcacag	tctctaacgt	tttgggcctg	agtctgaagt	28200
ctcattgcta	agtactggga	agatgaaaac	tttacctagt	gtcagcattt	ggagcagagc	28260
ctttgggatt	tgagatggtc	ttttgcagag	ctcctaattg	ctacatggag	agagggggcc	28320
tgggagagac	ccatacacct	tttgctgcct	tatgtcacct	gacctgctcc	ttgggaagct	28380
ctagcaagaa	ggccttccct	ggatcaccca	ccaccttgca	cctccagAAC	tcagagccaa	28440
attaaacttt	cttgttactg	tcgtaaaagc	acagtcggtc	tgggttgtat	cactgtcaat	28500
gggaaaacaga	cttgccctgga	tggataactt	gtacattgca	taatgtctag	aaatgaaaag	28560
tcctatagag	aaaaagaaaa	ttagctggca	cacagataga	ggccctggag	gaggctggct	28620
ttgtcctccc	cgaggaggtg	gcgagtaagg	tgtaaatgtt	catggatgta	aatgggcccc	28680
tatatgaggg	tctggggtaa	caagaaggcc	tgtgaatata	aagcactgaa	ggtatgtcta	28740
gtctggagaa	ggtcactaca	gagagttctc	caactcagtg	cccatacaca	cacacacaca	28800
cacacacaca	cacacacaca	cacacacaca	ccacaaagaa	aaaaagggaag	aaaaatctga	28860
gagcaagtac	agtacttaaa	attgtgtgat	tgtgtgtgtg	actctgatgt	cacatgctca	28920
tcttgcccta	tgagttgaaa	accaaattggc	ccctgagagg	cataacaacc	acactgttgg	28980
ctgtgtgtct	acgtttttct	taaagcgtct	gtctgggttg	ctgctagcat	caggcagact	29040
tgcagcagac	tacatatgct	cagccctgaa	gtccttctag	ggtgcatgtc	tcttcagaat	29100
ttcagaaagt	catctgtggc	tccaggaccg	cctgcactct	ccctctgccg	cgaggctgca	29160
gactctaggg	tggggtggaa	gcaacgctta	cctctgggac	aagtataaca	tgttggcttt	29220

tctttccctc	tgtggctcca	acctggacat	aaaatagatg	caagctgtgt	aataaatatt	29280
tcctcccgctc	cacttagttc	tcaacaataa	ctactctgag	agcacttatt	aatagggtggc	29340
ttagacataa	gctttggctc	attccccac	tagctcttac	ttctttaact	ctttcaaacc	29400
attctgtgtc	ttccacatgg	ttagttacct	ctccttccat	cctgggtcgc	ttcttccttc	29460
gagtcgacct	cagtgtctct	aggtgatgct	tgtaagatat	tctttctaca	aagctgagag	29520
tggtggcact	ctgggagttc	aaagccagcc	tgatctacac	agcaagctcc	aggatatcca	29580
gggcaatgtt	gggaaaacct	ttctcaaaca	aaaagagggg	ttcagttgtc	aggaggagac	29640
ccatgggtta	agaagtctag	acgagccatg	gtgatgcata	cctttcatcc	aagcacttag	29700
gaggcaaaga	aaggtgaaac	tctttgactt	tgaggccagc	taggttacat	agtataccc	29760
tgcttagtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtaatt	taaaagtcta	29820
aaaatgcatt	cttttaaaaa	tatgtataag	tatttgccctg	cacatatgta	tgtatgtatg	29880
tataccatgt	gtgtgtctgg	tgctgaagga	ctaggcatag	actccctaga	actagagtca	29940
tagacagitt	tgacactccc	caacccccca	ccatgtgggt	gcttgaaget	aaactcctgt	30000
cctttgtaaa	gcagcaggtg	tctatgaacc	ctgaaccatc	tctccagtct	ccagatgtgc	30060
attctcaaa	aggagtccct	catatttccc	taaactgaac	atccttatca	gtgagcatcc	30120
tcgagtcacc	aaagctactg	caaaccctct	tagggaacat	tcactattca	cttctacttg	30180
gctcatgaaa	cttaagtaca	cacacacaaa	cacacacaca	cacacagagt	catgcactca	30240
caaaagcatg	catgtacacc	attcttatta	gactatgctt	tgctaaaaga	ctttcctaga	30300
tactttaaaa	catcacttct	gccttttggg	gggcaggttc	caagattggg	actggcgtac	30360
tggaaactga	acaaggtaga	gatctagaaa	tcacagcagg	tcagaagggc	cagcctgtac	30420
aagagagagt	tcacacacct	ccaggaacac	tgagcagggg	gctgggacct	tgccctctcag	30480
cccaagaaac	tagtgcggtt	cctgtatgca	tgccctctcag	agattccata	agatctgcct	30540
tctgccataa	gatctcctgc	atccagacaa	gcctagggga	agttgagagg	ctgcctgagt	30600
ctctcccaca	ggccccctct	tgccctggcag	tattttttta	tctggaggag	aggaatcagg	30660
gtgggaatga	tcaaatacaa	ttatcaagga	aaaagtaaaa	aacatatata	tatatatatt	30720
aactgatcta	gggagctggc	tcagcagtta	agagttcttg	ctgcccctgc	ttcagatctt	30780
gctttgatcc	ccagcaccca	catgatggct	ttcaactgta	tctctgcttc	caggggatcc	30840
aacagcctct	tctgacctcc	atagacaaga	cctagtcttc	tgcaagagca	ccaaatgctc	30900
ttatctgttg	atccatctct	ctagcctcat	gccagatcat	ttaaaactac	tggacactgt	30960
cccattttac	gaagatgtca	ctgcccgatc	atttgccatg	agtggtatatt	tcgattcttt	31020
ctatgttctc	acccttgcaa	tttataagaa	agatatctgc	atttgtctcc	tgagagaaca	31080
aagggtggag	ggctactgag	atggctctag	gggtaaaggt	gcttgccaca	aaatctgaca	31140
acttaagttt	ggtcttgtaa	tccacatggt	ggagagagag	aagagattcc	cgtaagttgt	31200
cctcaaaact	cccacacatg	tgctgtggct	tatgtgtaac	ccaataagt	aaagatagtt	31260
ttaaacacta	cataaggtag	ggtttcttca	tgaccccaag	gaatgatgcc	cctgatagag	31320
cttatgctga	aaccccatct	ccattgtgcc	atctggaaa	agacaattgc	atcccggaaa	31380
cagaatcttc	atgaatggat	taatgagcta	ttaagaaagt	ggcttgggtta	ttgcacatgc	31440
tgggggcgta	atgacctcca	ccatgatgtt	atccagcatg	aaggtctctca	ccagaagtca	31500
tacaaatctt	cttaggcttc	cagagtcgtg	agcaaaaaaa	gcacacctct	aaataaatta	31560
actagcctca	ggtagttaac	caccgaaaat	gaaccaaggc	agttcttaata	caaaaccact	31620
tccttccctt	gttcaaacca	cagtgcctta	ttatctaaaa	gataaacttc	aagccaagct	31680
tttaggttgc	cagtatttat	gtaacaacaa	ggcccgttga	cacacatctg	taactcctag	31740
tactgggctt	caggggcaga	gacaggtgga	gccttgaggt	ttgaattcca	ggttctgtga	31800
gaaactctgt	ctgaaaagac	aatatgggtga	gtgacccggg	aggatatctg	atattgactt	31860
ctgggggctc	gaggggagta	tatgggagta	tatgggagta	gaggggagta	gaggggagta	31920

ctggccaaca	cacagccatc	ctgcaacac	ctgagctgca	agccctctgc	actaagcttg	31720
gccagagtca	gagtttgcaa	gtgtttgtgg	actgaatgca	cgtgttgctg	gtgatctaca	31980
aagtcaccct	ccttctcaag	ctagcagcac	tggtctgggc	cagctgctca	ttcaagcctc	32040
tttgcagagt	catcacgggg	atgggggagc	agggcccctc	cctagaacac	caagcctgtg	32100
gttgtttatt	caggacatta	ttgagggcca	agatgacaga	taactctatc	acttggccaa	32160
cagtcgggtg	ttgcggtgtt	aggttatttc	tgtgtctgca	gaaaacagtg	caacctggac	32220
aaaagaaata	aatgatatac	tttttcatte	aggcaactag	attccgtggt	acaaaaggct	32280
ccctggggaa	cgaggccggg	acagcgcggc	tcctgagtcg	ctatttccgt	ctgtcaactt	32340
ctctaacttc	ttgatttctt	ccctctgtct	gtttccttcc	tcttgctggg	gcccagtgga	32400
gtctgtgtac	tcacagggag	gaggggtggc	aagccctggt	cctctacggg	ctgggggaag	32460
gggggaagct	gtcgccccag	tgactttttc	ccctttctct	ttttcttaga	aaccagtctc	32520
aatttaagat	aatgagtctc	ctcattcacg	tgtgctcact	attcataggg	acttatccac	32580
ccccgccctg	tcaatctggc	taagtaagac	aagtcaaatt	taaaaggga	cgtttttcta	32640
aaaatgtggc	tggaccgtgt	gcgggcacga	aaccagggat	ggcgggtctaa	gttacctgct	32700
ctctgccagc	ccgggtgcct	tttccctttc	gaaaggagac	ccggaggtaa	aacgaagttg	32760
ccaacttttg	atgatgggtg	gcgccgggtg	actcttttaa	atgtcatcca	tacctgggat	32820
agggaaggct	cttcagggag	tcactctagc	ctcccttcag	gaaaagattc	cacttccggt	32880
ttagttagct	tcacactggg	cccttatecg	ctgtctctgc	ccactagtcc	tcacctatcc	32940
ggtttccgcc	ctcatccacc	ttgccctttt	agttccctaga	aagcagcacc	gtagtcttgg	33000
caggtggggc	attgggtcact	ccgtaccac	tgttaccatg	gccaccaagg	tgtcatttaa	33060
atatgagctc	actgagtcct	gcgggatggc	ttgggtggta	atatgcttgc	tgcaaaatcg	33120
tgagaaactg	agttcaattc	ccagcacatg	gatgtatttc	cagcacctgg	aaggcagggg	33180
gcagagatct	taaagctcct	ggccagacag	cccagcctaa	ttagtaatca	gtgagagacc	33240
ctgtctcaag	aaacaagatg	gaacatcaaa	ggccaacctc	ttgtctccac	acacacaaat	33300
acacacatgc	acatacatcc	acacacaggc	aaacacatgc	acacacctga	acaccctcca	33360
caaatacata	cataaaaaaa	taaatacata	cacacataca	tacatacacc	aacattccct	33420
ctccttagtc	tcttggtctc	gctcttgtca	ccccacttaa	ggcttcaact	tcttctatct	33480
cttcactctg	actcctctgt	actttgcctg	ccttttccag	caaaggcttt	tctttaaatc	33540
tccgtcattc	ataaactccc	tctaaatttc	ttcccctgcc	cttttcttcc	tctctagggg	33600
gataaagaca	cacactacaa	agtcaccgtg	ggaccagttt	attcaccac	ccaccctgc	33660
ttctgttcat	ccggccagct	aagtagtcca	acctctctgg	tgtgttacc	tggaccctgg	33720
cttcaccaca	gtcctctcat	gttaccacgc	cctgcaaac	ttcagctag	cctctggttc	33780
tccaaccagc	acaggcccag	tctggcttct	atgtcctaga	aatctccttc	attctctcca	33840
tttccctcct	gaatctacca	ccttctttct	ccctctcct	gacctcta	gtcttgggtc	33900
aacgattaca	aggaagccaa	tgaaattagc	agtttggggg	acctcagagt	cagcagggga	33960
gctgggatga	attcacattt	ccaggccttt	gctttgctcc	ccggattctg	acaggcagtt	34020
ccgaagctga	gtccaggaag	ctgaatttaa	aatcacactc	cagctgggtt	ctgaggcagc	34080
cctaccacat	cagctggccc	tgactgagct	gtgtctgggt	ggcagtggtg	ctggtgggtg	34140
tggtggtgct	gggtggtggt	gtggtggtg	tggtggtggt	gggtggtggt	tgtgtgtgtg	34200
ttttctgctt	ttacaaaact	tttctaattc	ttatacaaag	gacaaatctg	cctcatatag	34260
gcagaaagat	gacttatgcc	tatataagat	ataaagatga	ctttatgcca	cttattagca	34320
atagttactg	tcaaaagtaa	ttctatttat	acacccttat	acatggattt	gcttttgttg	34380
gagactctaa	aatccagatt	atgtatttaa	aaaaaaattc	cccagtcctt	aaaagggtgaa	34440
gaatggacc	agatagaagg	tcacggcaca	agtatggagt	cggagtgtgg	agtctgccca	34500
atggtctgga	cagaagcacc	cagagagggg	ccaagacaaa	tgccctgcct	cctaagggaac	34560

```

actggcagcc ctgatgaggt accagagatt gctaagtgga ggaatacagg atcagaccca 34620
tggaggggct taaagcgtga ctgtagcagc cctccgctga ggggctccag gtgggcgcce 34680
aaggtgctgc agtgggagcc acatgagagg tgatgtcttg gagtcacctc ggggtaccatt 34740
gttttagggag gtggggattt gtgggtgtgga gacaggcagc ctcaaggatg cttttcaaca 34800
atggttgatg agttggaact aaaacagggg ccatacact ggctccata gctctgggct 34860
tgccagcttc cacatctgcc cccaccccc tgtctggcac cagctcaagc tctgtgattc 34920
tacacatcca aaagaggaag agtagcctac tgggcatgcc acctcttctg gaccatcagg 34980
tgagagtgtg gcaagcccta ggctcctgtc caggatgcag ggctgccaga taggatgctc 35040
agctatctcc tgagctggaa ctatttttagg aataaggatt atgccgcgcc ggggttgccc 35100
agcaccocag cagcctgtgc ttgcgtaaaa gcaagtgtcg ttgatttata taaaaacaga 35160
gccgtggacc caccacagc acaagtatgt atgcactctg ttcatgtatc tgaaaagcga 35220
cacaaccatt ttccacatca tggcatcttc ctaaccccca ttcttttttg ttttgtttt 35280
ttgagacagg gtttctctgt gtagtcctgg ctgtcctgga actcactttg tagaccaggc 35340
tggcctcgaa ctgagaaatc ctgggattaa aggtgtgtgc caccacgcc ggccctaacc 35400
cccattctta atgggtgatc agtgggtgaa atttcgggcc acacacatgt ccattagggg 35460
ttagctgctg tcttctgagc tacctggtac aatctttatc ccttggggcc tgggctcctg 35520
atccctgact cgggcccgat caagtccagt tcttggggcc gatcaagtc agttcctggg 35580
cccgaacaag tccagtcctt agctcgatta gctcactctg gctccctggc ctgttcttac 35640
ttacactctt ccccttctc tggacttggt gctttcttta ctcaagttgt ctgccacagt 35700
ccctaagcca cctctgtaag acaactaaga taatacttcc ctcaagcacg gaaagtcctg 35760
agtcaccaca cctctggag gtgtgtggac acatgttcat gcgtgtggtt gcgcttacgt 35820
acgtgtgc 35828

```

<210> 18

<211> 9301

<212> DNA

<213> Homo sapien

<400> 18

```

tagaggagaa gtctttgggg agggtttgct ctgagcacac cctttccct cctccgggg 60
ctgaggga aa catgggacca gccctgcccc agcctgtcct cattggctgg catgaagcag 120
agaggggctt taaaaaggcg accgtgtctc ggctggagac cagagcctgt gctactggaa 180
gggtggcgtg cctcctctgg ctgggtaccat gcagctccca ctggccctgt gtctcgtctg 240
cctgctggta cacacagcct tccgtgtagt ggagggccag ggggtggcag cgttcaagaa 300
tgatgccacg gaaatcatcc ccgagctcg agagtacccc gagcctccac cggagctgga 360
gaacaacaag accatgaacc gggcggagaa cggagggcg cctccccacc accccttga 420

```

```

gaccaaagg atgggggtgga ggagagaatt cttagtaaaa gatcctgggg aggtttttaga 480
aacttctctt tgggaggctt ggaagactgg ggtagacca gtgaagattg ctggcctctg 540
ccagcactgg tcgaggaaca gtcttgctg gaggtggggg aagaatggct cgctggtgca 600
gccttcaa at tcaggtgcag aggcattgag caacagacgc tggtagagac ccagggcagg 660
gaggacgctg ggggtggtgag ggtatggcat cagggcattc gaacaggctc aggggctcag 720
aaaagaaaag gtttcaaaga atctcctcct gggaatatag gagccacgtc cagctgctgg 780
taccactggg aagggaaaca ggtaaggag cctcccatcc adagaacagc acctgtgggg 840

```

caccggacac tctatgctgg tgggtggctgt ccccaccaca cagacccaca tcatggaatc	900
cccaggaggt gaacccccag ctccaagggg aagaaacagg ttccaggcac tcagtaactt	960
ggtagtgaga agagctgagg tgtgaacctg gtttgatcca actgcaagat agccctgggtg	1020
tgtggggggg tgtggggggac agatctccac aaagcagtggt ggaggaaggc cagagaggca	1080
ccctgcaggt gtgcattgcc catggcctgc ccaggagct ggcacttgaa ggaatgggag	1140
ttttcggcac agtttttagcc cctgacatgg gtgcagctga gtccaggccc tggaggggag	1200
agcagcatcc tctgtgcagg agtagggaca tctgtcctca gcagccaccc cagtcccaac	1260
cttgctcat tccaggggag ggagaaggaa gaggaaccct gggttcctgg tcaggcctgc	1320
acagagaagc ccagggtaca gtgtgcatct ggctctataa ttggcaggaa tcctgaggcc	1380
atgggggctg ctgaaatgac acttcagact aagagcttcc ctgtcctctg gccattatcc	1440
aggtggcaga gaagtcact gcccaggctc ctggaccca gccctccccg cctcacaacc	1500
tgttgggact atggggtgct aaaaagggca actgcatggg aggccagcca ggacctccg	1560
tcttcaaaat ggaggacaag ggcgcctccc cccacagctc cctttctagg caaggtcagc	1620
tgggtccag cgactgcctg aagggtgtga aggaacccaa acacaaaatg tccaccttgc	1680
tggactccca cgagaggcca cagccctga ggaagccaca tgctcaaac aaagtcatga	1740
tctgcagagg aagtgcctgg cctagggcg ctattctcga aaagccgcaa aatgccccct	1800
tcctgggca aatgcccc tgaccacaca cacattccag ccctgcagag gtgaggatgc	1860
aaaccagccc acagaccaga aagcagcccc agacgatggc agtggccaca tctccctgc	1920
tgtgcttgct cttcagagtg ggggtggggg gtggccttct ctgtccctc tctggtttgg	1980
tcttaagact atttttcatt ctttcttgc acattggaac tatcccatg aaacctttgg	2040
gggtggactg gtactcacac gacgaccagc tatttaaaaa gctccaccc atctaagtcc	2100
accataggag acatggtcaa ggtgtgtgca ggggatcagg ccaggcctcg gagcccaatc	2160
tctgcctgcc cagggagtat caccatgagg cggccattca gataacacag aacaagaaat	2220
gtgccagca gagagccagg tcaatgtttg tggcagctga acctgtaggt tttgggtcag	2280
agctcagggc ccctatggta ggaaagtaac gacagtaaaa agcagccctc agctccatcc	2340
cccagcccag cctcccatgg atgctcgaa cagagccctc cactcttgcc ggagccaaaa	2400
ggtgctggga ccccaggga gtggagtccg gagatgcagc ccagcctttt gggcaagtgc	2460
tttctctggt ctgggcctca gtattctcat tgataatgag ggggttgga acactgcctt	2520
tgattccttt caagtcta atgattctgt cctgatcacc tccccttcag tcctcgcct	2580
ccacagcagc tgccctgatt tattaccttc aattaacctc taetcttttc tccatccctt	2640
gtccacccct cccaagtggc tggaaaagga atttgggaga agccagagcc aggcagaagg	2700
tgtgtcaggt acttacctg cccaggccag ggaccctgcg gcacaagtgt ggcttaaadc	2760
ataagaagac ccagaagag aaatgataat aataatacat aacagccgac gctttcagct	2820
atatgtgcca aatggtatct tctgcattgc gtgtgtaatg gattaactcg caatgcttgg	2880
ggcggcccat tttgcagaca ggaagaagag agagggttaag gaacttgccc aagatgacac	2940
ctgcagttag cgatggagcc ctggtgtttg aaccccagca gtcatttggc tccgagggga	3000
caggggtgcg aggagagctt tccaccagct ctagagcatc tgggaccttc ctgcaataga	3060
tgttcagggg caaaagcctc tggagacagg cttggcaaaa gcagggctgg ggtggagaga	3120
gacgggcggc tccagggcag ggggtggccag gcgggcggcc accctcacgc gcgcctctct	3180
ccacagagct gtccgagtac agctgccgcg agctgcactt caccgcctac gtgaccgatg	3240
ggcctgtgcc cagcgccaag ccggtcaccc agctgggtgtg ctccggccag tgcggcccg	3300
cgcgcctgct gcccacgcgc atcgccgcgc gcaagtgggt gcgacctagt gggcccgact	3360
tccgctgcat ccccgaccgc taccgcgcgc agcgcgtgca gctgctgtgt cccggtgggtg	3420
aggcgccgcg cgcgcgcaag gtgcgcctgg tggcctcgtg caagtgcag cgcctcacc	3480

gcttccacaa ccagtcggag ctcaaggact tccgggaccga ggccgctcgg ccgcagaagg	3540
gccggaagcc gcggcccccgc gcccgagcgc ccaaagccaa ccaggccgag ctggagaacg	3600
cctactagag cccgcgccgc cccctcccca ccggcgggcg ccccggccct gaaccgcgc	3660
cccacatttc tgcctcttgc gcgtggtttg attgtttata ttctattgta aatgcctgca	3720
acccagggca gggggctgag accttccagg ccttgaggaa tcccgggcgc cggcaaggcc	3780
cccctcagcc cgcagctga ggggtccac ggggcagggg aggggaattga gagtacaga	3840
cactgagcca cgcagcccg cctctggggc cgcctacctt tgcctgccc acttcagagg	3900
aggcagaaat ggaagcattt tcaccgccct ggggttttaa gggagcgggtg tgggagtggg	3960
aaagtccagg gactggttaa gaaagttgga taagattccc ccttgccact cgtgcccct	4020
cagaaagcct gaggcgtgcc cagagcacia gactgggggc aactgtagat gtggtttcta	4080
gtcctggctc tgccactaac ttgctgtgta acctggaact acacaattct ccttcgggac	4140
ctcaatttcc actttgtaaa atgaggggtg aggtgggaat aggatctcga ggagactatt	4200
ggcatatgat tccaaggact ccagtgcctt ttgaatgggc agaggtgaga gagagagaga	4260
gaaagagaga gaatgaatgc agttgcattg attcagtgcc aaggtcactt ccagaattca	4320
gagttgtgat gctctcttct gacagccaaa gatgaaaaac aaacagaaaa aaaaaagtaa	4380
agagtctatt tatggctgac atatttacgg ctgacaaact cctggaagaa gctatgctgc	4440
ttcccagcct ggcttccccg gatgtttggc tacctccacc cctccatctc aaagaaataa	4500
catcatccat tggggtagaa aaggagaggg tccgaggggtg gtgggagggg tagaaatcac	4560
atccgcccc aactcccaaa gacagcctc cctccccga cccatagcca tgttttaaag	4620
tcaccttccg aagagaagtg aaagggtcaa ggacactggc cttgcaggcc cgaggagca	4680
gccatcacaa actcacagac cagcacatcc cttttgagac accgccttct gccaccact	4740
cacggacaca tttctgccta gaaaacagct tcttactgct cttacatgtg atggcatatc	4800
ttactactaa agaataattat tgggggaaaa actacaagtg ctgtacatat gctgagaaac	4860
tgcagagcat aatagctgcc acccaaaaat ctttttgaaa atcatttcca gacaacctct	4920
tactttctgt gtagttttta attgttaaaa aaaaaagtt ttaaacagaa gcacatgaca	4980
tatgaaagcc tgcaggactg gtcgtttttt tggcaattct tccacgtggg acttgtccac	5040
aagaatgaaa gtagtgggtt ttaaagagtt aagttacata tttattttct cacttaagtt	5100
atttatgcaa aagtttttct tgtagagaat gacaatgtta atattgcttt atgaattaac	5160
agtctgttct tccagagtcc agagacattg ttaataaaga caatgaatca tgaccgaaag	5220
gatgtggtct cattttgtca accacacatg acgtcatttc tgtcaaagtt gacacccttc	5280
tcttggtcac tagagctcca accttgaca cacctttgac tgcctcttgg tggcccttgt	5340
ggcaattatg tcttcccttg aaaagtcattg tttatccctt cctttccaaa ccagaccgc	5400
atttcttcac ccagggcattg gtaataacct cagccttgta tcccttttagc agcctccct	5460
ccatgctggc ttccaaaatg ctgttctcat tgtatcactc cctgctcaa aagccttcca	5520
tagctcccc ttgccaggga tcaagtgcag tttccctatc tgacatggga ggcttctct	5580
gcttgactcc cacttccac tccaccaagc ttctactga ctccaaatgg tcatgcagat	5640
cctgcttcc ttagtttgcc atccacactt agcaccacca ataactaatc ctctttcttt	5700
aggattcaca ttacttgtea tctcttcccc taaccttcca gagatgttcc aatctcccat	5760
gatccctctc tctctgagg ttccagcccc ttttgtctac accactactt tggttcctaa	5820
ttctgttttc catttgacag tcattcatgg aggaccagcc tggccaagtc ctgcttagta	5880
ctggcataga caacacaaag ccaagtacaa ttcaggacca gctcacagga aacttcatct	5940
tcttcgaagt gtggatttga tgctctctgg gtgaaatgt aggatcttca aaagtgggc	6000
agcctcctgc acttctctca aagtctcgc tccccagggt gtcttaatag tgctggatgc	6060
tagctgagtt agcatcttca gatgaagagt aaccttaaag ttactcttca gttgccctaa	6120
aataaataaa tcaactaaaa acctttaaat taagtccac ctaccttqqr qaaaccacc	6180

```

cccacaaaga aagctgaggt cctcctgat gacttgtcag tttaactacc aataaccac 6240
ttgaattaat catcatcatc aagtccttga taggtgtgag tgggtatcag tggccggtcc 6300
cttctctggg ctcagccccc cgaggaggcc tcagttagcc cctgcagaaa atccatgcat 6360
catgagtgtc tcagggccca gaatatgaga gcaggtagga aacagagaca tcttccatcc 6420
ctgagaggca gtgcggtcca gtgggtggg acacgggctc tgggtcagggt ttgtgttgtt 6480
tgtttgtttt ttttgagaca gagtctcgt ctattgcccc ggctggagtg cagtgtcaca 6540
atctcggctt actgcaactt ctgccttccc ggattcaagt gattctctg cctcagcctc 6600
cagagtagct gggattacag gtgcgtgcca ccacgcctgg ctaattttt tatttttgat 6660
agagacgggg tttcaccatg ttggccaggc tagtctcgaa ctcttgacct caagtgatct 6720
gcctgcctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccaca cccagcccca 6780
ggttggtgtt tgaatctgag gagactgaag caccaagggg ttaaatgttt tgcccacagc 6840
catacttggg ctacgttctt tgccctaccc ctacttgag ctgcttagaa cctggtgggc 6900

acatgggcaa taaccaggtc acactgtttt gtaccaagtg ttatgggaat ccaagatagg 6960
agtaatttgc tctgtggagg ggatgaggga tagtggttag gaaagcttc acaaagtggg 7020
tgttgcctag agattttcca ggtggagaag ggggcttcta ggcagaaggc atagcccaag 7080
caaagactgc aagtgcattg ctgctcatgg gtagaagaga atccaccatt cctcaacatg 7140
taccgagtc ttgccatgtg caaggcaaca tgggggtacc aggaattcca agcaatgtcc 7200
aaacctaggg tctgctttct gggacctgaa gatacaggat ggatcagccc aggctgcaat 7260
cccattacca cgagggggaa aaaaacctga aggctaaatt gtaggctggg ttagaggtta 7320
tttatggaaa gttatattct acctacatgg ggtctataag cctggcgcca atcagaaaag 7380
gaacaaacaa cagacctagc tgggaggggc agcattttgt ttagggggc ggggcacatg 7440
ttctgggggt acagccagac tcagggcttg tattaatagt ctgagagtaa gacagacaga 7500
gggtagaag gaaataggtc cttttctctc tctctctctc tctctctctc actctctctc 7560
tctctcacac acacacacag acacacacac acgctctgta ggggtctact tatgctccaa 7620
gtacaaatca ggccacattt acacaaggag gtaaaggaaa agaacgttgg aggagccaca 7680
ggaccccaaa attccttgtt ttcttgaat caggcaggac ttacgcagct gggagggtgg 7740
agagcctgca gaagccacct gcgagtaagc caagttcaga gtcaagagaca ccaaaagctg 7800
gtgccatgtc ccacaccgc ccacctccca cctgctcctt gacacagccc tgtgctccac 7860
aaccggctc ccagatcatt gattatagct ctggggcctg caccgtcctt cctgccacat 7920
ccccaccca ttcttggaa cctgctctg tcttctcctt tgtccaaggg caggcaaggg 7980
ctcagctatt gggcagcttt gaccaacagc tgaggctcct tttgtggctg gagatgcagg 8040
aggcagggga atattcctct tagtcaatgc gaccatgtgc ctggtttgcc cagggtggct 8100
tcgtttacac ctgtaggcca agcgtaatta ttaacagctc ccacttctac tctaaaaaat 8160
gacccaatct gggcagtaaa ttatatggtg cccatgctat taagagctgc aacttgtctg 8220
gcgtggtggc tcacacctgt aatcccagta ctttgggacg tcaaggcggg tggatcacct 8280
gaggtcacga gttagagact ggctggcca gcatggcaaa accccatctt tactaaaaat 8340
acaaaaatta gcaaggcatg gtggcatgca cctgtaatcc caggtaactg ggaggctgag 8400
acaggagaat ggcttgaacc caggaggcag aggttgagc gagccaagat tgtgccactg 8460
cctccagcc ctggcaacag agcaagactt catctcaaaa gaaaaaggat actgtcaatc 8520
actgcaggaa gaaccaggt aatgaatgag gagaagagag gggctgagtc accatagtgg 8580
cagcaccgac tctgcagga aaggcgagac actgggtcat gggtaactgaa gggtgccctg 8640
aatgacgttc tgcttttagag accgaacctg agccctgaaa gtgcatgcct gttcatgggt 8700
gagagactaa attcatcatt cttggcagg tactgaatcc tttcttacgg ctgccctcca 8760
atgcccatt tcctacaat tgtctggggg gcctaagctt ctgccacca agagggccag 8820

```

agctggcagc gagcagctgc aggtaggaga gataggtacc cataagggag gtgggaaaga	8880
gagatggaag gagaggggtg cagagcacac acctccctg cctgacaact tcctgagggc	8940
tggatcatgcc agcagattta aggcggaggc aggggagatg gggcgggaga ggaagtgaaa	9000
aaggagaggg tggggatgga gaggaagaga gggatgatcat tcattcattc cattgctact	9060

gactggatgc cagctgtgag ccaggcacca ccctagctct gggcatgtgg ttgtaatctt	9120
ggagcctcat ggagctcaca gggagtgtg gcaaggagat ggataatgga cggataacaa	9180
ataaacattt agtacaatgt ccgggaatgg aaagtctctg aaagaaaaat aaagctggtg	9240
agcatataga cagccctgaa ggcggccagg ccaggcattt ctgaggaggt ggcatttgag	9300
c	9301

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 19

ccggagctgg agaacaacaa g 21

<210> 20

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PRimer for PCR

<400> 20

gcactggccg gagcacacc 19

<210> 21

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 21

aggccaaccg cgagaagatg acc 23

<210> 22

<211> 21

<212> DNA <213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 22

gaagtcagg gcgacgtagc a 21

<210> 23

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 23

aagcttggtgta ccatgcagct cccac 25

<210> 24

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 24

aagcttctac ttgtcatcgt cgtccttgta gtcgtaggcg ttctccagct 50

<210> 25

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 25

gcactggccg gagcacacc 19

<210> 26

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 26

gtcgtcggat ccatggggtg gcaggcgttc aagaatgat 39

<210> 27

<211> 57

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 27

gtcgtcaagc ttctacttgt catcgtcctt gtagtcgtag gcgttctcca gctcggc 57

<210> 28

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 28

gacttggatc ccaggggtgg caggcgttc 29

<210> 29

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 29

agcataagct tctagtaggc gttctcag 29

<210> 30

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 30

gacttggatc cgaagggaaa aagaaaggg 29

<210> 31

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 31

agcataagct ttaataccaa atcgatgga 29

<210> 32

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 32

actacgagct cggccccacc acccatcaac aag 33

<210> 33

<211> 34

<212> DNA <213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 33

acttagaagc tttcagtcct cagccccctc ttcc 34

<210> 34

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 34

aatctggatc cataacttcg tatagcatatc attatacgaa gttatctgca ggattcgagg 60
gcccct 66

<210> 35

<211> 82

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 35

aatctgaatt ccaccggtgt taattaaata acttcgtata atgtatgcta tacgaagta	60
tagatctaga gtcagcttct ga	82

<210> 36

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 36

atttaggtga cactatagaa ctcgagcagc tgaagcttaa ccacatggtg gctcacaacc	60
at	62

<210> 37

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 37

aacgacggcc agtgaatccg taatcatggt catgctgcc a ggtggaggag ggca	54
--	----

<210> 38

<211> 31 <212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 38

attaccaccg gtgacaccg ctctctgaca g	31
-----------------------------------	----

<210> 39

<211> 61

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 39
 attacttaat taaacatggc gcgccatatg gcgggcccct aattgcggcg catcgtaat 60
 t 61

<210> 40

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 40

attacggccg gccgcaaagg aattcaagat ctga 34

<210> 41

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer for PCR

<400> 41

attacggcgc gccccctaca ggccgcaccc agct 34

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US5837458A](#) [0014]
- [US5830721A](#) [0014]
- [US5811238A](#) [0014]
- [US5780263A](#) [0014] [0021] [0070]
- [US4851341A](#) [0017] [0167]
- [US5989912A](#) [0025]

- [WO9111465A \[0116\]](#)
- [US4331647A \[0126\]](#)
- [WO9109967A \[0129\]](#)
- [ZA859794 \[0133\]](#)
- [ZA888127 \[0133\]](#)
- [ZA902839 \[0133\]](#)
- [WO9222583A \[0136\] \[0137\]](#)
- [WO9306231A \[0137\]](#)
- [WO90091195A \[0137\]](#)
- [WO8901476A \[0137\]](#)
- [US4376110A \[0139\] \[0159\]](#)
- [US4486530A \[0139\] \[0159\]](#)
- [US5463564A \[0149\]](#)
- [WO9502566A \[0149\]](#)
- [WO9524186A \[0149\]](#)
- [WO9530642A \[0149\]](#)
- [WO9516918A \[0149\]](#)
- [WO9516712A \[0149\]](#)
- [US5288514A \[0149\]](#)
- [WO9516209A \[0149\]](#)
- [WO9320242A \[0149\]](#)
- [WO9504277A \[0149\]](#)
- [US5506337A \[0149\]](#)
- [WO9600148A \[0149\]](#)
- [US4528266A \[0151\]](#)
- [US4359535A \[0151\]](#)
- [WO9215679A \[0151\]](#)
- [WO9215677A \[0151\]](#)
- [WO9007862A \[0151\]](#)
- [WO9002809A \[0151\]](#)
- [USRE32011E \[0155\]](#)
- [US4902614A \[0155\]](#)
- [US4543439A \[0155\]](#)
- [US4411993A \[0155\]](#)
- [US4704362A \[0173\]](#)
- [US4801542A \[0173\]](#)
- [US4935349A \[0173\] \[0176\]](#)
- [US4784950A \[0173\]](#)
- [US4399216A \[0173\]](#)
- [US4766075A \[0173\]](#)
- [WO9102805A \[0181\]](#)
- [EP0415731A \[0181\] \[0203\]](#)
- [WO9007936A \[0181\] \[0203\]](#)
- [US4579821A \[0182\]](#)

- [US5175383A](#) [0189]
- [US5087571A](#) [0189]
- [US4736866A](#) [0189]
- [US5387742A](#) [0189]
- [US5347075A](#) [0189]
- [US5221778A](#) [0189]
- [US5175384A](#) [0189]
- [WO9510607A](#) [0192]
- [US5359051A](#) [0192]
- [WO9206693A](#) [0192]
- [EP612844A2](#) [0192]
- [US5254678A](#) [0193]
- [EP0360257A](#) [0193]
- [US4987071A](#) [0193]
- [US4744981A](#) [0195]
- [US5106951A](#) [0195]
- [US4018884A](#) [0195]
- [US4897255A](#) [0195]
- [US4988496A](#) [0195]
- [US5288641A](#) [0203]
- [WO9426914A](#) [0203]
- [WO939191A](#) [0203]
- [WO9513365A](#) [0203]
- [WO910285A](#) [0203]
- [WO9403622A](#) [0203]
- [WO9325698A](#) [0203]
- [WO9325234A](#) [0203]
- [US5219740A](#) [0203]
- [WO9311230A](#) [0203]
- [WO9310218A](#) [0203]
- [US4873191A](#) [0239]
- [US4959317A](#) [0241]
- [US5464764A](#) [0244]

Non-patent literature cited in the description

- **RIGGS**West J. Med., 1991, vol. 154, 63-77 [0002]
- **KHOSLARIGSS**Mayo Clin. Proc., 1995, vol. 70, 978-982 [0008]
- **OPITZ, H.SCHMID, F.**Handbuch der KinderheilkundeSpringer19670000vol. 6, 351-355 [0050] [0058]

- **COMIER, C.** Curr. Opin. in Rheu., 1995, vol. 7, 243- [0061] [0206]
- **W.C. SMITH** TIG, 1999, vol. 15, 13-6 [0069]
- **S. LEMURA et al.** Proc Natl Acad Sci USA, 1998, vol. 95, 9337-9342 [0069]
- **HSU, D.R.ECONOMIDES, A.N.WANG, X.EIMON, P.M.HARLAND, R.M.** The Xenopus Dorsalizing Factor Gremlin Identifies a Novel Family of Secreted Proteins that Antagonize BMP Activities Molecular Cell, 1998, vol. 1, 673-683 [0070]
- **PERUSKI** PERUSKI The Internet and the New Biology: Tools for Genomic and Molecular Research ASM Press, Inc. 19970000 [0072]
- Information Superhighway and Computer Databases of Nucleic Acids and Proteins Methods in Gene Biotechnology CRC Press, Inc. 19970000 123-151 [0072]
- Guide to Human Genome Computing Academic Press, Inc. 19980000 [0072]
- Short Protocols in Molecular Biology John Wiley & Sons 19950000 4-1-4-6 [0076]
- **WU et al.** Methods in Gene Biotechnology CRC Press, Inc. 19970000 33-41 [0076]
- **SARGENT** Isolation of Differentially Expressed Genes Meth. Enzymol., 1987, vol. 152, 423- [0080]
- Construction and Screening of Subtracted and Complete Expression cDNA Libraries Methods in Gene Biotechnology CRC Press, Inc. 19970000 29-65 [0080]
- Constructing and Screening cDNA Libraries in λ gt10 and λ gt11 **HUYNH et al.** DNA Cloning: A Practical Approach IRL Press 19850000 vol. I, 49- [0081]
- Use of the Polymerase Chain Reaction to Screen Phage Libraries **YU et al.** Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Application Humana Press, Inc. 19930000 vol. 15, 211-215 [0086]
- Use of Degenerate Oligonucleotide Primers and the Polymerase Chain Reaction to Clone Gene Family Members **PRESTON** Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications Humana Press, Inc. 19930000 vol. 15, 317-337 [0086]
- Screening λ expression libraries with antibody and protein probes **MARGOLIS et al.** DNA Cloning 2: Expression Systems Oxford University Press 19950000 1-14 [0089]
- **ADANG et al.** Plant Molec. Biol., 1993, vol. 21, 1131- [0091]
- **BAMBOT et al.** PCR Methods and Applications, 1993, vol. 2, 266- [0091]
- Use of the Polymerase Chain Reaction for the Rapid Construction of Synthetic Genes **DILLON et al.** Methods in Molecular Biology, Vol. 15: PCR Protocols: Current Methods and Applications Humana Press, Inc. 19930000 vol. 15, 263-268 [0091]
- **HOLOWACHUK et al.** PCR Methods Appl., 1995, vol. 4, 299- [0091]
- Directed Mutagenesis: A Practical Approach IRL Press 19910000 [0094]
- **TREUTER et al.** Molec. Gen. Genet., 1993, vol. 240, 113- [0096]
- Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon **CONTENT et al.** Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems Nijhoff 19870000 65-72 [0096]
- The EGF Receptor **HERSCHMAN et al.** Control of Animal Cell Proliferation Academic Press 19850000 vol. 1, 169-199 [0096]
- **COUMAILLEAU et al.** J. Biol. Chem., 1995, vol. 270, 29270- [0096]
- **FUKUNAGA et al.** J. Biol. Chem., 1995, vol. 270, 25291- [0096]
- **YAMAGUCHI et al.** Biochem. Pharmacol., 1995, vol. 50, 1295- [0096]

- **MEISEL et al.** Plant Molec. Biol., 1996, vol. 30, 1 [0096]
- **HAMER et al.** J. Molec. Appl. Genet., 1982, vol. 1, 273- [0104]
- **MCKNIGHT** Cell, 1982, vol. 31, 355 [0104]
- **BENOIST et al.** Nature, 1981, vol. 290, 304 [0104]
- **GORMAN et al.** Proc. Nat'l Acad Sci. USA, 1982, vol. 79, 6777- [0104]
- **FOECKING et al.** Gene, 1980, vol. 45, 101- [0104]
- Expression of Engineered Proteins in Mammalian Cell Culture **ETCHEVERRY et al.** Protein Engineering: Principles and Practice John Wiley & Sons, Inc. 1996 0000163-181 [0104]
- **ZHOU et al.** Mol. Cell. Biol., 1990, vol. 10, 4529- [0105]
- **KAUFMAN et al.** Nucl. Acids Res., 1991, vol. 19, 4485- [0105]
- **GLICK** J. Ind. Microbiol., 1987, vol. 1, 277- [0106]
- **WATSON et al.** Molecular Biology of the Gene Benjamin Cummins 1987 0000 [0106]
- Molecular Biology Labfax Academic Press 1991 0000 [0107]
- Bacillus Cloning Methods **HARDY** DNA Cloning: A Practical Approach IRL Press 1985 0000 [0107]
- Expression of foreign proteins in E. coli using plasmid vectors and purification of specific polyclonal antibodies **WILLIAMS et al.** DNA Cloning 2: Expression Systems Oxford University Press 1995 000015- [0108]
- Genetic Manipulation and Expression of Antibodies **WARD et al.** Monoclonal Antibodies: Principles and Applications Wiley-Liss, Inc. 1995 0000137- [0108] [0120]
- Expression of Proteins in Bacteria **GEORGIU et al.** Protein Engineering: Principles and Practice John Wiley & Sons, Inc. 1996 0000101- [0108]
- Manipulation of Baculovirus Vectors **BAILEY et al.** Methods in Molecular Biology, Volume 7: Gene Transfer and Expression Protocols The Humana Press, Inc. 1991 0000147-168 [0109]
- The baculovirus expression system **PATEL et al.** DNA Cloning 2: Expression Systems Oxford University Press 1995 0000205-244 [0109]
- **AUSUBEL** Baculovirus Expression Protocols The Humana Press, Inc. 1995 000016-3716-57 [0109]
- Insect Cell Expression Technology **LUCKNOW et al.** Protein Engineering: Principles and Practice John Wiley & Sons, Inc. 1996 0000183-218 [0109]
- Procedures for Introducing Foreign DNA into Plants **MIKI et al.** Methods in Plant Molecular Biology and Biotechnology CRC Press 1993 000067-88 [0111]
- Gene Transfer and Expression Protocols Humana Press 1991 0000 [0112]
- Expression of Engineered Proteins in Mammalian Cell Culture **ETCHEVERRY et al.** Protein Engineering: Principles and Practice Wiley-Liss, Inc. 1996 0000163- [0113]
- Purification of over-produced proteins from E. coli cells **GRISSHAMMER et al.** DNA Cloning 2: Expression Systems Oxford University Press 1995 000059-92 [0113]
- Baculovirus Expression Protocols The Humana Press, Inc. 1995 0000 [0113]
- Production of Polyclonal Antisera **GREEN et al.** Immunochemical Protocols Humana Press 1992 00001-5 [0116]
- Expression of foreign proteins in E. coli using plasmid vectors and purification of specific polyclonal antibodies **WILLIAMS et al.** DNA Cloning 2: Expression Systems Oxford

University Press19950000 [0116]

- **LOSMAN et al.**Int. J. Cancer, 1990, vol. 46, 310- [0116]
- **LARRICK et al.**Methods: A Companion to Methods in Enzymology, 1991, vol. 2, 106- [0120]
- Genetic Manipulation of Monoclonal Antibodies**COURTENAY-LUCK et al.**Monoclonal Antibodies: Production, Engineering and Clinical ApplicationCambridge University Press19950000166- [0120]
- **KOHLER et al.**Nature, 1975, vol. 256, 495- [0122]
- Current Protocols in ImmunologyJohn Wiley & Sons19910000vol. 1, 2.5.1-2.6.7 [0122]
- Production of monoclonal antibodies against proteins expressed in E. coli**PICKSLEY et al.**DNA Cloning 2: Expression SystemsOxford University Press1995000093- [0122]
- **GREEN et al.**Nature Genet., 1994, vol. 7, 13- [0124]
- **LONBERG et al.**Nature, 1994, vol. 368, 856- [0124]
- **TAYLOR et al.**Int. Immun., 1994, vol. 6, 579- [0124]
- Purification of Immunoglobulin G (IgG)**BAINES et al.**Methods in Molecular BiologyThe Humana Press, Inc.19920000vol. 10, 79-104 [0125]
- **NISONOFF et al.**Arch Biochem. Biophys., 1960, vol. 89, 230- [0126]
- **PORTER**Biochem. J.19590000vol. 73, 119- [0126]
- **EDELMAN et al.**Methods in EnzymologyAcademic Press19670000vol. 1, 422- [0126]
- **CHISWELL, D JMCCAFFERTY**J. Tibtech., 1992, vol. 10, 80-84 [0128]
- **MANIATIS et al.**Molecular CloningCold Spring Harbor Laboratory19890000 [0129]
- **SANGER et al.**PNAS, 1977, vol. 74, 5463- [0129]
- **KRAMER et al.**Nucl. Acids Res., 1984, vol. 12, 9441- [0129]
- **MOUNTAIN AADAIR, J RB**Biotechnology and Genetic Engineering ReviewsIntercept19920000 [0129]
- **PHILLIPS, G.B.G.P. WEI**Solid-phase Synthesis of BenzimidazolesTet. Letters, 1996, vol. 37, 4887-90 [0149]
- **RUHLAND, B. et al.**Solid-supported Combinatorial Synthesis of Structurally Diverse β -LactamsJ. Amer. Chem. Soc., 1996, vol. 111, 253-4 [0149]
- **LOOK, G.C. et al.**The Identification of Cyclooxygenase-1 Inhibitors from 4-Thiazolidinone Combinatorial LibrariesBioorg and Med. Chem. Letters, 1996, vol. 6, 707-12 [0149]
- **SCATCHARD**Ann. N.Y. Acad. Sci., 1949, vol. 51, 660-672 [0153]
- Monoclonal Antibodies, Hybridomas: A New Dimension in Biological AnalysesPlenum Press19800000 [0155]
- Antibodies: A Laboratory ManualCold Spring Harbor Laboratory Press19880000 [0155] [0159] [0162]
- **GLASKYREADING**Hybridoma, 1989, vol. 8, 4377-389 [0157]
- **WILLIAM D. HUSE et al.**Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage LambdaScience, 1989, vol. 246, 1275-1281 [0160]
- **L. SASTRY et al.**Cloning of the Immunological Repertoire in Escherichia coli for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA LibraryProc. Natl. Acad. Sci. USA, 1989, vol. 86, 5728-5732 [0160]

- **MICHELLE ALTING-MEES et al.** Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas Strategies in Molecular Biology, 1990, vol. 3, 1-9 [\[0160\]](#)
- **BIRD et al.** Science 19880000 vol. 242, 423-426 [\[0161\]](#)
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory Press 19890000 [\[0164\]](#) [\[0169\]](#) [\[0173\]](#)
- **KYTEDOOLITTLE J.** Mol. Biol., 1982, vol. 157, 105-132 [\[0165\]](#)
- **HOPP et al.** Bio/Technology, 1988, vol. 6, 1204- [\[0167\]](#)
- **WALDER et al.** Gene, 1986, vol. 42, 133- [\[0169\]](#)
- **BAUER et al.** Gene, 1985, vol. 37, 73- [\[0169\]](#)
- **CRAIK** BioTechniques, 1985, 12-19 [\[0169\]](#)
- **SMITH et al.** Genetic Engineering: Principles and Methods Plenum Press 19810000 [\[0169\]](#)
- **DRINKWATER KLINEDINST** PNAS, 1986, vol. 83, 3402-3406 [\[0171\]](#)
- **LIAOWISE** Gene, 1990, vol. 88, 107-111 [\[0171\]](#)
- **HORWITZ et al.** Genome, 1989, vol. 3, 112-117 [\[0171\]](#)
- **HINNEN et al.** Proc. Natl. Acad. Sci. USA, 1978, vol. 75, 1929-1933 [\[0173\]](#) [\[0179\]](#)
- **CZAKOMARTON** Plant Physiol., 1994, vol. 104, 1067-1071 [\[0173\]](#)
- **PASZKOWSKI et al.** Biotech., 1992, vol. 24, 387-392 [\[0173\]](#)
- **CHANG et al.** Nature, 1978, vol. 275, 615 [\[0175\]](#)
- **STUDIER et al.** Meth. Enzymol., 1990, vol. 185, 60-89 [\[0175\]](#)
- **ELVIN et al.** Gene, 1990, vol. 87, 123-126 [\[0175\]](#)
- **NICHOLSYAN OFSKY** Meth. in Enzymology, 1983, vol. 101, 155- [\[0175\]](#)
- **RUSSELL et al.** Gene, 1982, vol. 20, 231- [\[0175\]](#)
- **BOLIVAR et al.** Gene, 1977, vol. 2, 95- [\[0175\]](#)
- **MESSING** Meth. in Enzymology, 1983, vol. 101, 20-77 [\[0175\]](#)
- **VIEIRA MESSING** Gene, 1982, vol. 19, 259-268 [\[0175\]](#)
- **TURNBULL** Bio/Technology, 1989, vol. 7, 169- [\[0176\]](#)
- **STRUHL et al.** Proc. Natl Acad. Sci. USA, 1978, vol. 76, 1035-1039 [\[0176\]](#)
- **BROACH et al.** Gene, 1979, vol. 8, 121-133 [\[0176\]](#)
- **BEGGS** Nature, 1978, vol. 275, 104-108 [\[0176\]](#)
- **HITZEMAN et al.** J. Biol. Chem., 1980, vol. 255, 12073-12080 [\[0177\]](#)
- **ALBERKAWASAKI J.** Mol. Appl. Genet, 1982, vol. 1, 419-434 [\[0177\]](#)
- **YOUNG et al.** Genetic Engineering of Microorganisms for Chemicals Plenum 19820000355- [\[0177\]](#)
- **AMMERER** Meth. Enzymol., 1983, vol. 101, 192-201 [\[0177\]](#)
- **MCKNIGHT et al.** EMBO J., 1985, vol. 4, 2093-2099 [\[0177\]](#)
- **BOTSTEIN et al.** Gene, 1979, vol. 8, 17- [\[0178\]](#)
- **YELTON et al.** Proc. Natl. Acad. Sci. USA 19840000 vol. 81, 1740-1747 [\[0179\]](#)
- **RUSSELL** Nature, 1983, vol. 301, 167-169 [\[0179\]](#)
- **HINNEN et al.** PNAS USA, 1978, vol. 75, 1929- [\[0180\]](#)
- **ITOH et al.** J. Bacteriology, 1983, vol. 153, 163- [\[0180\]](#)
- **CULLEN et al.** Bio/Technology, 1987, vol. 5, 369- [\[0180\]](#)
- **OHNO et al.** Science, 1994, vol. 265, 781-784 [\[0181\]](#)
- **KOERING et al.** Hum. Gene Therap., 1994, vol. 5, 457-463 [\[0181\]](#) [\[0203\]](#)

- **BOSHART et al.**Cell, 1985, vol. 41, 521-530 [0182]
- **SUBRAMANI et al.**Mol. Cell. Biol., 1981, vol. 1, 854-864 [0182]
- **BERGMAN et al.**Proc. Natl. Acad. Sci. USA, 1983, vol. 81, 7041-7045 [0182]
- **GRANT et al.**Nucl. Acids Res., 1987, vol. 15, 5496- [0182]
- **LOH et al.**Cell, 1983, vol. 33, 85-93 [0182]
- **DENOTO et al.**Nuc. Acids Res., 1981, vol. 9, 3719-3730 [0183]
- **WIGLER et al.**Cell, 1978, vol. 14, 725- [0184]
- **CORSAROPPEARSON**Somatic Cell Genetics, 1981, vol. 7, 603- [0184]
- **GRAHAMVAN DER EB**Virology, 1973, vol. 52, 456- [0184]
- **NEUMANN et al.**EMBO J., 1982, vol. 1, 841-845 [0184]
- **Current Protocols in Molecular Biology**John Wiley and Sons, Inc.19870000 [0184]
- **THILLY**Mammalian Cell TechnologyButterworth Publishers [0184]
- **ATKINSON et al.**Pestic. Sci., 1990, vol. 28, 215-224 [0187]
- **SINKAR et al.**J. Biosci., 1987, vol. 11, 47-58 [0188]
- **HAMMER et al.**Nature, 1985, vol. 315, 680-683 [0189]
- **PALMITER et al.**Science, 1983, vol. 222, 809-814 [0189]
- **BRINSTER et al.**Proc. Natl. Acad. Sci. USA, 1985, vol. 82, 4438-4442 [0189]
- **Palmiter and Brinster**Cell, 1985, vol. 41, 343-345 [0189]
- **HIRASHIMA et al.**Molecular Biology of RNA: New PerspectivesAcademic Press19870000401- [0192]
- **Oligonucleotides: Antisense Inhibitors of Gene Expression**MacMillan Press19890000 [0192]
- **STEINCHENG**Science, 1993, vol. 261, 1004-1012 [0192]
- **FORSTERSYMONS**Cell, 1987, vol. 48, 211-220 [0193]
- **HASELOFFGERLACH**Nature, 1988, vol. 325, 596-600 [0193]
- **WALBOTBRUENING**Nature, 1988, vol. 334, 196- [0193]
- **HASELOFFGERLACH**Nature, 1988, vol. 334, 585- [0193]
- **Methods In Enzymology****INMAN**Affinity Techniques, Enzyme Purification: Part BAcademic Press19740000vol. 34, 30- [0195]
- **WILCHEKBAYER**The Avidin-Biotin Complex in Bioanalytical ApplicationsAnal. Biochem., 1988, vol. 171, 1-32 [0195]
- **Harrison's Principles of Internal Medicine**McGraw-Hill, Inc. [0199]
- **KOLLS et al.**PNAS, 1994, vol. 91, 1215-219 [0203]
- **KASS-EISLER**PNAS, 1993, vol. 90, 2411498-502 [0203]
- **GUZMAN et al.**Circulation, 1993, vol. 88, 62838-48 [0203]
- **GUZMAN et al.**Cir. Res., 1993, vol. 73, 61202-1207 [0203]
- **ZABNER et al.**Cell, 1993, vol. 75, 2207-216 [0203]
- **LI et al.**Hum Gene Ther, 1993, vol. 4, 4403-409 [0203]
- **CAILLAUD et al.**Eur. J. Neurosci., 1993, vol. 5, 101287-1291 [0203]
- **VINCENT et al.**Nat. Genet., 1993, vol. 5, 2130-134 [0203]
- **JAFFE et al.**Nat. Genet., 1992, vol. 1, 5372-378 [0203]
- **LEVRERO et al.**Gene, 1991, vol. 101, 2195-202 [0203]
- **FLOTTE et al.**PNAS, 1993, vol. 90, 2210613-10617 [0203]
- **PANICALIPAOLETTI**PNAS, 1982, vol. 79, 4927-4931 [0203]

- **OZAKI et al.**Biochem. Biophys. Res. Comm., 1993, vol. 193, 2653-660 [0203]
- **CRISTANO et al.**PNAS, 1993, 92122-92126 [0204]
- **CURIEL et al.**Hum. Gene Ther., 1992, vol. 3, 2147-154 [0204]
- **ACSADI et al.**Nature, 1991, vol. 352, 815-818 [0204]
- **WU et al.**J. of Biol. Chem., 1989, vol. 264, 16985-16987 [0204]
- **FELGNER et al.**Proc. Natl. Acad. Sci. USA, 1989, vol. 84, 7413-7417 [0204]
- **PICKERING et al.**Circ., 1994, vol. 89, 113-21 [0204]
- **WANG et al.**PNAS, 1987, vol. 84, 7851-7855 [0204]
- **WILLIAMS et al.**PNAS, 1991, vol. 88, 2726-2730 [0204]
- **VILEHART**Cancer Res., 1993, vol. 53, 3860-3864 [0204]
- **GUINNESS-HEY**Metab. Bone Dis. and Rel. Res., 1984, vol. 5, 177-181 [0206]
- **SHEFFIELD et al.**Human Molecular Genetics, 1994, vol. 3, 1331-1335 [0210]
- **LYONS et al.**J. Cell Biol., 1990, vol. 111, 2427-2436 [0216]
- standard protocol for rabbit immunization and antisera recovery **R & R ANTIBODY**STANWOOD, WASHort Protocols in Molecular Biology1992000011.37-11.41 [0228]
- **F.M. AUSUBEL et al.**Current Protocols in Mol Biol., 1998, vol. 2, 11.2.1-11.2.22 [0232]
- **MUNSON**PODBARDAnal. Biochem., 1980, vol. 107, 220-239 [0232]
- **G.W. MELLOR et al.**J of Biomol Screening, 1998, vol. 3, 291-99 [0233]
- **NICOLAS, V.**Calcif Tissue Int, 1995, vol. 57, 206- [0235]
- **HOESS et al.**PNAS USA, 1982, vol. 79, 3398- [0241]
- **P.L. FELGNER**Proc. Natl. Acad. Sci. USA, 1987, vol. 84, 7413- [0246]

PATENTKRAV

1. Antistof eller fragment deraf, der binder til et protein kodet af SEQ ID NO: 1.
- 5 2. Antistof eller fragment ifølge krav 1, hvor det kodede protein har sekvensen SEQ ID NO: 2.
3. Antistof eller fragment ifølge krav 1, hvor antistoffet eller fragmentet binder proteinet, når det er udtrykt af insektceller.
- 10 4. Antistof eller fragment ifølge krav 3, hvor antistoffet eller fragmentet binder proteinet, når det er udtrykt under anvendelse af et baculovirussystem i Sf9-celler.
5. Antistof eller fragment ifølge krav 1 eller 2, hvor antistoffet eller fragmentet binder
- 15 proteinet, når det er udtrykt af pattedyrsceller.
6. Antistof eller fragment ifølge krav 1 eller 2, hvor antistoffet eller fragmentet binder proteinet, når det er udtrykt af humane embryoniske nyreceller, eller primære osteoblaster.
- 20 7. Antistof eller fragment ifølge krav 6, hvor de humane embryoniske nyreceller er 293-HEK-celler.
8. Antistof eller fragment deraf, som binder til et protein med i det mindste 80% aminosyreidentitet med SEQ ID NO: 2, og som forøger knoglemineralindhold.
- 25 9. Antistoffragment ifølge ethvert af de foregående krav, der er en F(ab')₂, F(ab)₂, Fab', Fab eller Fv.
- 30 10. Antistof eller fragment ifølge ethvert af de foregående krav, der er monoklonalt.
11. Antistof eller fragment ifølge krav 10, der er murint eller humant.
12. Antistof eller fragment ifølge ethvert af kravene 1-10, der er humaniseret.
- 35 13. Antistof eller fragment ifølge ethvert af kravene 1-8, der er polyklonalt.

14. Antistof eller fragment ifølge ethvert af de foregående krav, der er et antistof eller fragment af IgG-klasse.

15. Antistof eller fragment ifølge krav 14, hvor IgG-klassen er IgG₁ eller IgG₄.

5

16. Antistof eller fragment ifølge ethvert af kravene 1-13, hvor antistoffet eller fragmentet er et IgE-, IgM- eller IgA-antistof- eller fragment.

17. Antistof eller fragment ifølge ethvert af de foregående krav, der er konjugeret til et effektor- eller reportermolekyle.

10

18. Antistof ifølge krav 17, hvor antistoffet eller fragmentet er konjugeret til en polymer.

19. Antistof ifølge krav 18, hvor antistoffet eller fragment er konjugeret til polyethylen-glycol.

15

20. Nukleinsyremolekyle, der koder for et antistof eller fragment ifølge ethvert af kravene 1-12.

21. Ekspressionsvektor indeholdende et nukleinsyremolekyle ifølge krav 20.

20

22. Celle, der producerer et antistof eller fragment ifølge ethvert af kravene 1-12.

23. Celle ifølge krav 22, der er et hybridoma.

25

24. Fremgangsmåde til fremstilling af et hybridoma, der producerer et monoklonalt antistof som defineret i krav 10, hvilken fremgangsmåde omfatter:

30

(i) immunisering af en rotte eller mus med et protein kodet af sekvensen i SEQ ID NO: 1 eller en del deraf;

(ii) aflivning af rotten eller musen og indhøstning af milten og/eller lymfeknuder fra rotten eller musen; og

(iii) fusionering af milt- eller lymfeknudecellesuspensioner med myelomaceller til dannelse af hybridomaer.

35

25. Fremgangsmåde ifølge krav 24, hvor fremgangsmåden yderligere omfatter screening af hybridomaerne til identifikation af et hybridoma, der producerer et antistof mod proteinet.

5 26. Fremgangsmåde ifølge krav 24, ved hvilken musen er blevet manipuleret til at producere humane antistoffer.

27. Fremgangsmåde til produktion af et monoklonalt antistof eller antistoffragment ifølge krav 10, hvilken fremgangsmåde omfatter isolering og rensning af antistoffet eller fragmentet fra et hybridoma som defineret i krav 23 eller tilvejebringelse af én eller flere replicerbare DNA indeholdende ekspressionsvektorer, som koder de variable og/eller konstante regioner for antistoffet og transformerer en egnet cellelinie, i hvilken produktionen af antistoffet finder sted.

15 28. Antistof eller fragment som defineret i ethvert af kravene 1-19 til anvendelse ved en fremgangsmåde til forøgelse af knoglemineralisering hos et varmblodet dyr.

29. Antistof eller fragment til anvendelse ifølge krav 28, hvor det varmblodede dyr har osteopeni eller en knoglefraktur.

20

30. Antistof eller fragment til anvendelse ifølge krav 29, hvor osteopenien er forårsaget af en anæmisk tilstand, steroider, heparin, en knoglemarvslidelse, skørbug, fejllærning, calciumdeficiens, idiopatisk osteoporose, kongenital osteopeni eller osteoporose, alkoholisme, kronisk leversygdom, senilitet, postmenopausal tilstand, oligomenorrhea, amenorrhea, graviditet, diabetes mellitus, hyperthyroidisme, Cushing's sygdom, akromegali, hypogonadisme, immobilisering eller inaktivitet, refleks-sympatetisk dystrofi-syndrom, forbigående regional osteoporose eller osteomalaki.

25

31. Antistof eller fragment til anvendelse ifølge krav 28, hvor dyret har osteoporose.

30

32. Antistof eller fragment til anvendelse ifølge krav 28, hvor dyret har achondroplasi.

33. Fragment eller antistof til anvendelse ifølge ethvert af kravene 28-32, hvor det varmblodede dyr er et menneske.

35

34. Farmaceutisk sammensætning indeholdende et antistof eller antistoffragment ifølge ethvert af kravene 1-19 samt et farmaceutisk acceptabelt bærerstof eller fortyndingsmiddel.

5 35. In vitro-fremgangsmåde til detektering af et protein kodet af sekvensen SEQ ID NO: 1, hvilken fremgangsmåde omfatter inkubering af et antistof eller fragment ifølge ethvert af kravene 1-19 under sådanne betingelser og i et tidsrum tilstrækkeligt til at tillade, at antistoffet eller fragmentet binder til proteinet, hvorefter bindingen detekteres.

10 36. Fremgangsmåde ifølge krav 35, ved hvilken antistoffet eller fragmentet er bundet til en fast understøtning.

37. Fremgangsmåde ifølge krav 36, ved hvilken antistoffet eller fragmentet er mærket.

15 38. Fremgangsmåde ifølge krav 37, ved hvilken antistoffet eller fragmentet er mærket med en markør valgt fra et enzym, et fluorescerende protein og en radioisotop.

39. Kit til detektering af et protein kodet af SEQ ID NO: 1, indeholdende en beholder, der indeholder et antistof eller fragment ifølge ethvert af kravene 1-19.

20

40. Anvendelse af et antistof eller fragment som defineret i ethvert af kravene 1-19 til fremstilling af et lægemiddel til forøgelse af knoglemineralisering hos et varmblodet pattedyr.

25 41. Anvendelse ifølge krav 40, ved hvilken pattedyret har osteopeni eller en knoglefraktur.

42. Anvendelse ifølge krav 41, ved hvilken pattedyret har osteoporose.

DRAWINGS

Common Cysteine Backbone

1				50	
human_gremlin.pro	-----	-----	-----	-----	-----
human_cerberus.pro	MHLLLFQLLV	LLPLGKTTRH	QDGRQNQSSL	SPVLLPRNQR	ELPTGNHEEA
human_dan.pro	-----	-----	-----	-----	-----
human_beer.pro	-----	-----	-----	-----	-----
	51				100
human_gremlin.pro	-----	-----M	SRTAYTVGAL	LLLGLTLLPA	AEGKKKGSQG
human_cerberus.pro	EEKPDLFVAV	PHLVAT.SPA	GEGQRQREKM	LSRFGRFWKK	PEREMHPSRD
human_dan.pro	-----	-----	-----	-----	-----
human_beer.pro	-----	-----	-----	-----MQLPLA	LCLVCLLVHT
	101				150
human_gremlin.pro	AI.PPPDKAQ	HNDSEQTQSP	QQPGSRNRGR	GQGRGTAMPG	EEVLESSQEA
human_cerberus.pro	SDSEPFPPGT	QSLIQPID.G	MKMEKSPLRE	EAKKFWHHFM	FRKTPASQGV
human_dan.pro	-----	-----	-----	MLRVLVGAVL	PAMLLAAPP
human_beer.pro	AFRVVEGQGW	QAFKNDTEI	IPELGEYPEP	PPELENNKTM	NRAENGGRPP
	151	↓	↓	↓	↓
human_gremlin.pro	LHVTERKYLK	RDWCKTQPLK	QTIHEEGCNS	RTIINRF.CY	GQCNSFYIPR
human_cerberus.pro	ILPIKSHEVH	WETCRTVPFS	QTITHEGCEK	VVVQNNL.CF	GKCGSVHFP.
human_dan.pro	INKLALFPDK	SAWCEAKNIT	QIVGHSGCEA	KSIQNR.ACL	GQCFSYSVFN
human_beer.pro	HHPFETKDVS	EYSCRELHFT	RYVTDGPCRS	AKPVTELVCS	GQCGPARLLP
	201	↓	↓		250
human_gremlin.pro	HIRKEGSFQ	SCSF...CKP	KKFTTMMVTL	NCPQLQPPTK	K.KRVTRVKQ
human_cerberus.pro	..GAAQHSHT	SCSH...CLP	AKFTTMHLPL	NCTELSSVIK	V...VMLVEE
human_dan.pro	TFPQSTESLV	HCDS...CMP	AQSMWEIVTL	ECPGHEEVPR	VDKLVEKILH
human_beer.pro	NAIGRGKWWR	PSGPDFRCIP	DRYRAQRVQL	LCPGGEAPRA	RKVRLVAS..
	↓↓				300
human_gremlin.pro	CRC.ISIDL	-----	-----	-----	-----
human_cerberus.pro	CQCKVKTEHE	DGHILHAGSQ	DSFIPGVSA-	-----	-----
human_dan.pro	CSCQACGKEP	SHEGLSVYVQ	GEDGPGSQPG	THPHPHPHPH	PGGQTPEPED
human_beer.pro	CKCKRLTRFH	NQSELKDFGT	EAARPQKGRK	PRPRARSACA	NQAELENAY-
	301	314			
human_gremlin.pro	-----	-----			
human_cerberus.pro	-----	-----			
human_dan.pro	PPGAPHTEEE	GAED			
human_beer.pro	-----	-----			

Figure 1

Human Beer Gene Expression by RT-PCR




Fig. 2




Fig. 4



BMP-5/Beer Dissociation Constant Characterization

.75 1.5 7.5 15 30 60 120 nM BMP-5



*Anti-FLAG immunoprecipitation *Anti-BMP-5 western blot

Ionic Disruption of BMP-5/ Beer Binding

NaCl(mM)	500	150	150
Beer	+	+	-
BMP-5	+	+	+



* Anti FLAG immunoprecipitation *Anti BMP-5 western

Fig. 6